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Malfunctioning of the β-cells of the pancreas leads to the metabolic disease known as diabetes
mellitus (DM), which is characterized by significant glucose variation due to lack of insulin
secretion, lack of insulin action, or both. DM can be broadly classified into two types: type 1
diabetes mellitus (T1DM) - which is caused mainly due to lack of insulin secretion; and type 2
diabetes mellitus (T2DM) - which is caused due to lack of insulin action. The most common
intensive insulin treatment for T1DM requires administration of insulin subcutaneously 3
- 4 times daily in order to maintain normoglycemia (blood glucose concentration at 70 to
120 mg
dl
). Although the effectiveness of this technique is adequate, wide glucose fluctuations
persist depending upon individual daily activity, such as meal intake, exercise, etc. For
tighter glucose control, the current focus is on the development of automated closed-loop
insulin delivery systems. In a model-based control algorithm, model quality plays a vital
role in controller performance.
In order to have a reliable model-based automatic insulin delivery system operating under
various physiological conditions, a model must be synthesized that has glucose-predicting
ability and includes all the major energy-providing substrates at rest, as well as during
physical activity. Since the 1960s, mathematical models of metabolism have been proposed
in the literature. The majority of these models are glucose-based and have ignored the
contribution of free fatty acid (FFA) metabolism, which is an important source of energy
for the body. Also, significant interactions exist among FFA, glucose, and insulin. It is
iv
important to consider these metabolic interactions in order to characterize the endogenous
energy production of a healthy or diabetic patient. In addition, physiological exercise induces
fundamental metabolic changes in the body; this topic has also been largely overlooked by
the diabetes modeling community.
This dissertation takes a more lipocentric (lipid-based) approach in metabolic modeling
for diabetes by combining FFA dynamics with glucose and insulin dynamics in the existing
glucocentric models. A minimal modeling technique was used to synthesize a FFA model, and
this was coupled with the Bergman minimal model [1] to yield an extended minimal model.
The model predictions of FFA, glucose, and insulin were validated with experimental data
obtained from the literature. A mixed meal model was developed to capture the absorption
of carbohydrates (CHO), proteins, and FFA from the gut into the circulatory system. The
mixed meal model served as a disturbance to the extended minimal model. In a separate
study, an exercise minimal model was developed to incorporate the effects of exercise on
glucose and insulin dynamics. Here, the Bergman minimal model [1] was modified by adding
equations and terms to capture the changes in glucose and insulin dynamics during and after
mild-to-moderate exercise.
A single composite model for predicting FFA-glucose-insulin dynamics during rest and
exercise was developed by combining the extended and exercise minimal models. To make the
composite model more biologically relevant, modifications were made to the original model
structures. The dynamical effects of insulin on glucose and FFA were divided into three
parts: (i) insulin-mediated glucose uptake by the tissues, (ii) insulin-mediated suppression
of endogenous glucose production, and (iii) anti-lipolytic effects of insulin. Labeled and
unlabeled intra-venous glucose tolerance test data were used to estimate the parameters of
the glucose model, which facilitated separation of insulin action on glucose utilization and
production. The model successfully captured the FFA-glucose interactions at the systemic
level. The model also successfully predicted mild-to-moderate exercise effects on glucose and
FFA dynamics.
A detailed physiologically-based compartmental model of FFA was synthesized and inte-
grated with the existing physiologically-based glucose-insulin model developed by Sorensen
[2]. Distribution of FFA in the circulatory system was evaluated by developing mass balance
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equations across the major FFA-utilizing tissues/organs. Rates of FFA production or con-
sumption were added to each of the physiologic compartments. In order to incorporate the
FFA effects on glucose, modifications were made to the existing mass balance equations in
the Sorensen model. The model successfully captured the FFA-glucose-insulin interactions
at the organ/tissue levels.
Finally, the loop was closed by synthesizing model predictive controllers (MPC) based
on the extended minimal model and the composite model. Both linear and nonlinear MPC
algorithms were formulated to maintain glucose homeostasis by rejecting disturbances from
mixed meal ingestion. For comparison purposes, MPC algorithms were also synthesized
based on the Bergman minimal model [1], which does not account for the FFA dynamics.
The closed-loop simulation results indicated a tighter blood glucose control in the post-
prandial period with the MPC formulations based on the lipocentric (extended minimal and
composite) models.
vi
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1.0 INTRODUCTION
The pancreas plays a vital role in regulating blood glucose concentration in the body. Gluco-
regulatory hormones, such as insulin, secreted by the pancreatic β-cells facilitate transport
of glucose from the circulatory system into the tissues [38]. Absolute or partial deficiency in
insulin secretion by the pancreas, lack of gluco-regulatory action of insulin, or both, leads to a
metabolic disease known as diabetes mellitus (DM) [3, 38, 39]. Several pathological processes
contribute to the development of DM, such as: autoimmune destruction of the pancreatic β-
cells; deficient insulin action resulting from diminished secretion by the pancreas; diminished
tissue response to the gluco-regulatory action of insulin at one or more points of the complex
pathways of hormone action; and genetic defects that prevent regulated secretion of hormone
[38, 39].
DM is largely classified into two categories. Insulin dependent diabetes mellitus (IDDM),
also known as Type 1 diabetes mellitus (T1DM), usually results from an absolute deficiency
of insulin secretion due to auto-immune destruction of the pancreatic β-cells [38]. Patients
with T1DM require exogenous insulin replacement therapy in order to regulate their blood
glucose levels [38]. The much more prevalent form is termed non-insulin dependent diabetes
mellitus (NIDDM), commonly known as Type 2 diabetes mellitus (T2DM). The cause of
T2DM is a combination of resistance to insulin action and an inadequate compensatory
insulin secretion response [38]. Most patients with this form of diabetes are obese, and
obesity may itself cause some degree of insulin resistance [38, 39, 40]. Non-obese T2DM
individuals often reflect elevated circulating levels of free fatty acids (FFA) and triglycerides
(TG). In case of T2DM, initially and often throughout the lifetime, the patients do not
require insulin replacement treatment to survive [38].
1
DM is becoming increasingly prevalent in U.S. and around the world. According to
the American Diabetes Association (ADA), approximately 17.5 million people in the U.S.
have been diagnosed with diabetes in 2007 [3]. This estimation is substantially higher than
the 2002 estimate of 12.1 million people by the ADA [41]. About 5-10% of the diabetic
patients have T1DM [38]. The total (direct plus indirect) estimated cost of diabetes has also
significantly risen from $132 billion in 2002 [41] to $174 billion in 2007 [3].
DM is usually associated with wide blood glucose (G(t)) fluctuations, resulting in hyper-
glycemia (G(t) > 120 mg
dL
) or hypoglycemia (G(t) < 70 mg
dL
) [42, 43]. Long-term effects of DM
are mainly caused by prolonged hyperglycemia, which may lead to complications such as loss
of vision, peripheral neuropathy with a risk of foot ulcer or even amputation, cardio-vascular
disease, nephropathy and sexual dysfunction [38, 42, 43]. Immediate disease consequences
are primarily caused by hypoglycemia, which may lead to dizziness, unconsciousness, or even
death [42, 43].
Over the years, researchers have shown that an intensive insulin therapy for diabetic
patients can delay the onset of serious complications [44, 45]. According to the findings
of the Diabetes Control and Complications Trial (DCCT) research group, intensive insulin
treatment reduced the risk of retinopathy, nephropathy and neuropathy by 35% to 90% when
compared with conventional treatment [44]. Intensive treatment was most effective when
begun early, before complications were detectable. As shown in Figure 1.1, the most common
insulin intensive treatment for T1DM involves self-monitoring of blood glucose (SMBG) by
finger-pricking at least 3-4 times a day followed by subcutaneous insulin injection in order
to achieve required glycemic goals (see Table 1.1) as recommended by the ADA [3].
Even with such intensive insulin therapy, wide glucose fluctuations persist mainly due to
daily activities such as meal intake and exercise. In an experiment performed by Raskin et
al. [46], the long-term effects of fast-acting insulin aspart (IAsp) and regular human insulin
(HI) on glycemic control were studied on T1DM patients. Blood glucose was measured at
8 time points and insulin was injected before breakfast, before lunch, before dinner, and at
bedtime. Their results revealed significant hyperglycemic events at post-prandial periods for
both the insulin regimens, with HI being worse. The ultimate goal in diabetes treatment
is the development of an automatic closed-loop insulin delivery system that can mimic the
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Figure 1.1: Schematic diagram of intensive insulin therapy: (A) blood glucose is measured by
using a self-monitoring blood glucose device by finger-pricking before meal intake/bed-time;
(B) estimated insulin dosage is injected subcutaneously via a syringe to achieve required
glycemic goals. This procedure is repeated 3-4 times a day [3, 7]
Table 1.1: Summary of glycemic recommendations for adults with diabetes (adapted from
[3])
Description Value
Glycosylated hemoglobin (A1C) <7.0%
Preprandial capillary plasma glucose 70-130 mgdL
Peak post-prandial (1-2 hr after the beginning <180 mgdL
of meal) capillary plasma glucose
A1C is the primary target for glycemic control
More stringent glycemic goals (i.e., A1C <6.0%)
may further reduce complications at the cost of
increased risk of hypoglycemia
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activity of a normal pancreas and is capable of maintaining physiological blood glucose levels
for T1DM patients. Such an artificial pancreas system can theoretically produce tight glucose
control without finger-stick blood glucose measurements, subcutaneous insulin injections, or
hypo-/hyper-glycemic events [47], thereby dramatically improving the quality of life for an
insulin-dependent diabetic patient. A device of this type would primarily contain three
components: (i) an insulin pump, (ii) a continuous glucose sensor, and (iii) a mathematical
algorithm to regulate the pump in order to maintain normoglycemia in presence of sensor
measurements [48, 49], as shown in Figure 1.2. In the case of a model-based closed-loop
insulin delivery system, the controller calculates the required insulin dosage for maintenance
of normoglycemia based on the blood glucose predictions obtained from a mathematical
model. Hence, model quality plays a vital role as theoretically available controller perfor-
mance is limited by model accuracy [50]. In addition, superior quality mathematical models
of DM provide numerous significant open-loop advantages. For example, a comprehensive
mathematical model facilitates a better understanding of the complex relationship between
insulin and the major energy-providing metabolic substrates [51]. High fidelity metabolic
models can predict the time-course and effect of insulin on plasma glucose in presence of
various external disturbances such as meal consumption, exercise, etc. Finally, an accurate
T1DM patient-specific metabolic model might be used to adjust daily insulin therapy dosage
for the same individual [51].
Over the years, numerous metabolic models have been published in the literature with
a primary goal of capturing the dynamics of the insulin-glucose system. Such glucocentric
(glucose-based) models largely ignore FFA metabolism and its interaction with glucose and
insulin. FFA is a major metabolic source of energy for the human body. Almost 70-80
% of muscle energy is derived from FFA oxidation during rest [52, 53]. This is because
the energy yeild from 1 g of FFA is approximately 9 kcal, compared to 4 kcal
g
for proteins
and carbohydrate (CHO) [54]. Moreover, significant interactions exist between glucose and
FFA metabolism. To further complicate matters, the FFA, glucose, and insulin dynamics
are significantly altered during exercise. In the development of a diabetes mellitus patient
model, it is important to consider all the major energy-providing substrates (glucose and
FFA) and their persisting metabolic interactions during rest and exercise. Such a complete
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Figure 1.2: Block diagram of closed-loop insulin delivery system
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metabolic model can provide more accurate glucose predictions under realistic conditions,
such as disturbances provided from mixed meal (containing CHO, protein, and fat) ingestion
and exercise. Finally, metabolic models describing the dynamics of insulin, glucose, and FFA
during rest and exercise can provide the control community an excellent platform for the
development of model-based controllers for maintenance of normoglycemia by rejecting the
various external disturbances.
In the following Section (1.1), a brief overview of the major metabolic interactions taking
place between the major energy-providing substrates and insulin at rest and during exercise
is presented. Sections 1.2 and 1.3 are dedicated for a concise review of the glucose-insulin
models and the closed-loop insulin delivery systems currently present in the literature,
respectively. Finally, a brief overview of the rest of the dissertation Chapters is presented in
Section 1.4.
1.1 A BRIEF OVERVIEW OF THE INSULIN-GLUCOSE-FFA SYSTEM
Glucose from the circulatory system is consumed by the hepatic tissues mostly for storage
in the form of glycogen and by the extra-hepatic tissues for oxidation purpose [55]. To
maintain plasma glucose homeostasis, stored glucose from the liver is released back into
the circulation via a process known as glycogenolysis [56]. Plasma insulin secreted by the
pancreas, or exogenously infused in the case of T1DM patients, facilitates the uptake of
glucose in the tissues [55]. Plasma insulin also inhibits hepatic glucose production [57]. FFA
from the circulatory system is consumed by the adipose tissue (AT) mostly for storage in
the form of triglycerides and by the peripheral tissues (except brain) for oxidation purpose
[54]. Whenever the body requires energy, stored FFA is released back into the circulatory
system via a process known as lipolysis [54]. Insulin acts as a strong anti-lipolytic agent,
in other words, it suppresses the lipolytic process [54]. In the early 1960s, Randle et al.
[58, 59] proposed that glucose and FFA compete for oxidation in the muscle tissues. This
phenomenon, popularly known as the glucose-FFA cycle, was later demonstrated in studies
performed by several researchers [8, 21], where it has been shown that an increase in plasma
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FFA concentration inhibits muscular glucose uptake rate. Several studies have also reported
that an increase in FFA inhibits insulin-mediated suppression of glycogenolysis [32, 19]. In a
recent publication, Ghanassia et al. [60] has mentioned that FFA and insulin act in synergy
and provide a fine-tuning for regulation of endogenous glucose production rate. Exercise
also plays a major role in influencing the dynamics of plasma glucose, FFA, and insulin.
An elevated exercise level up-regulates plasma glucose and FFA uptake rates [13, 61]. At
the same time, plasma insulin level decreases due to elevated insulin-mediated clearance
rate [62]. To maintain glucose homeostasis, hepatic glucose production also increases during
exercise [63]. Lactate production by working muscles is also increased during exercise [13].
Excess lactate in the plasma is absorbed by the liver for conversion to glucose (known as
gluconeogenesis [64]) in order to support the elevated glucose production rate. The schematic
diagram in Figure 1.3 captures all the major metabolic interactions between the insulin-
glucose-FFA system at rest and during exercise.
1.2 PREVIOUS LITERATURE ON MATHEMATICAL MODELS OF
METABOLISM
Metabolic models currently present in the literature can be classified into three groups (i)
strictly empirical, (ii) semi-empirical, and (iii) physiologically-based. The sole purpose of
a strictly empirical model is to capture the input-output data (insulin-glucose dynamics)
without consideration of any physiology [23, 65, 66, 67]. Hence such models are also called
black-box models. Since only the input-output data is used to develop the models, the
identification of the structure and parameters could be much simpler. Hence, time required
to synthesize these models can be short. As empirical model structures could be selected to
facilitate controller design, a vast number of model-based controllers employ dynamical em-
pirical models [68]. However, these models have several significant drawbacks. Since strictly
empirical models do not consider any biology, separation of specific physiological effects of
metabolic substrates taking place in the various tissues/organs is impossible. Also input-
output models provide no insight regarding the mechanisms underlying the observed system
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Figure 1.3: Schematic diagram of the major interactions taking place between plasma insulin,
glucose, and FFA during rest and exercise. The arrows with a solid line represent transport
clearance of metabolites and hormones. Dashed line arrows with + and − signs represent
upregulating and downregulating effects on plasma FFA, glucose, or insulin, respectively.
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dynamics. Moreover, biological processes responsible for glucose dynamics are nonlinear and
vary under many conditions; hence, simple linear input-output models are inadequate to
provide credible predictions for extended future horizons under realistic disturbances, such
as a meal [23].
The semi-empirical models consist of a minimum number of equations capturing the
insulin glucose dynamics with a primary focus on emulating the data by considering only
the necessary physiology [1, 69, 70, 71, 72, 73, 74, 75]. Unlike the strictly empirical models,
minimal models include several macroscopic metabolic parameters, like peripheral tissue
sensitivity to insulin and overall glucose effectiveness of extra-hepatic tissues [5]. However,
these models do not differentiate the distribution of metabolic substrates at various or-
gan/tissue levels, as that will add further model complexity. Hence, the goal in such models
is to capture the major physiological interactions in order to reproduce the data without
sacrificing the structural simplicity. Due to this very nature, semi-empirical models can be
an ideal candidate for the synthesis of model-based controllers capable of maintaining glucose
homeostasis by rejecting disturbances from mixed meal consumption and exercise.
Finally, the physiologically-based models are more detailed and complex in terms of
number of parameters and equations providing an in depth description of the physiology
behind the various metabolic interactions taking place in the body [2, 76, 77, 78]. In
such models, the distribution of metabolic substrates is captured at the organ/tissue and
intracellular levels. Physiologically-based models can be extremely useful, as they can
promote insight, as well as motivation for experiments that could be performed to validate
various model components. In terms of drawbacks, these models are usually time-intensive
to develop. They typically have large number of nonlinear equations with many parameters
that need to be estimated. Even though complexity is an issue, a valid physiologically-based
model can not only describe the dynamics of measurable quantities, but also correctly predict
all the unmeasurable variables relevant to the system.
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1.2.1 Empirical Models
Strictly empirical models are developed based on the input-output data without considering
the fundamental properties (physiology) of the system. Typically, the model structure is
chosen to facilitate parameter estimation or design of model-based controller. Mitsis and
Marmarelis [79] developed a non-parametric model of the glucose-insulin system by selecting
the Volterra-Wiener approach. The first and second order kernels of the Volterra model
were estimated from input-output data generated from a parametric model [1] by employing
the Laguerre-Volterra Network (LVN) methodology. The simulation results revealed that
synthesis of accurate nonlinear input-output models from insulin-glucose data generated
from parametric models was feasible. The authors also demonstrated the robustness of the
Volterra models under presence of additive output noise. Furthermore, such kind of models
are accommodating to adaptive and patient-specific estimation, which could be necessary
for a model-based blood glucose control algorithm.
A linear input-output model for glucose prediction based on recent blood glucose mea-
surement history was proposed by Bremer and Gough [23]. Autocorrelation function (ACF)
estimates at fixed time intervals were used to identify the model structure. An ACF estimate
provides a statistical measure of the dependence between individual measurements of a
process at different time points. Published data analyzed in their work indicated that
blood glucose dynamics are not random, and that blood glucose values can be predicted
from frequently sampled previous values, at least for the near future. However the model
prediction of blood glucose for extended horizon (in excess of 30 min) was not acceptable.
Parker et al. [65] developed a linear input-output step-response model of insulin delivery
rate (input) effects on glucose concentration (output) by filtering the impulse response
coefficients via projection onto the Laguerre basis. The identified linear input-output model
does not include all the gain information of the diabetic patient, but it does succeed in
capturing the dynamic behavior. Inability to capture the steady state characteristics did not
affect the closed-loop performance of the model. In a separate study, Florian and Parker [80]
synthesized empirical Volterra series models of glucose and insulin behavior by considering
input-output data generated from a physiologically-based metabolic model [2]. In absence
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of noise, the identified Volterra models accurately predicted the data. However, addition
of Gaussian distributed measurement noise significantly degraded the coefficient estimates.
Significant noise filtering was achieved by projecting the Volterra models onto the Laguerre
basis functions. Closed-loop performance of the nonlinear empirical model with measurement
noise in rejecting 50 g oral glucose challenge was mediocre. Best closed-loop performance
was achieved by a linear MPC with ability to filter noise effects by proper tuning.
Van Herpe et al. [66] developed a control-relevant black-box model for prediction of the
glycemic levels of critically-ill patients in the intensive care unit (ICU) by using real clinical
ICU input-output (insulin-glucose) data. An autoregressive exogenous input (ARX) model
structure was used for predicting blood glucose concentration by considering the following
input variables: insulin infusion rate, body temperature, total CHO calorie intake, total fat
calorie intake, glucocorticoids level, adrenalin level, dopamine level, dobutamine level, and
beta-blockers level. The estimated model coefficients showed clinical relevance with respect
to the behavior of glycemia in relation to insulin, insulin resistance, intake of CHO calories,
etc. However, the authors pointed out that further data is required to make the model more
patient specific especially to capture the diurnal variation of insulin resistance for critically-ill
patients.
In another study, several types of empirical models, like Auto-regressive with exogenous
input (ARX) and Box-Jenkins (BJ), were developed by Finan et al. to evaluate the ‘infinite-
step ahead’ glucose predictions [67]. The input-output models were identified from simulating
a semi-empirical model developed by Hovorka et al. [75]. The higher- and lower-order ARX
and BJ models described normal operating conditions with high accuracy. However, model
accuracy during abnormal situations (e.g., change in insulin sensitivity, underestimates in
CHO content of meals, mismatch between actual and patient-reported timing of meals) were
inaccurate, especially for the lower-order models.
A nonlinear neural network (NN) model of blood glucose concentration identified from
subcutaneous glucose sensor and subcutaneous insulin infusion data was developed by Tra-
jonski et al. [81]. The system identification framework combines a nonlinear autoregressive
with exogenous input (NARX) model representation, regularization approach for construct-
ing radial basis function NNs, and validation methods for nonlinear systems. Numerical
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studies on system identification and closed loop control of glucose were carried out by using
a comprehensive glucose model and pharmacokinetic model of insulin absorption from a
subcutaneous depot. Closed-loop simulation results showed that stable control is achievable
in the presence of large noise levels. However, one major drawback of the closed-loop system
is that, due to the subcutaneous route of insulin administration, rapid control actions were
not stable which are typically necessary after a standard OGTT.
Bellazzi et al. [82] proposed a fuzzy model for predicting blood glucose levels in T1DM
patients. The underlying idea in their approach consists of the integration of qualitative
modeling techniques with fuzzy logic systems. The resulting hybrid system uses a priori
structural knowledge on the system to initialize a fuzzy inference procedure, which estimates
a functional approximation of the system dynamics by using the experimental data in order
to predict the patient’s future blood glucose concentration. The results obtained showed that
the presented framework generates fuzzy systems that may be used reliably and efficiently
to predict blood glucose concentration for T1DM patients. A potential drawback is that, as
the initialization of the fuzzy system requires a priori knowledge of the qualitative model,
any erroneous approximation of unknown functions could lead to significant degradation of
the fuzzy model performance.
Bleckert et al. [83] developed a model of glucose-insulin metabolism by identifying the
system with stochastic linear differential equations using a mixed graphical models technique.
The model was identified in terms of biological parameters and noise parameters. Density
estimates of the unkown parameters were obtained from the input-output data by using
the exact inference algorithm [83]. The parameter estimates were given as a posteriori
distributions, which can be interpreted as fuzzy probability distributions. These density
estimates convey much more information about the unknown parameters than a point
estimate.
1.2.2 Semi-Empirical Models
The semi-empirical metabolic models consist of minimum number of equations capturing
only the necessary physiology in order to better understand the mechanisms of the glucose-
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insulin regulatory system. One of the pioneers in this field is Bolie. In 1961, he proposed
a 2-dimensional (2-D) metabolic model consisting of ordinary differential equations (ODE)
[69]. The two ODEs, one capturing glucose and the other capturing insulin concentration,
consisted of 5 parameters. Parameter values were estimated from published data; predomi-
nantly average values obtained from human, as well as animal, experiments. Ackerman et al.
[70] developed a similar 2-D glucose-insulin model which was published in 1965. The model
considered the important fact that changes in insulin and glucose concentration depend on
the concentration of both the components. Serge et al., in the early 1970’s, synthesized
a metabolic model consisting of linear ODEs to capture blood glucose kinetics of normal
T1DM and obese patients [84]. Although all these early models were easily identified from
available data, they oversimplified the actual physiological effects between glucose-insulin.
A huge impact in the field of modeling glucose-insulin dynamics was initiated by the
introduction of the “minimal” model developed by Bergman and colleagues in the late 1970’s
and early 1980’s [1, 85]. There are approximately 500 studies published in the literature,
that involve the Bergman minimal model [86]. The model consists of three ODEs that
capture plasma glucose dynamics, plasma insulin dynamics, and insulin concentration in
an unaccessible remote compartment (which can be conceptualized as interstitial insulin).
Structurally, the model consisted of a minimum number of lumped compartments and
parameters to accurately capture the various physiological phenomena, such as glucose
effectiveness and insulin sensitivity, during an intra-venous glucose tolerance test (IVGTT)
[1]. The addition of the remote insulin compartment and a bilinear term in the glucose
state increased the accuracy of the model without sacrificing any simplicity. However,
several shortcomings of the minimal model have been raised in the literature [87, 88].
Quon et al. reported that the Bergman minimal model tends to overestimate the effect
of glucose on glucose uptake and underestimate the contribution of incremental insulin [87].
Researchers have also raised questions that the minimal model might be too minimal [73].
Despite its shortcomings, the Bergman minimal model [1] has gained enormous popularity
in the diabetes research community, mainly because of its structural simplicity and easily
identifiable parameters [86, 89]. Because of this very nature, the minimal model was selected
in this work to provide a platform for the development of a lipid-based extended minimal
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model and an exercise minimal model which are detailed in Chapter 2 and 3, respectively.
Cobelli and colleagues have developed numerous metabolic models capturing the various
physiological interactions between glucose and insulin [5, 71, 72, 74, 90, 91]. The Bergman
minimal model [1] does not allow the separation of glucose production from utilization. To
overcome this limitation, Cobelli et al. proposed a revised minimal model which was fitted
to cold and hot (radio-labeled) IVGTT data [5], as the hot data reflects glucose utilization
only. In another publication by Cobelli et al. [74], the over-estimation of glucose effectiveness
(SG) and under-estimation of insulin sensitivity (SI) of the Bergman minimal model due to
under-modeling was addressed by adding a second non-accessible glucose compartment for
a better description of the glucose kinetics. The two-compartment glucose model improved
the accuracy of SG and SI estimates from a standard IVGTT in humans. In a series of
publications Cobelli and co-authors [71, 72, 90] developed an extensive model of glucose and
two hormones, insulin and glucagon. Glucagon is a counter-regulatory hormone secreted by
the α-cells of the pancreas. Its role is to enhance the release of glucose from the liver into the
plasma by speeding the breakdown of hepatic glycogen. The glucose sub-system explicitly
considered the net hepatic glucose balance (NHGB), renal excretion of glucose, and insulin-
dependent and insulin-independent glucose utilization by peripheral tissues, red blood cells
and the central nervous system. The insulin sub-system is divided into five compartments,
whereas the glucagon subsystem consisted of a single compartment. The nonlinear equations
employed saturating functions (hyperbolic tangents) to capture the saturation behavior
observed in biological systems (e.g., hepatic glucose production). Incorporation of all these
physiological interactions provided further insight into glucose-insulin metabolism.
Berger and Rodbard [92] developed a computer program for the simulation of plasma
insulin and glucose dynamics after subcutaneous injection of insulin. A pharmacokinetic
model was used to calculate the time courses of plasma insulin for various combinations of
popular preparations. The program can predict the time course of plasma glucose in response
to a change in CHO intake and/or insulin dose, with the use of a pharmacodynamic model
describing the dependence of glucose dynamics on plasma insulin and glucose levels. A set
of parameters for the model were estimated from the literature. The model can be used to
theoretically explore the impact of various factors associated with glycemic control in T1DM.
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Results of the glucose dynamics generated by the simulator were not exact, particularly after
perturbations from larger CHO intake sizes. One potential drawback is that, due to the
absence of FFA effects, the simulator may be incapable of predicting plasma glucose level
accurately in the presence of disturbances from mixed meals containing CHO and fat.
In a much more recent work, Hovorka et al. [75] extended the 2-compartment minimal
model developed by Cobelli et al. [74] by separating the effect of insulin on glucose distrib-
ution/transport, glucose disposal, and endogenous glucose production during an IVGTT by
employing a dual-tracer dilution methodology. The model consisted of a two-compartment
glucose sub-system, a single compartment for plasma insulin, and three remote insulin
compartments capturing the different physiological effects of insulin on glucose. By using
the dual-tracer technique along with the model, the authors demonstrated a novel approach
of separating the three actions of insulin on glucose kinetics successfully. The results
showed that the insulin-mediated suppression of endogenous glucose production accounts for
approximately one-half of the overall insulin action on glucose after an IVGTT. However, the
absence of any saturating functions, particularly for the mathematical expression capturing
the endogenous glucose production rate, could generate erroneous predictions for experiments
with higher insulin boluses.
Salzsieder et al. developed a biologically relevant model describing the in vivo glucose-
insulin relationship of T1DM patients [93]. Four linear state variables were used to model
the system. The physiologically relevant states represented the circulating concentration
of insulin and glucose, net endogenous glucose balance, and peripheral insulin-dependent
glucose uptake. The model was calibrated and validated using published data of dogs [94,
93, 95]. Slow dynamics, as well as steady state glucose behavior, were accurately captured by
the model. However, this accuracy was absent during faster insulin dynamics. The original
model was verified within the limit of linearity, which was the upper normoglycemic level.
This might prove to be disadvantageous, as during the post-prandial period the blood glucose
level often hovers in the hyperglycemic level, especially for T1DM patients.
In another glucose-insulin modeling effort, Boroujerdi et al. [96] developed a glucose
kinetics model which represented glucose utilization as two processes: insulin dependent and
insulin independent. The overall glucose disposal comprised of glucose transport and utiliza-
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tion and the effect of insulin on these processes. The model consisted of five compartments
representing, plasma glucose, insulin sensitive and insulin-insensitive glucose interstitial
space, and a glucose-transporter limited metabolism compartment for each of the interstitial
spaces. An important finding of their model was that saturation of the glucose-transporter
mechanism in diabetic patients leads to hyperglycemia. Inclusion of such physiological
phenomenon would definitely make the model more accurate. However, the model lacked in
specifying tissue-specific saturating phenomena and its characterization of insulin effects on
endogenous glucose production.
A semi-empirical model of glucose-insulin interaction was developed by Lehman and
Deutsch for T1DM patient evaluation [97]. The purpose of the model was to simulate
glycemic and plasma insulin responses to a given insulin therapy and dietary regimen for 24
hr. The model contains a single glucose pool into which glucose enters via both intestinal
absorption and hepatic glucose production. Glucose is removed from this space by insulin-
independent glucose utilization in red blood cells, insulin-dependent glucose utilization in
liver and periphery, and renal glucose excretion. Since the introduction of this model in the
World Wide Web (www.2aida.org) for noncommercial use, a significant number of copies
of this model have been downloaded to assist T1DM treatment [98]. Although, the main
purpose of the model is to provide valuable knowledge to T1DM patients regarding their
glucose dynamics after meal consumption, absence of FFA absorption from a mixed meal
intake might limit the accuracy of the model prediction. Also, the model was incapable of
predicting the glucose dynamics accurately during a continuous steady state insulin infusion
(to maintain basal level) experiment, as shown by Steil et al. [51]. Utilization of two glucose
compartments might have improved the accuracy of the model.
Tolic et al. [99] developed a model to evaluate insulin-glucose feedback regulation under
pulsatile supply of insulin. The feedback loops present in the model consist of glucose-
stimulated pancreatic insulin secretion, insulin-stimulated glucose uptake, insulin-stimulated
inhibition of hepatic glucose production, and glucose-stimulated enhancement of its own
uptake. Delays are also incorporated in the model to represent the physiologic delay of
insulin action on hepatic glucose production. The results obtained from the model have
shown that when hepatic glucose release rate is operating at its upper limit, an oscillatory
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insulin infusion will be more effective in lowering blood glucose level than constant infusion.
As the authors pointed out, more work is required to refine the model. For example, the
time delay between plasma insulin and hepatic glucose production needs to be replaced by
more physiologically relevant states. Also, the pulsatile effect of insulin on down-regulation
of the insulin receptors should be incorporated in the model.
Originally, the “minimal” model was developed to capture the glucose kinetics of a single
individual [1] and was never used to estimate the metabolic portrait for a whole population.
A population-based approach can be useful in the study of diabetes for classification of
patients being in risk groups or not. Furthermore, information from population estimates
can provide prior information for statistical analysis of a single individual. Vicini and Cobelli
[100] were the first to propose a Bayesian approach to the population-based minimal model.
They used IVGTT data from sixteen healthy individuals to obtain distributions of glucose
effectiveness and insulin sensitivity in the population. The mean and standard deviation
obtained from the distributions were used as a prior information for individual analysis.
Their method produced precise glucose effectiveness and insulin sensitivity estimates, even
with a small sampling size. However, the method was employed on only the glucose part
of the model. Recently, Andersen and Hojbjerre [101], proposed a similar version of the
stochastic minimal model, where they combined both the glucose and insulin parts of the
model. The population-based minimal model accounted for error terms associated with the
measurement and the process. The Markov chain Monte Carlo technique was successfully
implemented in estimation of the parameters by using the Bayesian approach. The method
was demonstrated on experimental IVGTT data performed on 19 normal glucose-tolerant
subjects.
Engelborghs and co-authors [102] developed a semi-empirical model with two delayed
differential equations (DDE) for the plasma glucose and insulin concentration in a diabetic
patient connected to an exogenous insulin delivery system. The model has two delays: the
intrinsic delay involved with the external device, and the physiological delay associated with
the action of insulin on glucose. Bifurcation analysis of steady state solutions and periodic
solutions revealed two categories of diabetic patients for which the insulin delivery system
had different efficiencies.
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For better understanding of the insulin absorption kinetics produced by continuous
subcutaneous infusion of insulin, Kraegen and Chisholm [103] used a kinetic model to
quantitate the dynamics. The authors used a two-pool system to reasonably capture the
systemic insulin delivery profile following a subcutaneous infusion. The model revealed that
subcutaneous insulin degradation is low regardless of the input profile. Such kinetic models
of subcutaneous insulin absorption should be useful to predict the impact of programming
strategies for continuous subcutaneous insulin infusion therapy. Later, Puckett and Lightfoot
[104] developed a three-compartment model representing the link between dosage and blood
insulin levels. A comparison study revealed that the 3-D model fitted the data of individual
patients better than the 2-D model from [103]. They also performed parameter identification
and sensitivity analysis which highlighted insulin kinetic features that may significantly
influence glucose dynamics. Their results showed significant inter-, as well as intra-patient
variability of insulin absorption kinetics.
A semi-empirical model capable of capturing the absorption kinetics of subcutaneously
injected insulin was developed by Wach et al. [105]. The model consisting of partial
differential equations (PDE), described the diffusion of soluble insulin, equilibration between
monomeric and dimeric insulin, and absorption of monomeric insulin molecules. The authors
solved the PDEs numerically by dividing the subcutaneous region into spherical shells for
space distribution. Parameters of the model were estimated by fitting published glucose-
clamp data. The model predictions of dose- and concentration-dependent insulin abosrption
within the therapeutic range were in good accordance with the experimental data. According
to the authors, the model could be used in a clinical setup to describe the subcutaneous
insulin absorption kinetics of individual patients.
1.2.3 Physiological Models
In the mid-70s, Tiran and co-authors [76, 106] were among the first to attempt to develop
physiologically-based “circulation model” of the glucose-insulin system. Several compart-
ments were used to represent major organs and tissues in the human body. Each com-
partments were divided into two regions representing the capillary and interstitial space.
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Glucose and insulin were distributed in these compartments via the blood circulation path-
ways. Nonlinear effects of glucose metabolism were also incorporated in the model. The
model performed reasonably well in predicting venous glucose concentration in response to
perturbations from glucose boluses of small sizes (<30 g). However, the model over-predicted
glucose concentration for bolus sizes in excess of 30 g. The model also lacked in capturing the
threshold metabolic behaviors of the physiological system. As the authors pointed out, the
whole body model has the potential to serve as a basis for examining hypothesis regarding
the glucose-insulin system.
A physiologically-based model of metabolism was developed by Sorensen, in his Ph.D.
dissertation [2], based on an earlier model by Guyton et al. [107]. The model is comprised
of 19 differential equations: 11 are used to define the glucose system, 7 define the insulin
system, and one models glucagon. The glucose model consists of compartments representing
the vital glucose-utilizing body organs and tissues: brain, heart/lungs, gut, liver, kidney, and
periphery. In the model, ‘periphery’ represents skeletal muscle as well as adipose tissues (AT).
Blood pumped from the heart enters into each compartment through the arterial circulation
and exits to the venous circulation. Mass balances were performed across each tissue or
organ in order to capture the plasma glucose distribution. Some of the compartments (such as
‘brain’ and ‘periphery’) were divided into sub-compartments (capillary and interstitial space)
to incorporate resistance to glucose transport. Metabolic sinks representing glucose uptake
were added to all the compartments. As the liver consumes, as well as produces glucose,
both metabolic sink and source were incorporated in the ‘liver’ compartment. Most of the
metabolic sinks/sources were functions of glucose, insulin, or glucagon concentration. The
model accepted exogenous glucose input in the form of meal consumption. The insulin model
has a similar structure to the glucose model [2]. The only difference, is that the ‘brain’ in the
insulin model had a single compartment, because insulin does not cross the brain capillary
barrier. Metabolic sinks representing insulin clearance were added to the ‘liver’, ‘kidney’,
and ‘periphery’ compartments. The model does an excellent job in capturing the glucose and
insulin distributions in all the major organs and tissues. Validation studies revealed that the
model accurately predicted plasma glucose concentrations after intravenous and oral glucose
tolerance tests. Because of its high accuracy and structural integrity, the Sorensen model
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[2] was selected to provide a platform for the development of a physiologically-based FFA
model to capture the fatty acid distribution at organ/tissue levels, as described in Chapter
5.
A semi-physiologic nonlinear model of glucose and insulin was developed by Cobelli
et al. [78]. The model consisted of mathematical functions capturing peripheral glucose
consumption, renal glucose excretion, hepatic glucose production and utilization, glucose
absorption from a meal, insulin secretion, and insulin degradation. Delay terms were also
included in the model to incorporate the physiologic delay involved in the gluco-regulatory
action of insulin on glucose. Simulation studies revealed that the model successfully described
physiological events occurring in a normal human after the ingestion of standard meals on a
24 hour horizon. However, the model does not account for glucose distribution at the major
glucose-consuming organ levels.
1.2.4 Metabolic Models Considering FFA and Exercise Effects
All the metabolic models so far discussed spanning five decades exclusively focus on the
interactions between glucose and insulin. Effects of FFA and exercise on plasma glucose
dynamics have been largely neglected. For the synthesis of high quality and robust closed-
loop model-based controllers for maintenance of glucose homeostasis, it is essential to develop
models that take into account the external disturbances encountered by a T1DM patient in
his/her daily life, like mixed meal ingestion and exercise. There are only few metabolic
models present in the literature that consider FFA and exercise effects on glucose dynamics.
A physiologically-based model of insulin, glucose, and fatty acids has been proposed by
Srinivasan et al. [77]. The model is made of interconnected sub-systems, each representing
one or more physiological processes. Known physiology was incorporated with an intention to
reproduce the effects of FFA and glucose metabolism for a short-term period (< 2 hr). This
complex model was the first of its kind to include FFA dynamics in the glucose-insulin system.
The model, qualitatively, did a reasonable job in predicting glucose and FFA dynamics
after an IVGTT. One potential drawback is that the model ignored the effects of blood
circulation on metabolism. Also, as pointed out by the authors, the model lacked the ability
20
to adequately reproduce the finer details of plasma glucose, FFA, and insulin changes caused
due to introduction of disturbances in the metabolic system. According to the authors,
further refinement of the mathematical functions and inclusion of more hormonal controls
might yield better results. From a control point of view, a major drawback of the model is
its inability to predict plasma glucose and FFA dynamics at longer time periods (in excess
of 2 hr).
Recently, Kim et al. [108] developed a physiologically-based model of metabolism to
capture the whole-body fuel homeostasis during exercise. The model was divided into seven
physiologic compartments representing the brain, heart, liver, GI (gastrointestinal) tract,
muscle, AT, and other tissues. Dynamic mass balance equations along with cellular metabolic
reactions were considered in each of the compartments. Hormonal control by insulin and
glucagon over the cellular metabolic processes were incorporated in the model to predict
the changes in fuel homeostasis during exercise. Model simulations were validated with
experimental data where normal subjects performed moderate intensity exercise for 60 min.
The model successfully captured the exercise-induced changes in hormonal signals at various
tissues in order to regulate metabolic fluxes for maintenance of glucose homeostasis. The
model also successfully captured the dynamics of variables like, hepatic glycogenolysis and
gluconeogenesis, which are hard to measure. In addition, the model can also indicate the
relative contributions to fuel oxidation of glucose and FFA in the muscle during exercise. This
novel mechanistic model that links cellular metabolism to whole-body fuel homeostasis can
be used for testing hypotheses of hormonal control and dynamical predictions of metabolite
concentrations in various tissues during exercise. However, due to the scale and complexity
in terms of number of equations and parameters, the model has limited applicability in a
clinical setup to be calibrated to individual patients. Also, the model fails to capture the
experimental data of arterial lactate concentration.
From a control prospective, the complexity of both the above mentioned models [77, 108]
can prove to be a liability for the synthesis of a model-based control system for T1DM
patients. Due to the sheer scale of the model, it is hard to design experimental protocols
to identify parameters for individual patients. Hence, parametric identifiability can be a
major issue. One potential method for overcoming the parameter estimation problem is a
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priori identifiability, which is discussed as a potential direction of future work in Section
7.2.2. A further complication of the detailed models is the difficulty in using them in an
adaptive control environment, as no identifiable parameter or combination of parameters are
necessarily available to be updated online. As the long-term goal of the present work is to
develop models that can be used for the synthesis of a model-based controller, development
of accurate lower-order structurally simple metabolic models capturing the insulin, glucose,
and FFA dynamics during rest and exercise is essential.
1.3 OVERVIEW OF CLOSED-LOOP INSULIN DELIVERY SYSTEMS
A fully automated closed-loop (CL) insulin delivery system (also known as an artificial
pancreas) could potentially be the ultimate answer for blood glucose control in diabetic
patients. According to Klonoff [47], the artificial pancreas is a system of integrated devices
containing only synthetic materials, which substitutes for a pancreas by sensing plasma
glucose concentration, calculating the amount of insulin needed, and then delivering the
correct amount of insulin. Typically, such a device is comprised of a glucose monitoring
sensor, an insulin pump, and a control algorithm to regulate the pump. Such an approach
of glucose measurement, determination of proper insulin dose, and delivery of insulin can
theoretically result in physiologic glycemic levels with a high level of precision.
The first CL insulin delivery device (an ‘on-off’ system) was developed by Kadish [109]
in 1964. The device measured venous blood glucose concentration every 15 seconds and
delivered either insulin (if the blood glucose level was above 150 mg
dL
) or glucagon (if the
blood glucose level was below 50 mg
dL
) to maintain the glycemic level within a range of 50–150
mg
dL
. The performance of the Kadish device was hampered due to the lack of computational
power at the time. Also, the size of the device was equivalent to a large back-pack.
In the mid 1970’s, Albisser et al. [110, 111] synthesized a true artificial pancreas. In
order to automate insulin delivery, the integrated device consisted of a continuous glucose
monitor with control algorithms implemented on a micro-computer. The device used a two
channel system, one of which was dedicated to dextrose infusion and the other one was
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for insulin infusion. One of the major limitations of the device is that the control algorithm
required several patient-dependent parameters. In addition, the initial controller response to
a glucose surge was sluggish. The first commercially available CL insulin-delivery system, the
Biostator (Miles laboratory), was available in 1977 [112]. A nonlinear proportional-derivative
(PD) control algorithm was used to regulate a dual infusion system (insulin and dextrose) to
maintain glucose homeostasis. For the feedback signal, venous blood was sampled at a regular
interval to measure plasma glucose concentration and the associated measurement noise was
filtered by using a 5-point moving average. The device suffers from serious limitations,
mainly due its size, and necessity of constant supervision. Also, it requires individualization
before use. The Biostator is no longer commercially available. A modified version of the
Albisser [110] algorithm based on glucose measurement and rate of change of glucose was
presented by Botz [113], Marliss [114], and Kragen et al. [115] to reduce post-prandial hypo-
/hyper-glycemic events. In a review paper, Broekhuyse et al. [116] concluded that none of
the above-mentioned algorithms were superior.
Fischer and colleagues have extensively studied closed-loop feedback control of blood
glucose in T1DM [94]. They raised the question of whether or not only an adaptive algorithm
would guarantee optimal feedback control of glycemia in insulin-dependent diabetes. In
their experiment, insulin was applied intravenously and an oral glucose load was given to
fasting diabetic dogs at rest. Three different control strategies were employed: (i) online
identification of the glucose-insulin system for 4 hr followed by an adaptive feedback control
algorithm where the control parameters were adapted continuously at every sampling time
(∆t=1min), [Test A]; (ii) online system identification just like the previous test followed by a
fixed command control using the initial estimates without any further changes in the control
parameters [Test B]; and (iii) fixed command control employed on the basis of individually
optimized oﬄine control constants (no online system identification was performed) [Test C].
Normal glycemic profiles were obtained with the adaptive control setup (Test A) and the
fixed command control optimized to meet individual needs (Test C).
Recently, Medtronic Minimed has developed an external physiological insulin delivery
system (ePID) [117]. The fundamental design criterion of the controller is to emulate the
characteristics of the β-cell, in particular the first and the second phase insulin secretion as
23
observed during hyperglycemic glucose clamps [118, 119]. This was achieved by adapting a
proportional-integral-derivative (PID) controller [120] which can be considered to reproduce
the first phase insulin secretion by linking insulin administration to the rate of change in
glucose concentration (the derivative component of the controller) and the second phase by
linking insulin administration to the difference between the actual and target glucose (the
proportional and integral component of the controller). A recent evaluation of the ePID
system on 6 T1DM patients revealed satisfactory performance. However, the controller was
unable to prevent hypoglycemic events during the post-prandial periods [117].
In 1982, Swan [121] developed an optimal controller for maintenance of normoglycemia
in diabetic patients. He used a linear diabetic patient model and a quadratic performance
criterion to estimate the optimal insulin infusion rate by solving the nonlinear algebraic
Riccati equation. The authors did not examine the controller performance during post-
prandial conditions. Ollerton [122] applied optimal control theory to the minimal model
developed by Bergman [1] for maintenance of glucose homeostasis, where he utilized an
integral-squared error objective function based on deviation from the target glucose value.
In order to reduce calculation time, the Bergman minimal model was discretized with a
10 min sampling time. The control formulation was sensitive to oscillations in the glucose
profile about the basal state.
In another study by Fisher and Teo [123], blood glucose control during post-prandial,
as well as fasting condition was examined. Various insulin infusion protocols were tested
to minimize the objective function, which was basically the sum-squared error in glucose
setpoint tracking. An insulin impulse at t=0 provided superior setpoint tracking if a good
meal estimate was available.
One of the most promising control approaches is a model predictive controller (MPC).
As the name suggests, MPC is a model-based control approach where a metabolic model of
a patient is used to predict future plasma glucose concentration. The controller solves an
optimization problem by minimizing a quadratic objective function at every sampling time.
The terms in the objective function include setpoint error, which is the difference between
predicted future blood glucose concentration and the desired reference trajectory, as well as a
penalty for the insulin delivery rate. MPC performance depends largely on the ability of the
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model to accurately predict future glucose concentration based on the current physiological
condition [50] and available measurements.
Trajonski et al. [81] developed a MPC framework for glycemic control of diabetic
patients. Using the subcutaneous route for insulin infusion and glucose measurement, a
radial basis function (RBF) neural network model for glucose prediction was identified from
past insulin infusion rates and glucose measurements. A nonlinear MPC was synthesized
based on the identified model for maintenance of glucose homeostasis. According to the
simulation results, stable control was achievable in the presence of large noise levels.
Parker et al. [65] used a linear version of the physiologically-based Sorensen model
[2] to synthesize a MPC, both with and without state estimation, for glycemic control
[65]. Input constraints were implemented for both input delivery rate and rate of change
of insulin delivery rate. For simulation purposes, the full nonlinear Sorensen model was
treated as the patient in order to represent the effects of plant-model mismatch. The control
formulation was tested successfully to regulate blood glucose for both meal disturbance
rejection and hyperglycemic initial condition. A linear MPC based on the input-output
model was sufficient to maintain normoglycemia after a 50 g oral glucose tolerance test
(OGTT).
Lynch and Bequette [124] synthesized a constrained MPC based on a modified version
of the Bergman minimal model [1] developed by Fisher [125]. A Kalman filter was used for
state estimation based on subcutaneous blood glucose measurements. In order to incorporate
plant-model mismatch, the patient was represented by the higher-order Sorensen model [2].
With proper tuning, the closed-loop controller successfully returned blood glucose to the
normoglycemic range by rejecting disturbances from meal consumption.
A nonlinear MPC was developed by Hovorka et al. [126] to maintain normoglycemia of
T1DM patients during fasting conditions. The controller employed a compartment model
developed by Hovorka et al. [75], which represents the glucoregulatory system, and included
submodels representing absorption dynamics of the subcutaneous short-acting insulin. The
controller used Bayesian parameter estimation to determine time-varying model parameters.
The algorithm also employed gradually decreasing setpoint trajectory in order to facilitate
controlled normalization of hyperglycemic glucose levels, and faster normalization of hy-
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poglycemic glucose levels. The closed-loop system employed inta-venous glucose sampling
every 15 min and subcutaneous infusion of insulin. For clinical evaluation, the controller was
implemented on ten T1DM patients over a period of 8–10 hr. The authors concluded that
the performance of the adaptive nonlinear MPC was promising for glucose control during
the fasting state. However, the controller was not examined for the post-prandial state.
Advanced control strategies were developed by Parker et al. [6] by utilizing the MPC
framework to deliver exogenous insulin to T1DM patients for maintenance of normoglycemia.
To satisfy the performance requirement of a diabetic patient, an asymmetric objective
function MPC was synthesized to minimize the post-prandial hypoglycemic events. This
technique was compared to another formulation where a prioritized objective function MPC
was synthesized to ensure desired objectives were met according to their level priority. The
asymmetric objective function MPC performed well in avoiding hypoglycemia as compared
to the PO MPC [6].
Out of all these control approaches, MPC is of particular interest as it has many po-
tential advantages. An unconstrained MPC provides optimal insulin delivery by solving
an optimization problem at every sampling time [127]; this optimality is purchased at the
expense of computational effort, in general. One of the major benefits of a MPC controller is
that it can adjust the insulin delivery rate in response to a predicted future hyper- or hypo-
glycemic event much before the actual incident has actually occurs. A MPC controller has
the capability, within reason, to compensate for the dynamics associated with the glucose
sensor and the appearance of insulin in the circulatory system after being released from
the pump [51]. Also, the lower and upper constraints for insulin delivery rate can be
intrinsically formulated in the MPC algorithm [127], which is an important safety issue
for such biomedical systems. Finally, the MPC framework can be tailored to fulfill inherent
requirements of a physiological system by altering the objective function [6, 128].
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1.4 THESIS OVERVIEW
The goal of this dissertation is to incorporate the FFA dynamics and its physiologic interac-
tions with glucose and insulin at rest, as well as during exercise, into the published glucose-
insulin metabolic models [1, 2]. This will be accomplished by synthesizing physiologically-
relevant mathematical expressions (ordinary differential and algebraic equations) calibrated
to experimental data obtained from the literature. Validation of the models will be performed
by comparing model predictions with new data sets procured from the literature.
Chapter 2 concentrates on a minimalistic approach for the synthesis of a lipid-based
(FFA) model. The “minimal” model developed by Bergman [1] was extended to incorporate
the FFA dynamics and the physiological interactions that exist between FFA, glucose, and
insulin. This enables the model to provide valuable insight regarding the disturbance
provided by FFA on plasma glucose level after consumption of a mixed meal, i.e. meal
containing CHO, protein, and fat. Hence, a mixed meal model has also been developed in
Chapter 2 to capture the absorption of CHO, protein, and fat (as FFA) from gut into the
circulatory system. The mixed meal model served as a disturbance to the extended minimal
model.
The exercise effects on glucose and insulin dynamics were addressed in Chapter 3. Here,
once again the Bergman minimal model was modified to incorporate the physiological effects
of mild-to-moderate exercise on plasma glucose and insulin levels. Chapter 4 focuses on a
lower-order model of the insulin-glucose-FFA system which is capable of predicting plasma
insulin, glucose, and FFA concentrations at rest, as well as during exercise. Basically, this
model combines the FFA model from Chapter 2 and the exercise model from Chapter 3 with
relevant physiologically-motivated modifications to form a lower-order composite model.
In Chapter 5, the focus was shifted from developing minimal models to physiologically-
based metabolic models. A physiological multi-compartmental FFA model was synthesized
and coupled with the glucose-insulin model developed by Sorensen [2]. This model is more
complex than the FFA minimal model (developed in Chapter 2), in terms of number of
equations and parameters. The model is capable of predicting insulin, glucose, and FFA
dynamics at the organ/tissue levels.
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One objective of developing accurate metabolic models is to synthesize model-based
insulin delivery systems for maintaining normoglycemia [65, 124]. The current treatment
procedure for T1DM (insulin intensive treatment) is unable to produce tight glucose control
causing prolonged periods of hypoglycemic and/or hyperglycemic events. To minimize
the glucose fluctuations caused due to meal intake, a part of the thesis focused on the
development of a model-based closed-loop insulin delivery system, which have been shown
to produce superior glucose control [126]. Hence, in Chapter 6 the loop was closed by
employing a MPC algorithm based on the metabolic models for meal disturbance rejection
and maintenance of normoglycemia. A summary of all the conclusions of this work, as well
as possible future directions are presented in the penultimate Chapter (Chapter 7).
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2.0 AN EXTENDED “MINIMAL” MODEL OF FFA, GLUCOSE, AND
INSULIN1
One of the most widely used and validated metabolic models of glucose-insulin dynamics is
the so-called “minimal” model developed by Bergman and colleagues [1, 85]. The model was
proposed more than 25 years ago, and over the years it has become a major clinical tool for
analyzing glucose effectiveness (ability of glucose to promote its own disposal) and insulin
sensitivity (ability of insulin to enhance glucose effectiveness) during an IVGTT for diabetic
patients [1, 131]. Prior to the Bergman minimal model [1], only few mathematical models
of metabolism existed [69, 70, 77, 84]. These models were either too simple [69, 70, 84]
or too complex [77], as discussed in Chapter 1. Hence, Bergman et al. hypothesized the
existence of a metabolic model with “optimal” complexity. In other words, a model complex
enough to account for the feedback relationship between insulin and glucose, but simple
enough so that it can be used to evaluate metabolic functions of a diabetic patient with a
simple clinical protocol. Because of these characteristics, the Bergman minimal model [1]
has gained immense popularity in the diabetes treatment and research community, despite
of its shortcomings as pointed by Quon et al. [87] and others [5, 73].
The primary focus of the Bergman minimal model [1] was to describe the feedback rela-
tionship within the glucose-insulin system. The model has proven to be effective particularly
in quantifying the glucose disposal process, by providing a measure of insulin sensitivity and
glucose effectiveness [5]. Such non-invasive measurements of glucose kinetics are essential to
understand the etiology of various forms of impaired glucose tolerances.
Historically, insulin was believed to be the exclusive regulator of blood glucose concentra-
tion, hence, majority of the published mathematical models dealt with the glucose-insulin
1Portions of this chapter have been published in [129] and [130]
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feedback system only. However, in the last three decades researchers have demonstrated
that FFA plays a significant role in altering the glucose-insulin system [132, 133, 8, 134].
Despite FFA being an important metabolite, its incorporation in the metabolic models has
been largely overlooked. This void in the literature has motivated us to synthesize “lipid-
based” metabolic models with a long-term goal of developing model-based controllers for
maintaining normoglycemia by rejecting disturbances from mixed meal ingestion.
FFA in the human plasma pool is mostly composed of long chain carbon molecules
with varying numbers of unsaturated bonds. The primary constituents of this mixture
are: palmitate (16:0), stearate (18:0), oleate (18:1), linolate (18:2), palmitoleate (16:1), and
myristate (14:0) [135]. The nomenclature (A:B) describes the length of the carbon chain,
A, and the number of unsaturated bonds, B. Approximately 80% of the muscle energy is
derived from FFA metabolism when the body is at rest [52, 53]. The main reason for this is
because FFA, when compared with plasma glucose, accounts for a greater energy flux [54];
ATP yield from the breakdown of 16-carbon fatty acid is approximately 2.5 times greater
than glucose per gram [136].
Significant interactions exist between FFA, glucose, and insulin. Randle et al. proposed
that an increased delivery of FFA to muscle tissue enhanced the rate of fat oxidation, which
led to increased acetyl-CoA and resulted in downregulation of the rate-limiting glucose
metabolizing enzymes, thereby attenuating glucose uptake into the tissues [58, 59]. In vitro
studies have also revealed that prolonged hyperglycemia promotes release of stored FFA
from the AT into the the circulatory system [9, 137]. As a first step towards the synthesis
of lipid-based models, the Bergman minimal model [1] was extended to include plasma FFA
dynamics, and its interactions with glucose and insulin, with a primary focus on T1DM
patients. Care was taken to include all the major physiological interactions between glucose,
insulin, and FFA without sacrificing the simplifying approach of the minimal model.
The following Section (2.1) provides a detailed description regarding the structure of the
Bergman minimal model [1]. The structure of the extended minimal model capturing the
dynamics of FFA, glucose, and insulin is introduced in the Section 2.2. Section 2.3 presents
a detailed description of the parameter estimation technique and goodness of fit. Results
of the extended minimal model along with structural justifications are provided in Section
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2.4. One of the objectives in synthesizing the extended minimal model is to evaluate the
effects of mixed meal ingestion on closed-loop glucose control. Hence, in Section 2.5 a mixed
meal model was developed to capture the gut absorption of glucose, protein, and FFA from a
mixed meal into the circulatory system. The outputs of the meal model served as disturbance
inputs to the extended minimal model. Finally, the chapter ends with a brief summary 2.6.
2.1 BERGMAN MINIMAL MODEL
In order to quantify the insulin sensitivity and glucose effectiveness of a T1DM patient
during an IVGTT, Bergman et al. [1] developed a three compartment mathematical model,
as shown in Figure 2.1. Compartment I(t), X(t), and G(t) represent the plasma insulin
(µU
ml
), remote insulin (µU
ml
), and plasma glucose concentration (mg
dl
), respectively. The model
as written assumes that all the necessary insulin is infused exogenously (u1(t)), thereby
modeling the insulin-dependent diabetic patient. A portion of the infused insulin enters into
the remote compartment, X(t), from the circulatory system, I(t). The unaccessible remote
insulin (X(t)) actively takes part in promoting uptake of plasma glucose (G(t)) into the liver
and peripheral (extra-hepatic) tissues.
The Bergman minimal model, adapted from [1], is mathematically given by:
dI(t)
dt
= −nI(t) + p5u1(t); I(0) = Ib = p4
n
u1b (2.1)
dX(t)
dt
= −p2X(t) + p3[I(t)− Ib]; X(0) = 0 (2.2)
dG(t)
dt
= −p1G(t)− p4X(t)G(t) + p1Gb + u2(t)
V olG
; G(0) = Gb (2.3)
Here, Ib and Gb are the basal plasma insulin and glucose concentrations, respectively. The
exogenous insulin infusion rate to maintain Ib is represented by u1b (mU/min). The rate
constant n represents clearance of plasma insulin. Parameter p5 represents the inverse of
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Figure 2.1: Bergman minimal model of insulin and glucose dynamics, adapted from [1]
insulin distribution space. The rates of appearance of insulin in, and disappearance of remote
insulin from, the remote insulin compartment (X(t)) are governed by the parameters p2 and
p3, respectively. Dietary absorption or external infusion of glucose is indicated by u2(t), and
the glucose distribution space is indicated by V olG. Parameter p1 represents the rate at
which glucose is removed from the plasma space into the liver (mostly for storage) or into
the periphery (mostly for oxidation) independent of the influence of insulin. Glucose uptake
under the influence of insulin is governed by the parameter p4. Parameter values for the
Bergman minimal model [1] are provided in Table 2.1.
2.2 EXTENDED MINIMAL MODEL
The Bergman minimal model [1] was extended to incorporate FFA dynamics and its inter-
action with glucose and insulin. Modifications were made to the original model structure
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Table 2.1: Parameters of the Bergman minimal model, from [1]
Parameter Value Units Parameter Value Units
p1 0.068 1min p5 0.000568
1
mL
p2 0.037 1min n 0.142
1
min
p3 0.000012 1min Gb 98.0
mg
dL
p4 1.0 mLmin·µU V olG 117.0 dL
by adding extra compartments, as shown in Figure 2.2. Compartment F (t) represents the
plasma FFA concentration. Similar to compartment X(t) in the Bergman minimal model,
an unaccessible compartment Y (t) was added to the FFA model representing the remote
insulin concentration inhibiting FFA release from the AT into the circulatory system. An
additional first order filter, compartment Z(t), was added to the model to represent the
remote FFA concentration affecting glucose uptake dynamics.
Similar to the Bergman minimal model, the extended minimal model assumes that no
insulin is produced endogenously. Equations, (2.1) and (2.2) from the Bergman minimal
model (Section 2.1) are used to describe the dynamics of plasma insulin and remote insulin
concentration for the extended minimal model, respectively.
The plasma glucose dynamics are represented by the following equation:
dG(t)
dt
= −p1G(t)− p4X(t)G(t) + p6G(t)Z(t) + p1Gb − p6GbZb + u2(t)
V olG
(2.4)
Parameters p1, p4, Gb, V olG and u2(t) are same as in equation (2.3). The additional impairing
action of plasma FFA on glucose uptake is represented by the parameter p6.
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Figure 2.2: Extended minimal model of insulin, glucose, and free fatty acid dynamics
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The release of stored FFA into the circulatory system, which is known as lipolysis, is
inhibited by the insulin in the unaccessible compartment Y (t). The remote insulin dynamics
for FFA (Y (t)) are represented as follows:
dY (t)
dt
= −pF2Y (t) + pF3[I(t)− Ib] (2.5)
The rate of disappearance of insulin from this remote insulin compartment is governed by
the parameter pF2, and the rate at which plasma insulin enters into the remote insulin
compartment is governed by the parameter pF3.
Plasma FFA is taken up by the periphery (for oxidation) and by the AT (for storage).
Prolonged hyperglycemia, i.e., high glucose levels, induces lipolysis, thereby promoting
release of FFA from the AT into the circulatory system. The dynamical equation representing
plasma FFA is given by:
dF (t)
dt
= −p7F (t)− p8Y (t)F (t) + p9(G)F (t)G(t) + p7Fb − p9(G)FbGb + u3(t)
V olF
(2.6)
Here, the basal FFA concentration and FFA distribution space are given by Fb and V olF ,
respectively. Dietary FFA absorption or external lipid infusion is represented by u3(t). The
combined rate at which FFA is taken up by the AT and periphery without the influence
of insulin is governed by the parameter p7. Similarly, parameter p8 represents the rate
of disappearance of plasma FFA under the influence of insulin, or, in other words, the
anti-lipolytic effect of insulin. The lipolytic effect of plasma glucose concentration level is
indicated by the parameter p9(G), which is a function of glucose concentration, as follows:
p9(G(t)) = ae
−bG(t) (2.7)
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FFA from the circulatory system enters in the unaccessible compartment Z(t), which affects
glucose uptake in the liver and peripheral tissues. The remote FFA dynamics (Z(t)) are
represented by:
dZ(t)
dt
= −k2[Z(t)− Zb] + k1[F (t)− Fb] (2.8)
Here, Zb represents the basal remote FFA concentration. The rate of FFA concentration
disappearance from, and appearance in compartment Z(t) are governed by the parameters
k2 and k1, respectively.
2.3 PARAMETER ESTIMATION AND GOODNESS OF FIT TECHNIQUE
The parameters for the extended model were estimated using the nonlinear ‘least square’
technique as described by Carson and Cobelli [138]. The normalized residual is obtained as:
χ2 ≡
N∑
i=1
[
yi − y(ti, θ1...θM)
σi
]2
(2.9)
Here, yi is the measured data at time ti, which has a standard deviation of σi. The model
prediction is given by y(ti, θ1...θM), where θi represent model parameters. Equation (2.9) is
the objective of a weighted minimization having ( 1
σ
)2 as the weights and θi as the degrees
of freedom. N is the number of data points, and M is the total number of estimated model
parameters.
The parameters n, p1, p2, p3, p4, p5, and n, were fixed to the values in Table 2.1. First, the
rate constants representing plasma FFA concentration with (p8, pF2, and pF3) and without
(p7) the influence of insulin were estimated in order to fit published data [4]. Next, the
lipolytic effect of glucose (p9(G)) was estimated using data from the literature [9]. Finally,
the parameters representing the effect of plasma FFA on glucose uptake (p6) and the remote
FFA concentration (k1 and k2) were estimated from published data [8]. All the estimated
parameter values of the extended model are given in Table 2.2.
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Table 2.2: Parameters of the extended minimal model, in addition to those in Table 2.1. 95%
confidence interval (CI) bounds were calculated by using the nlparci.m MATLAB function.
Parameter Value Lower 95% CI Upper 95% CI Units
p6 0.00006 4.5e− 5 7.5e− 5 L/(min ·µ mol)
p7 0.03 0.026 0.033 1/min
p8 4.5 3.86 5.14 mL/(min ·µ U)
a 0.21e− 3 0.2079e− 3 0.2121e− 3 dL/(min · mg)
b 0.0055 0.00536 0.00563 dL/mg
k1 0.02 0.0158 0.0242 1/min
k2 0.03 0.0231 0.0369 1/min
pF2 0.17 0.1438 0.1961 1/min
pF3 0.00001 8.577e− 6 1.1423e− 5 1/min
Fb 380 – – µ mol/L
V olF 11.7 – – L
The quality of the model fits was assessed by measuring the statistical correlation between
data and model predictions (R2). R2 can be defined as:
R2 = 1− χ
2
SST
(2.10)
Here, χ2 is the weighted sum squared error from equation (2.9), and SST is the weighted
sum of squares about the data mean. SST can be calculated using the following equation:
SST ≡
N∑
i=1
[
yi − y¯
σi
]2
(2.11)
Here, N is the number of data points and y¯ is the mean of all the data points. R2 takes
values between 0 and 1, with a value closer to 1 indicating a better fit.
Akaike’s Information Criterion (AIC) [139] was employed to establish a statistical com-
parison between the extended model with and without the remote insulin compartment,
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Y (t), and remote fatty acid compartment, Z(t), as described below in Section 2.4.5. The
value of AIC can be calculated from the following equation:
AIC = (N) ln
(
χ2
N
)
+ 2(M) (2.12)
Here, M is the number of model parameters. The criterion may be minimized over choices
of M to form a tradeoff between the fit of the model, which lowers the sum squared error
(χ2), and the model’s complexity, which is quantitated by M . Hence, AIC not only rewards
goodness of fit, it discourages over-parameterizing. When comparing two models having
different values of M , it is always desirable to prefer the model that has a lower AIC value.
However, in settings where the sample size (N) is small, AIC tends to favor inappropriately
the high-dimensional candidate models [140].
2.4 RESULTS OF THE EXTENDED MINIMAL MODEL
2.4.1 Antilipolytic Effect of Insulin
FFA movement across AT capillary walls is bi-directional, unlike any other tissue [54]. In
other words, plasma FFA is taken up by the AT for storage purposes, and at the same time,
stored FFA from AT is released back into the circulatory system whenever necessary. Insulin
plays a major role in altering the balance between lipid storage and release in AT, by acting
as a strong antilipolytic agent. Basically, insulin inhibits the release of stored FFA into the
circulatory system. This antilipolytic effect of insulin was well demonstrated by an in vivo
study performed by Howard et al. [4].
In the experiment, an euglycemic hyperinsulinemic clamp was employed in healthy
subjects, as shown in Figure 2.3. Insulin was infused at three different rates in order to
maintain the plasma insulin concentration at 20, 30, and 100 µU
ml
[4]. The plasma FFA
concentration decreased significantly below the basal state in response to the insulin clamps.
Parameters p7, p8, pF2, and pF3 of equations (2.5) and (2.6) were adjusted in order to
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Figure 2.3: Predicted (solid lines) and published (cross) [4] (µ ± σ) plasma FFA
concentration in response to euglycemic hyperinsulinemic clamp. Plasma insulin
concentration was maintained at 20 µU
ml
[R2 = 0.77] (top), 30 µU
ml
[R2 = 0.94] (middle),
100 µU
ml
[R2 = 0.98] (bottom)
minimize equation (2.9) using the published data from [4], as described in Section 2.3. The
resulting model predictions of plasma FFA concentration are consistent with the published
data, as shown in Figure 2.3. Estimated parameter values are provided in Table 2.2.
2.4.2 Lipolytic Effect of Hyperglycemia
Prolonged hyperglycemia enhances lipolysis in adipocytes [9, 137]. The rate-limiting step of
adipocyte lipolysis is due to the hydrolysis of stored triglycerides by hormone-sensitive lipase
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Figure 2.4: Predicted values of parameter p9 in response to increasing glucose clamps for 90
min. [R2 = 1]
(HSL) enzyme [137]. Hyperglycemia induces activation of HSL, which in turn enhances
lipolysis [137]. In an in vitro study by Szkudelski et al., isolated rat adipocytes were
treated with increasing glucose concentration (36, 144, and 288 mg
dl
) [9]. After 90 min of
incubation the increment in lipolysis was measured by analyzing the total glycerol released
in the incubating medium (recorded as, 342 ± 7, 445 ± 5, and 506 ± 12 nmol
ml−106cells−90min ,
respectively). In order to estimate the value of parameter p9, the glucose concentration of
the FFA minimal model during a 90 min simulation was held constant at 36, 144, or 288
mg
dl
, and p9 was adjusted to acquire the respective increment in FFA concentration. The
variation of p9 with increasing glucose concentration clamps is shown in Figure 2.4. The
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relationship of p9 with G is provided in equation (2.7) and Table 2.2. In a separate in vitro
study, Moussalli et al. [141] treated isolated human adipocytes with 36 mg
dl
of glucose. The
glycerol released from the human AT (331 ± 15 nmol
ml−106cells−90min) was similar to that of the
rat AT (342 ± 7 nmol
ml−106cells−90min) treated at the same glucose concentration in [9]. Due to the
comparable glycerol release rates, the lipolytic effects of glucose on rat and human adipocytes
were treated as equivalent for the present study. The validation of this assumption at higher
glucose concentrations requires additional experimental data.
2.4.3 Impairing Effect of FFA on Glucose Uptake Rate
Studies as early as 1963 [58] had revealed that high plasma FFA concentration impairs net
glucose uptake rate. The postulated mechanism is that increased FFA oxidation causes
accumulation of glucose-6-phosphate in the muscle and AT, which would inhibit hexokinase
II expression (an important enzyme required for glycolysis) resulting in decreased glucose
uptake [142]. To demonstrate this impairing effect of elevated FFA concentration, Thiebaud
et al. [8] performed an in vivo experiment with 25 healthy subjects where plasma glucose
and insulin concentrations were maintained at 93 ± 2 mg
dl
and 60 ± 4 µU
ml
, respectively
(euglycemic-hyperinsulinemic condition). Intralipid was infused at low and high rates to
achieve plasma FFA concentrations of 340 ± 13 and 650 ± 10 µmol
l
, respectively. It can be
observed from Figure 2.5 that the total glucose uptake rate increased to a maximum level
of 3.53 ± 0.012 mg
dl·min for the control (no intralipid infusion) as soon as the insulin clamps
were applied. Furthermore, glucose uptake rate was lowest (2.09 ± 0.013 mg
dl·min) when the
intralipid infusion rate was highest. The net glucose uptake rate, GUP (
mg
dl−min), obtained
from equation (2.4) can be written as;
GUP (t) = −p1G(t)− p4X(t)G(t) + p6G(t)Z(t) + p1Gb − p6GbZb (2.13)
Parameters p6, k1, and k2 were estimated in order to fit the data [8] (see Table 2.2 for
the estimated parameter values). While the model slightly over-predicts GUP at the 20
min time point, the remainder of the model prediction is consistent with the experimental
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data (Figure 2.5). Improving the model fit is possible through the inclusion of additional
dynamics; however, this is at the expense of model complexity and an increased number of
parameters, thereby decreasing confidence in parameter estimates.
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Figure 2.5: Predicted and published (µ ± σ) glucose uptake rate in response to no intralipid
infusion - control [R2 = 0.9771] (top); low intralipid infusion rate [R2 = 0.9528] (middle);
and high intralipid infusion rate [R2 = 0.9115] (bottom)
2.4.4 Model Validation
2.4.4.1 Anti-lipolytic action of insulin: In order to verify the anti-lipolytic action
of insulin in the model, an euglycemic hyperinsulinemic clamp simulation was performed.
Insulin concentration was elevated to 100 µU
ml
, thereby matching the conditions of a study
on healthy subjects by Coon et al [143]. The conditions employed in the experimental
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study [143] are identical to that of Figure 2.3 (bottom). After allowing the simulated initial
condition to match the study data (see Figure 2.6), the insulin clamp led to a decrease in
simulated plasma FFA concentration below its basal level. The model predictions (without
parameter value changes) are consistent with this data set [143].
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Figure 2.6: Model simulation validation versus published data (µ ± σ) of plasma FFA
concentration in response to euglycemic hyperinsulinemic clamp (100 µU
ml
) [R2 = 0.901]
2.4.4.2 Intra-venous glucose tolerance test: In an IVGTT simulation, the model
was subjected to a bolus of glucose, as shown in Figure 2.7. Exogenous insulin infusion (bolus
at t = 0, then constant infusion at 24 mU
min
) yielded a decline in plasma glucose concentration
until it returned to its basal level of 87 ± 6 mg
dl
. Comparison between the model predictions
of plasma glucose and insulin concentrations with published data [1] are shown in Figure 2.7.
It can be observed that the simulated results are consistent with the published data, which
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is to be expected as the glucose-insulin dynamics of the extended model are essentially those
of Bergman et al. [1], except for modifications to equation (2.3), as shown in (2.4).
In response to the IVGTT, the simulated plasma FFA concentration declined significantly
below its basal level. Comparison between the model prediction and published data of FFA
concentration in response to an IVGTT [144] are shown in Figure 2.8. It can be observed
that the model predictions are within the measurement error.
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Figure 2.7: Model simulation validation versus published data (µ ± σ) of plasma insulin [R2
= 0.974] (top) and glucose [R2 = 0.98] (bottom) concentration dynamics in response to an
intra-venous glucose tolerance test
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Figure 2.8: Model simulation validation versus published data (µ ± σ) of FFA concentration
dynamics in response to an intra-venous glucose tolerance test [R2 = 0.8756]
2.4.5 Model Structure Justification
While designing an empirical mathematical model, it is generally preferable to decrease the
complexity of the model by reducing the number of parameters. Simultaneously, it is equally
important to capture the observed dynamics of the system, i.e, to have high model accuracy.
The trade-off between the fit of the model and model complexity, as measured by the number
of parameters, can be quantified by using the AIC as discussed in Section 2.3.
A remote insulin compartment Y (t) was added to the model to slow down the insulin-
mediated FFA uptake from the circulatory system into the AT. This addition was necessary
to capture the dynamic response observed in the published data [4]. The extended model
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prediction of FFA dynamics with and without the compartment Y (t) is shown in Figure 2.9.
By omitting Y (t) from the extended model structure, equation (2.6) becomes:
dF (t)
dt
= −p7F (t)− p8X(t)F (t) + p9(G)F (t)G(t) + p7Fb
−p9(G(t))FbGb + u3(t)
V olF
(2.14)
AIC [139] was employed to establish a statistical comparison between the extended model
with and without the Y (t) compartment, as shown in Table 2.3. As it can be observed, the
model with the Y (t) compartment has a lower AIC value and hence is more desirable.
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Figure 2.9: Extended model prediction versus data (cross) [4] (µ ± σ) of plasma FFA
concentration in response to euglycemic hyperinsulinemic clamp (100 µU
ml
) with (solid line)
and without (dashed line) the Y (t) sub-compartment
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Similarly, to slow down the impairing effect of FFA on glucose uptake, a remote compart-
ment Z(t) was added to the extended model based on the published data [8]. The extended
model prediction of glucose uptake rate with (solid line) and without (dashed line) the Z(t)
compartment is shown in Figure 2.10. By excluding Z(t) from the extended model structure,
equation (2.4) changes to:
dG(t)
dt
= −p1G(t)− p4X(t)G(t) + p6G(t)F (t) + p1Gb − p6GbFb + u2(t)
V olG
(2.15)
Hence, the net glucose uptake rate, equation (2.13), can be written as:
GUP (t) = −p1G(t)− p4X(t)G(t) + p6G(t)F (t) + p1Gb − p6GbFb (2.16)
AIC comparison of the extended model with and without the Z(t) sub-compartment is also in
Table 2.3. Again, it can be observed that the AIC value favors the extended model having the
Z(t) compartment. However, Figure 2.10 clearly reveals that the model overpredicts glucose
uptake rate at the 20 min time point. This can be rectified by incorporating additional FFA
filter equations at the cost of model complexity. An AIC comparison was used to quantitate
the worthiness of an extra FFA filter compartment in order to achieve better GUP (t) fit,
especially at the 20 min point. Hence the net glucose uptake rate (equation 2.13) with a
second FFA filter (Z2(t)) can be re-written as:
GUP (t) = −p1G(t)− p4X(t)G(t) + p6G(t)Z2(t) + p1Gb − p6GbZ2b (2.17)
dZ(t)
dt
= −k2[Z(t)− Zb] + k1[F (t)− Fb] (2.18)
dZ2(t)
dt
= k3(Z(t)− Z2(t)) (2.19)
The additional unmeasurable variable, Z2(t), adds an extra lag in the dynamics of plasma
FFA effects on GUP (t), as shown in Figure 2.10 (dotted line). At basal steady state, Z2b is
equal to Zb.
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Table 2.3: Calculated AIC values of the extended minimal model with and without the Y (t)
and Z(t) sub-compartments
AIC Extended Minimal Model
without with
FFA dynamics Eq. (2.14) Eq. (2.6)
(Y (t)) 22.7782 14.8778
Glucose uptake dynamics Eq. (2.16) Eq. (2.13)
(Z(t)) 36.5598 33.2001
Glucose uptake dynamics Eq. (2.13) Eq. (2.19)
(Z2(t)) 33.2001 32.90
Table 2.3 indicates that two FFA filters in series, Z(t) and Z2(t) (AIC = 32.90), only
marginally improves the model fit as compared to only one filter, Z(t) (AIC = 33.2001).
Hence, it is probably not worth incorporating the added complexity in terms of the new
parameter (k3).
In order to justify the selection of an exponential function to capture the effect of glucose
on parameter p9(G(t)) (equation (2.7)) as opposed to a linear fit, an AIC evaluation was per-
formed. A linear expression capturing the glucose effects on p9(G(t)) can be mathematically
written as:
p9(G(t)) = −5.232× 10−7G(t) + 1.869× 10−4 (2.20)
The dynamics of p9(G(t)) as a function of glucose obtained from the equations (2.7) and
(2.20) are indicated in Figure 2.11. It is clear from the data that higher values of glucose
will generate negative values for parameter p9(G(t)) in case of the equation (2.20), thereby
making the system unstable; a phenomenon which will be absent in case of equation (2.7).
Moreover, the calculated AIC value for equation (2.7) (−54.509) is much lower than that of
equation (2.20) (−25.461).
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Figure 2.10: Extended model prediction versus data (cross) [8] (µ ± σ) of plasma glucose
uptake rate in response to low intralipid infusion rate (0.5 ml
min
) with only Z(t) sub-
compartment (solid line), with Z(t) and Z2(t) sub-compartments (dotted line), and without
any filter sub-compartment (Z(t) or Z2(t)) (dashed line) sub-compartment
2.5 MIXED MEAL MODELING
A diabetic patient consume meals at least three times a day causing substantial fluctuations
of the plasma glucose and FFA levels. One of the key objective of developing the extended
minimal model was to evaluate the physiological response of the major energy-providing
metabolites to disturbances from mixed meal ingestion. Hence, a mixed meal model was
developed to capture the absorption of CHO (as glucose), protein, and fat (as FFA) from
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Figure 2.11: Published data [9] (cross) versus predicted values of parameter p9(G(t)) from
equation (2.7) (solid line) and equation (2.20) (dashed line) in response to increasing glucose
clamps for 90 min
the gut into the circulatory system. The meal model outputs served as disturbance inputs
to the extended minimal model.
2.5.1 Mixed Meal Modeling
A mixed meal usually consist of all the three major nutrients: glucose, protein, and fat. After
ingestion, the stomach converts the meal contents to chyme via a combination of mechanical
and chemical processes. The partly digested meal then empties into the intestine for further
digestion and absorption into the circulatory system. The extended minimal model accepts
50
meal-induced disturbance in the form of glucose (u2(t)), as well as, FFA (u3(t)) absorption
from the gut into the circulatory system. The meal models proposed in the literature typically
focus on the gut absorption of glucose only [145, 146]. Thus, a mixed meal model describing
CHO, protein, and FFA absorption is needed to test the accuracy of the extended minimal
model. The present study employs the Lehmann and Deutsch meal model [145] structure to
explicitly account for protein, fat, and CHO, absorption from the gut into the circulatory
system.
The model assumes that the gastric emptying rate (Gemp) has a trapezoidal shape
(adapted from [145]), which can be mathematically written as:
Gemp(t) =

Vmax
Tasc
t t < Tasc
Vmax Tasc < t ≤ Tasc + Tmax
Vmax − VmaxTdes (t− Tasc − Tmax) Tasc + Tmax ≤ t < Tmax + Tasc + Tdes
0 otherwise
(2.21)
Vmax =
2Ntot
Tasc + 2Tmax + Tdes
(2.22)
Here, Vmax is the maximum rate of gastric emptying. The duration for which Gemp is
maximum (Vmax) and constant is given by Tmax (min). Tasc (min) and Tdes (min) are the
respective ascending and descending periods of Gemp. Total nutrient consumed is given by
Ntot (g). The gastric emptying function is an input to the model of intestinal absorption.
Nutrient absorption from the gut into the circulatory system is given by the following
differential equations:
N˙G(t) = xGGemp(t)− kGNG(t) (2.23)
N˙P (t) = xPGemp(t)− kPNP (t) (2.24)
N˙F (t) = xFGemp(t)− kFNF (t) (2.25)
Here, NG(t), NP (t), and NF (t) are the amount of digestible glucose, protein and FFA in the
gut, respectively. The mass fraction of digestible glucose, protein and FFA in the meal are
given by xG, xP , and xF , respectively. Similarly, the intestinal absorption rate constant for
digestible glucose, protein, and FFA are given by kG, kP , and kF , respectively. The model
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assumes that 60% of the protein is converted to glucose [147]. Hence, the rates of appearance
of glucose and FFA in the circulatory system, i.e., u2(t) from equation (2.4) and u3(t) from
equation (2.6), are given by:
u2(t) = kGNG(t) + 0.6[kPNP (t)] (2.26)
u3(t) = kFNF (t) (2.27)
The second part of the right hand side (RHS) of equation (2.26) enabled the model to capture
the effects of protein on plasma glucose and FFA concentrations after ingestion of a mixed
meal. Graphical representations of the Gemp of the total meal, and rate of appearance of the
three nutrients in the circulatory system are given in Figure 2.12, based on the simulation
conditions described in the next section (Section 2.5.2).
2.5.2 Mixed Meal Tolerance Test (MTT)
A mixed meal (CHO = 70 g, protein = 18 g, and FFA = 20 g) was consumed by healthy
subjects in 10 min in an MTT study by Owens et al. [10]. Blood samples were taken at
various times after the meal consumption to measure glucose and insulin concentrations.
To investigate MTT response in simulation, the mixed meal model was coupled with the
extended minimal model from Section 2.2. Since insulin concentration measurements were
available, the insulin dynamics, equation (2.1) from Section 2.1, were replaced by a piecewise
linear approximation of the normal subject’s insulin profile (Figure 2.13, top). Parameters
Tmax, kG, kP , and kF of the mixed meal model were estimated using the nonlinear least
square technique (Section 2.3) to fit the glucose profile obtained from [10] (as shown in
Figure 2.13, bottom). Parameters of the FFA minimal model were directly obtained from
Table 2.2. The parameter values of the meal model are Tmax = 35 min, kG = 0.022 min
−1,
kP = 0.015 min
−1, and kF = 0.0097 min−1. Vmax calculated from equation (2.22) is 2.2
g
min
. This is similar in value to other maximum Gemp rates reported in the literature using
similar meal sizes [148]. Literature data also suggested that the time to reach Vmax for a
medium size mixed meal, such as the one used here, is typically 10 - 15 min [149]. Based
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on that, the Tasc and Tdes values were fixed at 10 min. It can be observed that the meal
model, when coupled to the FFA minimal model, yielded glucose concentration predictions
consistent with experimental data (see Figure 2.13). The slight underprediction of glucose
in the first 50 min could be due to differences in dynamics between the patients modeled in
the FFA minimal model and the patient responses in [10]. More accurate glucose predictions
could be achieved by reducing Tasc to a lower value; however this would violate generally
accepted physiological limits on Tasc [149].
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Figure 2.12: Model simulation of total meal gastric emptying rate (top); glucose (G)
appearance, protein (P) appearance, and G plus glucose derived from protein (G(P))
appearance (middle); and FFA appearance (bottom), in response to 108 g mixed meal
tolerance test.
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Figure 2.13: Insulin concentration data from normal subjects [10] (µ ± σ) and piecewise
linear approximation (top), model simulation versus published data [10] (µ ± σ) of plasma
glucose concentration dynamics in response to mixed meal tolerance test (bottom).
2.6 SUMMARY
Bergman’s minimal model [1] was extended to include FFA dynamics. Differential equations
representing FFA dynamics, as well as remote insulin and fatty acid concentrations, were
added to the minimal model. This model successfully captured plasma FFA concentration
behavior, plasma glucose and insulin concentrations, and the physiological interactions that
exist between these species. The addition of parameter p6 in equation (2.4) made it possible
to capture the impairing effect of FFA on net glucose uptake. The model also successfully
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predicted the anti-lipolytic effect of insulin. This was possible due to the addition of
parameter p8 in equation (2.6).
By incorporating the FFA dynamics and its effect on plasma glucose, the ability of
the model to predict glucose concentration dynamics after a mixed meal (meal containing
carbohydrates (CHO) and fat) has been increased. With the given structure, the extended
model is capable of predicting the fluctuations in FFA level due to meal intake. This
broadens the scope of further investigation regarding plasma FFA disturbance effects on
glucose dynamics and the glucoregulatory action of insulin. Also, when coupled with a
mixed meal model, the extended model can be utilized to determine the different dynamics
of glucose and FFA absorption and distribution via the circulatory system when ingested in
various proportions.
With the long term goal of synthesizing an automatic closed-loop insulin delivery system
comprised of a continuous glucose measuring device, an insulin pump, and a model-based
control algorithm, it is necessary to develop accurate models that characterize expected
physiological conditions [50]. Hence, this more complete model of the major energy providing
metabolic substrates provides the control community with a more detailed model for use in
control design. Also, due to the easily identifiable parameters, the model could be used in
an adaptive control environment, thus facilitating patient specificity. The extended minimal
model could be considered as an important step towards the development of an externally
wearable pancreas which will be capable of maintaining normoglycemia by rejecting mixed
meal (CHO and fat) disturbances. However, validation of the extended model requires
additional experimental data. For example, in vivo studies involving human adipocytes are
needed to verify the lipolytic effect of hyperglycemia.
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3.0 “MINIMAL” MODEL WITH EXERCISE EFFECTS ON GLUCOSE
AND INSULIN1
Exercise induces several fundamental metabolic changes in the body [62]. Elevated physical
activity promotes a drop in plasma insulin concentration from its basal level [151]. This
suppression of insulin level could be necessary to enhance hepatic glucose production and
lipolysis of free fatty acids from AT to meet the augmented energy uptake by the working
tissues [12]. It has been shown by Seals et al. (1984) that exercise reduces insulin secretion
[152]. In addition, a more recent study [153] has demonstrated that exercise augments
clearance of insulin from the plasma in both healthy as well as T1DM patients. A study
performed by Wolfe et al. (1986) [12] has revealed that clamping insulin at its basal level
during exercise increased the rate of glucose uptake above normal, and the rate of glucose
production was not sufficient to fully compensate the elevated muscle glucose uptake rate.
An increase in exercise intensity also amplifies glucose uptake by the working tissues
[154]. In order to maintain plasma glucose homeostasis, hepatic glucose release increases
with increasing work intensity [155]. During mild-to-moderate exercise (also known as the
aerobic exercise range, i.e., when the body utilizes oxygen to breakdown glucose [156]),
the increased splanchnic glucose release is primarily due to by elevated hepatic glycogenol-
ysis. Glycogenolysis is a metabolic process in which stored glycogen (a polymeric form
of glucose) is catabolized into glucose. As the duration of exercise increases, the rate of
hepatic glycogenolysis diminishes due to the limited supply of liver glycogen stores [15].
Simultaneously, hepatic gluconeogenesis is accelerated during elevated physical work [13].
Gluconeogenesis is the generation of glucose from non-sugar carbon substrates like pyruvate,
lactate, glycerol, and glucogenic amino acids. However, the rate of glucose produced via
1Portions of this chapter have been published in [150]
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liver gluconeogenesis does not fully compensate for the decrease in glucose release by liver
glycogenolysis (the former is a slower process), thereby resulting in a net decrease in hepatic
glucose release during prolonged exercise [157]. Due to this imbalance between glucose uptake
and hepatic glucose release, the plasma glucose concentration declines, and hypoglycemia
occurs [13, 15]. As an added complication in glucose regulation, studies have shown that
liver glycogen content declines more rapidly with increasing exercise intensity [15, 11].
During the recovery period after short term exercise, both the elevated glucose uptake
rate by working muscles and the rate of hepatic glucose release, decline gradually to their
respective basal levels. On the other hand, glucose fluxes after prolonged exercise are quite
different. Due to the substantial depletion of liver glycogen stores during prolonged exercise,
the rate of glycogenolysis is significantly suppressed leading to a net decrease in hepatic
glucose release rate. During the recovery period, the elevated muscle glucose uptake rate
gradually declines to the basal level. The already suppressed hepatic glucose release rate also
declines back to its basal level [157]. In vivo studies have revealed a significant increment in
hepatic lactate consumption immediately after prolonged exercise, and this lactate serves as
a substrate for the repletion of the liver glycogen stores [158, 15].
The existing control-relevant metabolic models present in the literature fail to consider
most of the above-mentioned physiologic effects of exercise on glucose and insulin dynamics.
With the ultimate goal of developing a closed-loop model-based insulin delivery system,
it is essential to synthesize lower-order metabolic models which are capable of predicting
fluctuations in glucose dynamics during exercise. Open-loop simulations from such models
can also give prior intimation to T1DM patients regarding the time-span during which
exercise could be performed at a given intensity without reaching hypoglycemia.
In this chapter, the various effects of exercise were incorporated into the classical Bergman
minimal model [1] (described in Section 2.1) in order to capture the plasma glucose and
insulin dynamics during, as well as after, periods of mild-to-moderate exercise. In Section
3.1, a technique to quantitate exercise intensity is presented. In the following Section (3.2),
a detailed description regarding the structure of the exercise minimal model is introduced.
The data fitting results along with model validation simulations are presented in Section 3.3.
Finally, Section (3.4) explores model structure justification by employing AIC technique.
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3.1 QUANTITATING EXERCISE INTENSITY
The maximum rate of oxygen consumption for an individual during exercise is given by
V Omax2 (
ml
kg−min). Oxygen consumption is approximately linearly proportional to energy
expenditure [159]. Hence, it is possible to indirectly measure the maximum capacity of an
individual for aerobic work by measuring oxygen consumption. When physical activity is
expressed as a percentage of V Omax2 (PV O
max
2 ), exercise effects may be compared between
individuals of the same sex and similar body weight at the same PV Omax2 . The average
PV Omax2 for a person in the basal state is 8% [151]. Ahlborg et al. [63] demonstrated that
PV Omax2 increases rapidly at the onset of exercise, reaches its ultimate value within 5-6 min
and remains constant for the duration of exercise. The exercise model developed in this
study uses PV Omax2 to quantify exercise intensity. The ordinary differential equation for
PV Omax2 is given by:
dPV Omax2 (t)
dt
= −0.8PV Omax2 (t) + 0.8uEx(t); PV Omax2 (0) = 0 (3.1)
Here, PV Omax2 (t) is the exercise level above basal as experienced by the individual, and
uEx(t) is the ultimate exercise intensity above the basal level – an input to the model with
a maximum span of 0 to 92%. However, for the proposed model the range of uEx(t) is valid
only within the mild-to-moderate exercise level (≤ 68% PV Omax2 (t)). The parameter value
of 0.8 ( 1
min
) was selected to achieve a PV Omax2 (t) settling time of approximately 5 min,
consistant with the observations in [63].
3.2 EXERCISE MINIMAL MODEL
The glucose and insulin dynamics adapted from the Bergman minimal model [1], when
coupled with the major mild-to-moderate exercise effects, are mathematically given by:
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dI(t)
dt
= −nI(t)− Ie(t) + p5u1(t) (3.2)
dX(t)
dt
= −p2X(t) + p3[I(t)− Ib]
dG(t)
dt
= −p1[G(t)−Gb]− p4X(t)G(t) + W
V olG
[Gprod(t)−Ggly(t)]
− W
V olG
Gup(t) +
u2(t)
V olG
(3.3)
dGprod(t)
dt
= a1PV O
max
2 (t)− a2Gprod(t) (3.4)
dGup(t)
dt
= a3PV O
max
2 (t)− a4Gup(t) (3.5)
dIe(t)
dt
= a5PV O
max
2 (t)− a6Ie(t) (3.6)
The insulin dynamics, equation (3.2), have been modified from the Bergman minimal model,
equation (2.1), by adding the final term. Here, Ie(t) (
µU
ml−min) is the rate of insulin removal
from the circulatory system due to exercise-induced physiological changes. The plasma
glucose dynamics, equation (3.3), differ from equation (2.3) of the Bergman minimal model
by addition of the following terms: W
V olG
[Gprod(t) − Ggly(t)] − WV olGGup(t). Variables Gup(t)
( mg
kg−min) and Gprod(t) (
mg
kg−min) represent the rates of glucose uptake and hepatic glucose
production induced by exercise, respectively. W (kg) represents the weight of the subject.
Variable Ggly(t) (
mg
kg−min) represents the decline of glycogenolysis rate during prolonged ex-
ercise due to depletion of liver glycogen stores. The dynamics of hepatic glucose production,
glucose uptake, and plasma insulin removal induced by exercise are represented in equations
(3.4), (3.5), and (3.6), respectively. Initial conditions of the above ODEs are listed in Table
3.1.
The rate of glycogenolysis (Ggly(t)) starts to decrease when the energy expenditure
exceeds a critical threshold value (ATH) which is a function of exercise intensity and duration.
ATH can be mathematically represented as:
ATH = uEx(t)tgly(uEx(t)) (3.7)
Here, tgly(uEx(t)) is the duration of exercise that can be performed at intensity uEx(t) before
the rate of hepatic glycogenolysis starts to decrease. The rate of hepatic glycogen depletion
increases with increasing exercise intensity [15, 11]. Hence, tgly(uEx(t)) is a function of
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Table 3.1: Initial condition of the equations belonging to the exercise minimal model
Variable Value Units
I(0) p5n u1b
muU
ml
X(0) 0 muUml
G(0) Gb
mg
dl
Gprod(0) 0
mg
kg·min
Gup(0) 0 mgkg·min
Ie(0) 0 µUml·min
exercise intensity, as shown in Figure 3.1. A linear equation, decreasing with increasing
work intensity, captures the dependence of tgly(uEx(t)) on uEx(t), as follows:
tgly = −1.1521uEx(t) + 87.471 (3.8)
By substituting equation (3.8) into equation (3.7),
ATH = −1.1521[uEx(t)]2 + 87.471uEx(t) (3.9)
Hence, the dynamics of glycogenolysis during prolonged exercise can be mathematically
represented as follows:
dGgly(t)
dt
=

0 A(t) < ATH
k A(t) ≥ ATH
−Ggly(t)
T1
uEx(t) = 0
(3.10)
Here, A(t) is the integrated exercise intensity (uEx(t)), which is calculated by the following
set of equations:
dA(t)
dt
=
 uEx(t) uEx(t) > 0−A(t)
T2
uEx(t) = 0
(3.11)
With the onset of exercise (uEx(t) > 0), A(t) will increase at a rate proportional to
uEx(t). At the end of physical activity (uEx(t) = 0), A(t) will return back to its initial
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Figure 3.1: Dependence of time at which hepatic glycogen starts to deplete, tgly, on exercise
intensity (uEx(t)). Published data (cross) from Pruett et al. [11] and linear fit (solid line)
[R2 = 0.9908]
condition (which is zero) at rate governed by T2. Both rat and human studies have revealed
that majority of the liver glycogen stores are repleted within 1 hr of the recovery period
[160, 161]. Hence, the time constant T2 was assigned a value of 10 min. As long as A(t) is
less than the critical threshold value (ATH), enough glycogen is still available to maintain
a sufficient rate of hepatic glucose release. However, once A(t) reaches ATH , the rate of
glycogenolysis rate starts to decline at a rate given by k, due to the depletion of available
liver glycogen stores. The end of exercise (when uEx(t) returns to zero), which is also the
beginning of the recovery period, marks the commencement of repletion of glycogen stores
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via a continued elevation in the rate of hepatic gluconeogenesis. The time required for Ggly(t)
to return to its basal value after exercise is governed by the pseudo-time constant T1.
3.2.1 Parameter Estimation Technique
Parameters for the exercise minimal model were estimated using the nonlinear least square
technique, as described in Section 2.3 (equation (2.9)). Data from [12] were used to estimate
the parameters a5 and a6, thereby quantifying the depletion of plasma insulin during exercise
and its repletion during the recovery period. After fixing a5 and a6, the insulin model was
validated by comparing with the data from [13]. Parameters a1 and a2 forGprod dynamics and
a3 and a4 forGup(t) dynamics were also estimated from [12]. The glucose model was validated
by comparing the model predictions of Gprod(t), Gup(t) and G(t) with T1DM patient data
from [14]. After fixing the parameters a1−6 to their estimated values, the effects of glycogen
depletion during prolonged exercise, and recovery were modeled. In order to capture these
effects, data from [13] was used to estimate the parameters k and T1 in equation (3.10).
For further validation of the model during prolonged exercise, plasma glucose concentration
was compared with the data from another study performed at higher exercise intensity [15].
All the parameter values for the exercise minimal model along with their 95% confidence
interval (CI) bounds calculated by using the nlparci.m function from the MATLAB Statistics
Toolbox ( c©2008 The Mathworks Inc., Natick, MA) are given in Table 3.2. The quality of the
model fits was assessed by using the R2 technique (for details see Section 2.3). Calculated
R2 values for every model fit and validation are provided in the figure legends.
3.3 RESULTS OF THE EXERCISE MINIMAL MODEL
3.3.1 Plasma Insulin Dynamics During Exercise
Simulation study of mild exercise (PV Omax2 (t) = 40) for 60 min was performed to evaluate
the physiological effects of exercise on plasma insulin concentration. With the onset of
exercise, plasma insulin declined from its basal level (12.2 µU
mL
), and continued to do so along
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Table 3.2: Parameters of the exercise minimal model with 95% confidence intervals (CI), in
addition to those in Table 2.1
Parameter Value Lower Limit Upper Limit Unit
95% CI 95% CI
a1 0.00158 0.0013 0.0019 mg/kg·min2
a2 0.056 0.0441 0.0679 1/min
a3 0.00195 0.0015 0.0024 mg/kg·min2
a4 0.0485 0.0355 0.0617 1/min
a5 0.00125 0.001 0.0015 µ U/mL·min
a6 0.075 0.0588 0.0912 1/min
k 0.0108 0.0085 0.0131 mg/kg·min2
T1 6.0 1.86 10.14 min
a first-order-type response trajectory until the end of the experiment, as shown in Figure 3.2.
During the recovery period (t > 60 min), the plasma insulin concentration climbed back to
its basal level. Quantitatively, the model predictions were consistently within one standard
deviation of the mean of experimental data [12] from which the relevant parameters (a5 and
a6) were estimated. The 95% CI bounds of plasma insulin concentration were simulated by
choosing a set of parameter values from Table 3.2 that had the maximum overestimation (a5
= 0.001, a6 = 0.0912) and maximum underestimation (a5 = 0.0015, a6 = 0.0588) of insulin
concentration, as shown in Figure 3.2 (dotted lines).
For validation of the model, a separate simulation study was performed keeping the
parameter values of a5 and a6 unchanged with a different exercise intensity level (PV O
max
2 (t)
= 30) which lasted for a longer time duration (tex = 0 to 120min). With the onset of exercise,
the insulin level declined well below the basal level (10.2 µU
mL
), and this hypoinsulinemic state
persisted until the end of the experiment. A comparison between model prediction of insulin
and experimental data [13] with same exercise protocol is shown in Figure 3.3. Plasma
insulin gradually returned back to the basal level during the recovery period (t > 120 min).
Overall, the insulin model fits the experimental data sets.
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Figure 3.2: Plasma insulin concentration in response to mild exercise (PV Omax2 = 40) lasting
from tex = 0 to 60 min. Published data (circles) (µ ± σ) from Wolfe et al. [12], model fit
(solid line), and 95% confidence interval of the model output (dotted line).
3.3.2 Plasma Glucose Dynamics During Exercise
To evaluate the exercise effects on plasma glucose concentration, a simulation study of mild
exercise was performed (PV Omax2 (t) = 40) for 60 min. With the onset of exercise, Gup(t)
increased from its basal state to 1.15 mg
kg·min . During the recovery period (t > 60 min), Gup
returned to its basal level. Model prediction of Gup(t) along with experimental data [12] with
same exercise protocol from which parameters a3 and a4 were estimated is shown in Figure
3.4 (Top). The 95% CIs of Gup(t) were simulated by choosing a set of parameter values from
Table 3.2 that had the maximum underestimation (a3 = 0.0015, a4 = 0.0617) and maximum
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Figure 3.3: Plasma insulin concentration in response to mild exercise (PV Omax2 = 30) lasting
from tex = 0 to 120 min. Model simulation validation (solid line) and published data (cross)
(µ ± σ) from Ahlborg et al. [13]
overestimation (a3 = 0.0024, a4 = 0.0355) of glucose uptake rate, as shown by the dotted
lines in Figure 3.4 (Top). In order to maintain plasma glucose homeostasis, hepatic glucose
production rate (Gprod(t),
mg
kg·min) also increased from its basal level to 0.95
mg
kg·min for the
duration of exercise. In conjunction with glucose uptake rate, Gprod(t) decreased to its basal
level after the end of exercise. Parameters a1 and a2 were estimated to fit the data, as shown
in Figure 3.4 (Bottom). Again, 95% CIs of Gprod(t) were simulated by choosing a set of
parameter values from Table 3.2 that had the maximum underestimation (a1 = 0.0013, a2 =
0.0679) and the maximum overestimation (a1 = 0.0019, a2 = 0.0441) of glucose production
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rate, as shown by the dotted lines in Figure 3.4 (Bottom). Both Gup(t) and Gprod(t) are
represented in deviation form in Figure 3.4.
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Figure 3.4: Model simulation (solid lines), 95% confidence intervals of model outputs (dotted
lines) and published data (circles) (µ ± σ) from Wolfe et al. [12] in response to mild exercise
(PV Omax2 = 40) lasting from tex = 0 to 60 min. Top: hepatic glucose uptake rate (Gup),
and Bottom: hepatic glucose production rate (Gprod). Both Gup and Gprod are plotted in
deviation form.
The accelerated glucose uptake rate during exercise is compensated for by enhanced
hepatic glucose production; hence, normoglycemia is maintained throughout the course
of physical activity. A comparison between the model prediction of glucose concentration
including Gup(t) plus Gprod(t) effects and experimental data [12] is provided in Figure 3.5.
The predictions of the glucose model are in good accordance with the published data. In
order to simulate the 95% CIs for plasma glucose concentration, a combination of parameter
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Figure 3.5: Plasma glucose concentration (G) in response to mild exercise (PV Omax2 = 40)
lasting from tex = 0 to 60 min. Model simulation (solid line), 95% confidence intervals of
model output (dotted lines), and published data (circles) (µ ± σ) from Wolfe et al. [12].
values were chosen from Table 3.2 that generated the maximum underestimation (a1 =
0.0013, a2 = 0.0679, a3 = 0.0024, a4 = 0.0355, a5 = 0.001, a6 = 0.0912) and the maximum
overestimation (a1 = 0.0019, a2 = 0.0441, a3 = 0.0015, a4 = 0.0617, a5 = 0.0015, a6 =
0.0588) of plasma glucose, as indicated by the dotted lines in Figure 3.5.
For the validation of the glucose model, another simulation test was performed at
moderate level of exercise for 45 min at PV Omax2 (t) = 50. Again, with the onset of exercise,
both Gup(t) and Gprod(t) increased. During the recovery period (t > 45 min), Gup(t) and
Gprod(t) gradually declined to their respective basal levels. Model validation simulations (i.e.,
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Figure 3.6: Response to moderate exercise (PV Omax2 = 50) lasting from tex = 0 to 45 min.
Model simulation validation (solid lines) and published data (cross) (µ ± σ) from Zinman
et al. [14]. Top: glucose uptake rate (Gup); Middle: hepatic glucose production rate (Gprod);
Bottom: difference [Gprod − Gup]. Both Gup and Gprod are shown in deviation form.
no model parameter changes) are plotted alongside experimental data of T1DM patients
[14] in Figure 3.6, top and bottom (both in deviation form). Figure 3.7 reveals the model
prediction of plasma glucose concentration including the combined effects of Gup(t) and
Gprod(t) during exercise along with experimental data [14] with the same group of patients.
To evaluate the plasma glucose dynamics during prolonged exercise, data from Ahlborg
et al. [13] was considered (see Figure 3.8). With the onset of exercise, both Gup(t) and
Gprod(t) rates were elevated from the basal level; this resulted in the maintenance of glucose
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Figure 3.7: Plasma glucose concentration (G) in response to moderate exercise (PV Omax2 =
50) lasting from tex = 0 to 45 min. Model simulation validation (solid line) versus published
data (cross) (µ ± σ) from Zinman et al. [14].
homeostasis during the first hour of exercise. As the integrated exercise intensity exceeded
a critical threshold (which is a function of exercise intensity and duration), the hepatic
glycogenolysis rate started to decline as a result of which net liver glucose production rate,
[Gprod(t) - Ggly(t)], decreased until the end of exercise (Figure 3.8: Bottom). However, Gup
remained elevated due to continuing physical activity (Figure 3.8: Middle). This mismatch
between Gup(t) and Gprod(t) resulted in a net decrease of plasma glucose level (Figure 3.8:
Top). During the post-exercise recovery period, lactate consumption by the liver increases
significantly, serving as a substrate for accelerated post-exercise gluconeogenesis [157]. It is
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Figure 3.8: Model response to mild exercise (PV Omax2 = 30) lasting from tex = 0 to 120 min.
Published data (circles) (µ ± σ) from Ahlborg et al. [13], model fit (solid line), and 95%
confidence interval of fit (dashed line). Top: model prediction of plasma glucose (G); Middle:
model prediction of hepatic glucose uptake rate (Gup); and Bottom: model prediction of net
liver glucose production. Both Gup and [Gprod - Ggly] are shown in deviation form.
believed that the purpose of this elevated gluconeogenesis is to replete the liver glycogen
stores and restore normoglycemia [157]. Keeping parameters a1−6 unchanged, parameters
k and T1 from equation (3.10) were adjusted to capture the dynamical behavior of plasma
glucose concentration. To simulate the 95% CIs for plasma glucose concentration during
prolonged exercise, the same combination of parameter values were chosen from Table 3.2 as
in Figure 3.5, with the addition of (k = 0.0131, T1 = 10.14) for maximum underestimation
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Figure 3.9: Model response to moderate exercise (PV Omax2 = 60) lasting from tex = 0 to 210
min. Published data (cross) (µ ± σ) from Ahlborg et al. [15] and model prediction validation
(solid line). Top: model prediction of plasma glucose (G); Middle: model prediction
of hepatic glucose uptake rate (Gup); and Bottom: model prediction of net liver glucose
production. Both Gup and [Gprod - Ggly] are shown in deviation form.
and (k = 0.0085, T1 = 1.86) for the maximum overestimation, as shown by the dotted lines
in Figure 3.8 (Top). To simulate the CIs for Gup(t), the same parameter value sets as those
used in Figure 3.4 (Top), were chosen (see Figure 3.8: Middle). Finally, to simulate the 95%
CIs of net liver glucose production rate, a combination of parameter values were chosen from
Table 3.2 to generate the maximum underestimation (a1 = 0.0013, a2 = 0.0679, k = 0.0131,
T1 = 10.14) and the maximum overestimation (a1 = 0.0019, a2 = 0.0441, k = 0.0085, T1=
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1.86) of [Gprod(t) - Ggly(t)], as shown by the dotted lines in Figure 3.8 (Bottom). In order
to validate the model during prolonged exercise, a separate simulation study was performed
where exercise was performed for 3 hours at a moderate exercise intensity (PV Omax2 = 60).
Due to the higher exercise intensity, glycogen stores depleted at a faster rate; the result is
an inability to maintain glucose homeostasis beyond tex = 30 min (see Figure 3.9: Top).
A comparison between model simulations (without changing any parameters) and data [15]
are given in Figure 3.9.
3.4 MODEL STRUCTURE JUSTIFICATION
The purpose of the proposed model was to extend the classical minimal model [1] in order to
capture the vital physiological effects induced by mild-to-moderate exercise on glucose and
insulin dynamics during and immediately after physical activity. The states added (equations
(3.4), (3.5), (3.6), and (3.10)) were essential to describe accurately the acute exercise effects
on plasma insulin and glucose concentrations. However, including extra equations certainly
added complexity to the proposed model. Hence, this Section explores reduced versions of
the proposed exercise model. AIC (see Section 2.3) was employed to establish a statistical
comparison between the proposed model and its reduced versions.
3.4.1 Validity of Ie(t) (Equation 3.6)
Equation (3.6) was added to the proposed model to capture the dynamics of Ie(t), which
represents the rate of insulin clearance from the circulatory system due to exercise. As
mentioned in Section 3.2.1, parameters a5 and a6 from equation (3.6) were estimated using
the data from Wolfe et al. [12] (for the values, refer to Table 3.2). In the reduced version,
Ie(t) (equation 3.6) was omitted. Hence, the exercise induced plasma insulin clearance was
captured directly by the PV Omax2 (t) variable coupled with a new parameter, b1. Thus,
equation (3.2) could be re-written as follows:
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dI(t)
dt
= −nI(t) + p4u1(t)− b1PV Omax2 (t) (3.12)
The parameter value of b1 = 0.0148
µU
ml·min was estimated from the data [12] via the
nonlinear least square technique (Section 2.3). The calculated AIC values with and without
the variable Ie(t) (equation (3.6)) are presented in Table 3.3. It is clearly evident that the
proposed model is superior to the reduced version, in terms of their AIC values. Simulation
of these two models, along with the experimental data [12] are shown in Figure 3.10. Insulin
dynamics during exercise without the filter equation (3.6) is much faster as compared to the
data [12].
3.4.2 Validity of Gup(t) (Equation 3.5)
In the proposed model, exercise-induced glucose uptake (Gup(t)) was captured by equation
(3.5). Parameters a3 and a4 belonging to equation (3.5) were estimated by using the data
from [12], as mentioned in Section 3.2.1 (for the values, refer Table 3.2). In the reduced
version, equation (3.5) (Gup(t)), was omitted. Hence, the exercise induced glucose uptake
rate, Gup(t), was captured by the term b2PV O
max
2 (t), which is a product of a new gain
parameter, b2, and exercise intensity, PV O
max
2 (t). Therefore, equation (3.3) could be re-
written as follows:
dG(t)
dt
= −p1[G(t)−Gb]−X(t)G(t) + W
V olG
[Gprod(t)−Ggly(t)]
− W
V olG
Gup(t) +
u2(t)
V olG
(3.13)
Gup(t) = b2PV O
max
2 (t) (3.14)
The value of parameter b2 (0.03114
mg
kg·min) was estimated by using the data obtained
from [12] via the nonlinear least square technique. The calculated AIC values of the proposed
and reduced models are provided in Table 3.3. Once again, from the AIC values it is clearly
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Figure 3.10: Plasma insulin concentration in response to mild exercise (PV Omax2 = 40)
lasting from tex = 0 to 60 min. Published data (circles) (µ ± σ) from Wolfe et al. [12],
proposed model fit [AIC = −32.194] (solid line), and reduced model fit [AIC = −11.83]
(dashed line).
evident that the proposed model is superior to the reduced version. By not including equation
(3.5) makes the model prediction of exercise-induced glucose uptake rate significantly faster
than the observed data [12] (see Figure 3.11: Top).
3.4.3 Validity of Gprod(t) (Equation 3.4)
In order to maintain glucose homeostasis, hepatic glucose production rate (Gprod(t)) is also
increased during exercise. In the proposed model, the dynamics of Gprod(t) are captured by
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Figure 3.11: Proposed model simulation (solid lines), reduced model simulation (dotted
lines) and published data (circles) (µ ± σ) from Wolfe et al. [12] in response to mild exercise
(PV Omax2 = 40) lasting from tex = 0 to 60min. Top: glucose uptake rate (Gup), and Bottom:
hepatic glucose production rate (Gprod). Both Gup and Gprod are plotted in deviation form.
equation (3.4). As mentioned earlier, parameters a1 and a2 belonging to equation (3.4) were
estimated by using the data from [12] via nonlinear least square algorithm.
In the reduced version, equation (3.4) (Gprod(t)) is eliminated. Therefore, the acceler-
ated plasma glucose production induced by exercise is captured directly by the PV Omax2 (t)
variable coupled with the new parameter, b3. Hence, equation (3.3) could be re-written as
shown below:
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dG(t)
dt
= −p1[G(t)−Gb]−X(t)G(t) + W
V olG
[Gprod(t)−Ggly(t)]
− W
V olG
Gup(t) +
u2(t)
V olG
(3.15)
Gprod(t) = b3PV O
max
2 (t) (3.16)
Data from [12] was utilized to estimate the parameter, b3 = 0.02491
mg
kg·min via the nonlinear
least square technique. From the AIC values it is clearly evident that the proposed model is
superior to the reduced model. The model prediction of exercise-induced glucose production
(Gprod(t)) without equation 3.4 is significantly faster than the observed data [12] (see Figure
3.11: Bottom).
By comparing all the AIC values of the proposed exercise model and its reduced versions,
it is evident that the originally proposed additional states (equation (3.4), (3.5), and (3.6))
are essential to accurately capture the dynamics of plasma glucose and insulin concentrations
under the influence of exercise. Any further simplification than the proposed structure will
compromise the quality of the model.
Table 3.3: Calculated AIC values of the exercise minimal model with and without the Ie(t),
Gup(t) and Gprod(t) filter equations
AIC Exercise Minimal Model
without with
Insulin clearance dynamics Eq. (3.12) Eq. (3.2)
(Ie(t)) −11.830 −32.194
Glucose uptake dynamics Eq. (3.14) Eq. (3.5)
(Gup(t)) 8.880 −15.705
Glucose production dynamics Eq. (3.16) Eq. (3.4)
(Gprod(t)) 4.20 −26.78
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3.5 SUMMARY
A model of exercise effects on plasma glucose-insulin dynamics was developed. The principal
goal was to extend the Bergman minimal model [1] by adding state equations in order to to
predict plasma glucose and insulin concentrations. This was accomplished by mathematically
capturing the necessary physiological phenomenon induced by exercise. All the added
equations in the proposed model are linear in nature thus maintaining the simplifying
approach of the original minimal model [1]. The model successfully captured the effects of
mild-to-moderate aerobic exercise on plasma glucose and insulin concentrations. Inclusion
of separate dynamics in the model for glucose uptake (equation (3.5)) and hepatic glucose
production (equation (3.4)) made it possible to capture the simultaneous rise of these rates
with the onset of short term exercise in order to maintain glucose homeostasis. These
equations were also successful in capturing the dynamics of glucose fluxes during the post-
exercise recovery period. As the integrated exercise intensity extends beyond a critical
threshold (which is a function of exercise intensity and duration), a decline in splanchnic
glucose release is expected. As glucose uptake rate remains elevated, maintenance of glucose
homeostasis is no longer possible. Due to this, plasma glucose continues to decline until the
end of physical activity. At the end of prolonged exercise, the hepatic gluconeogenesis rate is
increased, and this facilitates repletion of glycogen stores and helps to achieve normoglycemia
[157]. A substantial amount of lactate is released from the post-exercising muscles during the
recovery period, which serves as a substrate for gluconeogenesis. To capture the dynamics
of plasma glucose during the various stages of prolonged exercise, equation (3.10) was
incorporated. The model also successfully captured the clearance of plasma insulin from
the circulatory system during physical exercise due to the addition of equation (3.6).
With a focus on closed-loop insulin delivery systems for T1DM patients, it is necessary
to develop models that can accurately predict plasma glucose concentration during rest, as
well as during physical exercise. Hence, this model provides the control community with
an alternative benchmark problem in glucose control for diabetic patients by allowing the
analysis of meal and exercise disturbances alone or in combination. The exercise model can
also be used to predict the duration of exercise at a given intensity that can be executed while
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keeping plasma glucose within the normoglycemic range. However, a prospective validation
of the components of the minimal exercise model is necessary before the model, or a model-
based controller, is employed in any clinical setting.
The proposed model as presented in this Chapter does not include the FFA dynamics
and its interactions with blood glucose. As discussed in Chapter 2, FFA plays a significant
role in influencing plasma glucose concentration. Also, FFA dynamics is profoundly altered
during physical activity. Hence, in the following Chapter a lower-order composite model was
synthesized by combining the FFA model from Chapter 2 and the exercise model from this
Chapter. The composite model, as proposed in Chapter 4, is capable of predicting plasma
FFA, glucose, and insulin dynamics during rest, as well as exercise.
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4.0 A LOWER-ORDER MODEL OF FFA, GLUCOSE, AND INSULIN AT
REST AND DURING EXERCISE
So far in the dissertation, two different metabolic models were developed by modifying the
Bergman minimal model [1] in order to incorporate various physiological effects of FFA and
exercise on the insulin-glucose system [129, 150]. The extended minimal model developed
in Chapter 2 is capable of predicting FFA along with glucose dynamics during pre- and
post-prandial states. The model is also equipped to capture the inhibitory effects of FFA on
glucose uptake rate by the peripheral and hepatic tissues. However, the extended minimal
model does not consider the exercise effects on insulin, glucose, and FFA kinetics. In Chapter
3, an exercise minimal model was developed to capture the effects of exercise on glucose and
insulin dynamics. The model successfully captured insulin-glucose concentrations during
and immediately after mild-to-moderate exercise. The model is also capable of predicting
the plasma glucose excursion towards hypoglycemia during prolonged exercise periods. The
major drawback of this model is the absence of FFA dynamics and its interactions with
glucose and insulin.
Instead of having two different minimal models capturing the effects of FFA and exercise
on the glucose-insulin system separately, a single low-order metabolic model capturing all the
physiological effects on the glucose-insulin system can be developed. Hence, in this Chapter a
composite metabolic model capable of predicting plasma glucose, insulin, and FFA dynamics
at rest, as well as during mild-to-moderate exercise was developed.
One objective of the model was to represent the physiology more accurately. Hence,
necessary modifications were made to the original model structures obtained from Chapters
2 and 3. For example, insulin action on glucose was divided into two parts having separate
dynamics: one capturing the insulin-mediated tissue glucose uptake, and the other part
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capturing the insulin-mediated suppression of endogenous glucose production. Moreover,
saturating functions were used to represent the effects of insulin on endogenous glucose
and FFA production rates. In order to accurately model literature data, unobservable
filter equations capturing the interactions between insulin, glucose, FFA, and exercise were
added wherever necessary. However, addition of extra equations increased the complexity
of the model in terms of number of parameters which are required to be estimated. Hence,
the trade-off between model accuracy and model complexity was measured by using AIC
(equation (2.12)) as described in Section 2.3. The model structure with a lower AIC value
was selected in synthesizing the composite model. The resulting composite model consisted
of four parts: insulin, glucose, FFA, and exercise sub-models.
In the following Section (4.1), a brief overview of the physiological interactions between
the plasma insulin, glucose, and FFA at rest and during exercise is presented. In Section 4.2,
a detailed description of the structure of the composite model is introduced. A parametric
sensitivity analysis is performed in Section 4.3. Finally, the results of model validation
simulations are presented in Section 4.4.
4.1 INTERACTIONS BETWEEN INSULIN, GLUCOSE, AND FFA
DURING REST AND EXERCISE
The major metabolic interactions captured by the composite model are given in Figure
4.1. Basically, the lower-order model is divided into four parts capturing the plasma insulin
(section-I), plasma glucose (section-II), plasma FFA (section-III), and exercise (section-IV)
dynamics, as shown in the schematic diagram. The continuous lines in the diagram represent
transport or clearance of metabolic substrates and hormones; the dashed lines represent
interactions taking place between the substrates, hormones, and exercise.
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Figure 4.1: Schematic diagram of the composite model. Sections I, II, III, and IV represent
the insulin, glucose, FFA, and exercise sub-models, respectively. I: Insulin; G: Glucose;
F: FFA; uI : Exogenously infused insulin; uG, uF : Glucose or FFA absorbed from meal or
infused; uEx: Exercise intensity; PVO
max
2 : Percentage of maximum rate of oxygen uptake;
xG, xEGP , xEFP1: Remote insulin compartments; yIU , yGU , yGP , y1FU , y1FP : 1
st-order filters
capturing exercise effects.
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The insulin model assumes that all of the insulin present in the system is infused
exogenously, as indicated by uI (
mU
min
). Compartment I, in section-I (Figure 4.1), represents
the observable insulin concentration at the systemic level. Insulin from the plasma space
enters into three unobservable remote insulin compartments, xi (where, i ∈G, EGP , EFP1).
Insulin-mediated glucose uptake in the tissues is governed by xG. Insulin also plays a
major role in suppressing the hepatic glucose production [57], which is captured by xEGP .
Finally, the inhibitory action of insulin on endogenous FFA production rate (anti-lipolysis)
is captured by xEFP1.
In section-II (Figure 4.1), compartment G represents circulating plasma glucose concen-
tration. Glucose from the circulatory system is consumed by the peripheral tissues for
oxidation purposes and by the hepatic tissues mostly for storage purposes in the form
of glycogen [55]. Whenever the body requires energy, stored glycogen is catabolized into
glucose which is then released back into the circulatory system; a process commonly known
as glycogenolysis [56]. Glucose infused intravenously or absorbed from meal is represented
by uG (
g
min
).
The plasma FFA dynamics is captured in section-III (Figure 4.1), where compartment
F represents measurable FFA level in the circulatory system. FFA is consumed by the
peripheral tissues for oxidation purposes, while uptake by the AT is mostly for storage in the
form of triglycerides [54]. FFA absorbed from the meal or infused intravenously is captured
by uF (
g
min
). The inhibitory effects of FFA on the glucose uptake rate, as proposed by
Randle et al. [58, 59], is indicated by the dashed line initiating from the F compartment and
terminating at the G compartment.
The dynamics of exercise intensity in terms of PVOmax2 is captured in section-IV (Figure
4.1). The significant effects of physical activity on insulin, glucose, and FFA are captured by
the first-order filter compartments yi (where, i ∈ IU , GP , 1FU , and 1FP ). As mentioned in
the previous chapter, exercise accelerates the clearance of plasma insulin, which is captured
by yIU in the composite model. Alterations in the glucose kinetics due to exercise is
captured by yGU and yGP ; where, the former represents exercise-induced increase in muscle
glucose uptake rate and the latter represents increased hepatic glucose production rate
due to exercise. During mild-to-moderate exercise, fat oxidation in the muscle increases
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approximately 4-5 folds above its resting amount [162, 61]. This increased FFA oxidation due
to exercise is captured by y1FU in the model. Availability of FFA also increases significantly
during exercise [61]. Majority of the increased supply of FFA is provided by lipolysis which
typically exceeds the FFA uptake rate [162, 18]. In the model, y1FP governs the increased
FFA production rate during exercise.
In the following section, the mathematical structure of the composite model is introduced.
Most of the parameter values were estimated from published data by using the nonlinear
least square technique, as described in Section 2.3 (Chapter 2), and the rest were directly
obtained from the literature. All the parameter values of the composite model in its final
form are provided in Table 4.1.
4.2 COMPOSITE MODEL STRUCTURE
4.2.1 Insulin Dynamics
The model assumes an absolute deficiency of the pancreatic β-cells to secrete any insulin;
hence, all of the gluco-regulatory hormone is externally infused (uI(t)). Exercise promotes
the clearance of insulin, causing a drop in the plasma insulin level. This phenomenon is
essential to enhance the hepatic glucose production and lipolysis during exercise [12]. The
insulin dynamics along with exercise effects can be mathematically written as:
dI(t)
dt
= −nI(t)− yIU(t)I(t) + uI(t)
VI
(4.1)
dPV Omax2 (t)
dt
= mPV (uEx(t)− PV Omax2 (t)) (4.2)
dyIU(t)
dt
= mIU1PV O
max
2 (t)−mIU2yIU(t) (4.3)
Here, equation (4.1) captures the plasma insulin concentration (I(t), µU
ml
), similar to equation
(3.2) in Chapter 3. The insulin clearance rate, n, and the insulin distribution space, VI ,
are directly obtained from the literature [1]. Notice, the only difference in this equation
from equation (3.2) in Chapter 3 is the 2nd term in the right hand side (RHS) of both the
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equations representing the exercise-induced clearance rate of insulin. Unlike the exercise
minimal model in Chapter 3, introduction of the bilinear term (yIU(t)I(t)) in the composite
model will prevent I(t) from reaching negative values during exercise in absence of any
plasma insulin, which might happen for T1DM patients. Equation (4.2), which quantifies the
exercise intensity above its basal level, is same as equation (3.1) in Chapter 3. The dynamics
of the unobserved variable yIU(t) (
1
min
) is represented by equation (4.3). Parameters mIU1
and mIU2 were estimated by utilizing data obtained from Wolfe et al. [12], where healthy
subjects performed bicycle exercise for 60 min at an intensity PV Omax2 = 40%. Blood
samples were collected during exercise and the recovery period to measure the plasma insulin
concentration, as shown in Figure 4.2. With the onset of exercise, plasma insulin declined
below its basal level due to the elevated clearance rate and remained low until the end of
exercise. During the recovery period, plasma insulin climbed back to its basal value.
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Figure 4.2: Plasma insulin concentration in response to mild exercise (PV Omax2 = 40%)
lasting from time tEx = 0 to 60 min. Published data (circles) (µ ± σ) from Wolfe et al. [12]
and model fit (solid line)
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4.2.2 FFA Dynamics
FFA is released from the AT into the plasma via the lipolytic process. The circulating FFA
is consumed by the various organs and tissues mostly for oxidation, except the AT where it
is consumed for storage purposes. Insulin is one of the major hormones that regulates the
lipolytic process by suppressing the activation of hormone sensitive lipase (HSL), which is
the primary enzyme responsible for lipolysis [137]. The following equations capture the FFA
dynamics at rest.
dF (t)
dt
= −pF1F (t) + EFP (t) + uF
VF
(4.4)
EFP (t) = EFP0
(
1− kEFP
(
xEFP1N (t)
xEFP1N (t) + sEFPN
))
(4.5)
dxEFP1(t)
dt
= pF2(I(t)− xEFP1(t)) (4.6)
xEFP1N (t) =
xEFP1(t)
xEFP1B
(4.7)
Here, equation (4.4) represents the plasma FFA concentration (F (t), µmol
l
). The plasma
FFA distribution volume (VF , l) is directly obtained from the literature [18]. Parameter pF1
represents the rate at which FFA is consumed by the tissues. The rate of endogenous FFA
production (i.e., lipolysis) is captured by the variable EFP (t) ( µmol
l·min), which is a function
of insulin concentration as shown in equations (4.5)–(4.7). The unobserved variable xEFP1
(µmol
l
) represents the effect of remote insulin concentration on lipolysis. Variable xEFPN (t)
is the remote insulin concentration normalized with respect to its basal level (xEFPB ,
µmol
l
),
as shown in equation (4.7).
To establish the correlation between endogenous FFA production rate and insulin con-
centration, data was obtained from Campbell et al. [16], where the lipolytic rate of healthy
humans was measured at various steady state hyperinsulinemic levels. As we can see in
Figure 4.3, an increasing insulin level significantly suppressed the FFA production rate. In
fact, saturation was reached for the EFP when insulin level was approximately 40 fold
above its basal level. The rate of lipolysis at zero insulin in equation (4.5), EFP0 (
µmol
l·min),
was obtained from the literature [16]. The gain parameter, kEFP , was also extracted from the
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data [16] by considering the data-point having the lowest EFP value (EFPlo), as indicated
by the point (a) in Figure 4.3, as follows: When,
EFP (t) = EFPlo
xEFP1N >> sEFPN
Hence,
xEFP1N (t)
xEFP1N (t) + sEFPN
≈ 1
As a result, equation (4.5) reduces to:
kEFP = 1− EFPlo
EFP0
(4.8)
In order to fit the data [16] in Figure 4.3, only the saturation constant, sEFPN , from equation
(4.5) was estimated.
The value of parameter pF1 representing the plasma uptake rate of FFA can be directly
obtained from equation (4.4) at the basal steady state condition, as shown below:
pF1 =
EFPB
FB
(4.9)
Here, EFPB (
µmol
l·min) is the lipolytic rate at basal conditions and FB (
µmol
l
) is the basal plasma
FFA concentration. Both these values were directly obtained from the literature [16].
In order to capture the dynamical effects of insulin on endogenous FFA production,
parameter pF2 in equation (4.6) was estimated by utilizing data from two different studies
simultaneously [4, 17]. In [4], euglycemic-hyperinsulinemic clamps were employed on normal
subjects. Plasma insulin concentration was elevated to 20, 30, and 100 µU
ml
, as shown in the
top, middle, and bottom panels in Figure 4.4, respectively. Due to the antilipolytic action of
elevated insulin levels, plasma FFA was suppressed in all the three cases. In the second study
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Figure 4.3: Model fit (solid line) versus published data (µ ± σ) (circle) [16] of steady
state endogenous FFA production rate, EFP , as a function of normalized remote insulin
concentration xEFP1N . Data-point (a) indicates the lowest FFA production rate, EFPlo.
[17], a modified insulin frequently sampled intravenous glucose tolerance test (MI-FSIGT)
was performed, where boluses of insulin at time t = 0 and 20 min were administered to
normal subjects, as indicated by the top panel of Figure 4.5. Due to the insulin boluses,
plasma FFA concentration was suppressed well below its basal level as shown in the bottom
panel of Figure 4.5. The model predictions indicated in Figure 4.4 and 4.5 were obtained by
adjusting the parameter pF2 = 0.014782
1
min
. The AIC value of the model estimated by using
the technique as discussed in Section 2.3 is −22.74. By analyzing the model performances
in both the studies, it is evident that the model predictions underestimate the FFA data,
particularly in the first 50 min of the bottom panels in both the Figures (4.4 and 4.5).
Therefore, to delay the FFA action on lipolysis a second filter compartment (xEFP2) was
introduced in series, as shown in Figure 4.6.
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Figure 4.4: Euglycemic hyperinsulinemic clamp study, where plasma insulin concentration
was maintained at 20 µU
ml
(top); 30 µU
ml
(middle); and, 100 µU
ml
(bottom). Model prediction
(solid line) using only one insulin filter (xEFP1) and published data (µ ± σ) (circle) [4] of
plasma FFA concentration.
Hence, the endogenous FFA production rate after addition of the extra lag can be mathe-
matically expressed as follows:
EFP (t) = EFP0
(
1− kEFP
(
xEFP2N (t)
xEFP2N (t) + sEFPN
))
(4.10)
dxEFP2(t)
dt
= pF3(xEFP1(t)− xEFP2(t)) (4.11)
xEFP2N (t) =
xEFP2(t)
xEFP2B
(4.12)
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Figure 4.5: MI-FSIGTT study, where plasma insulin boluses were administered at t = 0 and
20 min. Model prediction (solid line) and published data (µ ± σ) (circle) [17] of plasma
insulin concentration (top); model prediction (solid line) of the unobserved remote insulin
concentration xEFP1 (middle); model prediction using only one insulin filter (xEFP1) (solid
line) and published data (µ ± σ) (circle) [17] of plasma FFA concentration (bottom)
The additional filter equation (4.11) introduced a new parameter, pF3. Once again, para-
meters pF2 and pF3 were adjusted to capture the data from [4] and [17], simultaneously.
Introduction of the new lag slowed down the FFA dynamics significantly thereby increasing
the accuracy of the model predictions, as indicated in Figures 4.7 and 4.8. Although, in
Figure 4.8 the FFA data seems to have reached a pseudo-basal level which is higher than the
initial basal concentration. This could be due to diurnal variations of plasma FFA, which
are unrelated to the insulin or glucose kinetics, as pointed out by the authors [17]. The two
separate filter equations in the insulin dynamics could be visualized as the lag associated
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Figure 4.6: Schematic diagram of the modified insulin model section (I) of the composite
model with modifications
with transport of insulin in the adipocyte from the circulatory system and the lag associated
with the action of insulin on deactivation of HSL, due to which lipolysis is suppressed. Even
with the added complexity (in terms of the one added parameter), the AIC value of the
modified model is −54.42, which is much lower than the AIC value of the previous insulin
model structure.
Exercise increases FFA uptake, as well as production in the body. In order to incorporate
the effects of exercise on FFA dynamics, equation (4.4) can be re-written as follows:
dF (t)
dt
= −pF1F (t)− W
VF
y1FU(t) + EFP (t) +
W
VF
y1FP (t) +
uF (t)
VF
(4.13)
dy1FU(t)
dt
= mFU1PV O
max
2 (t)−mFU2y1FU(t) (4.14)
dy1FP (t)
dt
= mFP1PV O
max
2 (t)−mFP2y1FP (t) (4.15)
Here, y1FU(t) (
µmol
kg·min) represents the rate of disappearance of FFA by the working tissues
due to exercise. Exercise-induced production of FFA is captured by y1FP (t) (
µmol
kg·min). W
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Figure 4.7: Euglycemic hyperinsulinemic clamp study, where plasma insulin concentration
was maintained at 20 µU
ml
(top); 30 µU
ml
(middle); 100 µU
ml
(bottom). Model prediction (solid
line) using two insulin filters (xEFP1 and xEFP2) and published data (µ ± σ) (circle) [4] of
plasma FFA concentration.
(kg) is the weight of the patient. In order to estimate the parameters of equations (4.14)
and (4.15), data was obtained from an experiment performed by Klein et al. [18] where
healthy subjects performed exercise at PV Omax2 = 45% intensity for 240 min. FFA kinetics
were measured during and immediately after the physical activity, to measure the whole-
body plasma FFA appearance rate, RaF (
µmol
l·min), and plasma disappearance rate, RdF (
µmol
l·min),
was measured along with the FFA concentration at the systemic level. With the onset of
exercise, both RdF and RaF increased rapidly over the first 30 min. Thereafter, RdF and
RaF gradually increased until the end of exercise. As RaF exceeded RdF , plasma FFA
concentration increased steadily throughout the duration of exercise. During the recovery
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Figure 4.8: MI-FSIGTT study, where plasma insulin boluses were administered at t = 0 and
20 min. Model prediction (solid line) and published data (µ ± σ) (circle) [17] of plasma
insulin concentration (top); model predictions of the first, xEFP1 (solid line), and second
xEFP2 (dashed line) remote insulin concentrations (middle); model prediction (solid line)
using both the insulin filters (xEFP1 and xEFP2) and published data (µ ± σ) (circle) [17] of
plasma FFA concentration (bottom)
period, the FFA returned to its basal level slowly. On the RHS of equation (4.13), the first
two terms represent the rate of disappearance of plasma FFA (RdF ); whereas, the third
and fourth terms represent the rate of appearance of plasma FFA (RaF ). Parameters mFU1
= 0.0093287 ( µmol
kg·min2 ), mFU2 = 0.021622 (
1
min
), mFP1 = 0.0094836 (
µmol
kg·min2 ), and mFP2 =
0.019745 ( 1
min
) were estimated to obtain the model predictions as shown in Figure 4.9. The
calculated AIC value of the model is −14.6116. By closely analyzing the top and middle
panels of Figure 4.9, it is quite evident that equations (4.14) and (4.15) are inadequate to
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capture the rapid initial rise in RdF and RaF during exercise (especially the 30 min point).
To increase the model accuracy in terms of capturing the FFA kinetics during physical
activity, the exercise model structure was modified by incorporating two extra compartments
(y2FU and y2FP ), as shown in Figure 4.10. All the parameter values of the model are provided
in Table 4.1.
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Figure 4.9: Plasma FFA kinetics in response to mild exercise (PV Omax2 = 45%) lasting from
tex = 0 to 240min. The exercise model is comprised of two compartments, y1FU and y1FP , to
capture the FFA kinetics during exercise. Model prediction (solid line) and published data (µ
± σ) (circle) [18] of plasma FFA uptake rate (RdF ) (top); model prediction (solid line) and
published data (µ ± σ) (circle) [18] of plasma FFA production rate (RaF ) (middle); model
prediction (solid line) and published data (µ ± σ) (circle) [18] of plasma FFA concentration
(bottom)
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Figure 4.10: Schematic diagram of the exercise section (IV) of the composite model with
modifications
Hence, the equations capturing FFA kinetics during exercise for the updated model can be
written as follows:
dy1FU(t)
dt
= mFU1PV O
max
2 (t)−mFU2y1FU(t)−mFU3(y1FU(t)− y2FU(t)) (4.16)
dy2FU(t)
dt
= mFU3(y1FU(t)− y2FU(t)) (4.17)
dy1FP (t)
dt
= mFP1PV O
max
2 (t)−mFP2y1FP (t)−mFP3(y1FP (t)− y2FP (t)) (4.18)
dy2FP (t)
dt
= mFP3(y1FP (t)− y2FP (t)) (4.19)
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Figure 4.11: Plasma FFA kinetics in response to mild exercise (PV Omax2 = 45%) lasting
from tex = 0 to 240 min. The exercise model is comprised of four compartments, y1FU ,
y2FU , y1FP and y2FP , to capture the FFA kinetics during exercise. Model prediction (solid
line) and published data (µ ± σ) (circle) [18] of plasma FFA uptake rate (RdF ) (top); model
prediction (solid line) and published data (µ ± σ) (circle) [18] of plasma FFA production
rate (RaF ) (middle); model prediction (solid line) and published data (µ ± σ) (circle) [18]
of plasma FFA concentration (bottom).
Due to the addition of two new compartments, two extra parameters were introduced (mFU3
andmFP3). Once again, all the parameters (mFU1−FU3 andmFP1−FP3) capturing the exercise
effects on FFA kinetics were estimated by using data from Klein et al. [18]. As it can be
seen in Figure 4.11, the new structure of the exercise model provided a better fit of RdF
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and RaF during exercise. The superiority of the modified structure is further suggested
by calculating the AIC value (−34.35), which is far less than the previous exercise model
structure. However, the proposed model was unable to capture the sudden burst in plasma
FFA concentration at the commencement of the recovery period, as observed in the mean
data (Figure 4.11: bottom). In order to capture such kind of plasma FFA dynamics at the
end of the exercise period, additional equations are required. Incorporation of extra equations
will increase the number of unknown parameters which are required to be estimated, thereby
increasing the complexity of the model.
4.2.3 Glucose Dynamics
Glucose is taken up from the circulating pool by hepatic tissues for storage (primarily)
and by the peripheral tissue for oxidation purposes. Glucose influences its own uptake in the
hepatic and extra-hepatic tissue (known as glucose effectiveness [5]). Glucose uptake into the
tissues is further facilitated by insulin (known as insulin sensitivity [5]). To maintain plasma
glucose homeostasis, stored glucose in the liver is released back into the circulatory system
via glycogenolysis. The rate of hepatic glucose production (HGP) is indirectly regulated by
insulin [57]. Plasma insulin inhibits glucagon secretion from the pancreatic α-cells [163, 164],
and the latter is a crucial hormone for maintaining HGP [165]. Furthermore, increased
availability of FFA has an inhibitory effect on tissue glucose uptake [58, 59, 166, 167]. The
dynamics of plasma glucose at rest along with the actions of insulin on glucose uptake and
endogenous glucose production, plus the inhibitory effect of FFA on glucose uptake at the
systemic level can be mathematically expressed as given below:
dG(t)
dt
= (−pG1G(t)− xG(t)G(t)) fFG(t) + EGP (t) + uG(t)
VG
(4.20)
dxG(t)
dt
= pG2I(t)− pG3xG(t) (4.21)
fFG(t) = fFG0
(
1− kFG
(
F 3N(t)
F 3N(t) + s
3
FGN
))
(4.22)
FN(t) =
F (t)
FB
(4.23)
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EGP (t) = EGP0
(
1− kEGP
(
x3EGPN (t)
x3EGPN (t) + s
3
EGPN
))
(4.24)
dxEGP (t)
dt
= pG4(I(t)− xEGP (t)) (4.25)
xEGPN (t) =
xEGP (t)
xEGPB
(4.26)
Here, equation (4.20) represents plasma glucose concentration, G(t) (mg
dl
). The first term in
the parenthesis on the RHS of equation (4.20) represents the glucose uptake rate under its
own influence. The bilinear term, xG(t)G(t), captures glucose uptake under the influence of
insulin; xG(t) (
1
min
) represents the action of insulin on tissue glucose uptake. The dynamics
of xG(t) are captured by equation (4.21). The multiplier function fFG(t) is a dimensionless
variable that captures the inhibitory effect of FFA on glucose uptake rate (RdG). Variables
xEGPN and FN are the remote insulin and FFA concentrations normalized with respect to
their basal levels, xEGPB and FB, respectively. The rate of endogenous glucose production
is represented by EGP (t), which is a function of plasma insulin as shown in equation
(4.24). EGP0 (
mg
dl·min) is the rate of hepatic glucose production in the absence of insulin.
The dynamical effect of insulin on EGP (t) is captured by the unobserved remote insulin
concentration, xEGP (t) (
µU
ml
).
To establish the correlation between HGP and insulin concentration, data was obtained
from [19, 20]. In these studies, the rate of glucose production was estimated by measuring
the arterial-venous glucose concentration difference across the liver along with the hepatic
blood flow rate. Due to the nature of the EGP dynamics with respect to the normalized
remote insulin concentration (xEGPN ), a 3
rd-order Hill function was selected for superior
model accuracy, as indicated in equation (4.24). The value of EGP0 and kEGP were directly
obtained from the literature [20]. Only the saturation constant sEGPN was estimated to fit
the data, as shown in Figure 4.12.
Randle et al. were the first to introduce the glucose-FFA cycle [58, 59] to explain the
interaction between CHO and fat metabolism. It was proposed that an increase in FFA
availability will enhance fat oxidation, thus causing an increase in acetyl-CoA production,
which will result in downregulating the rate-limiting CHO metabolizing enzymes. Due to
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Figure 4.12: Model fit (solid line) versus published data (µ± σ) (circle) [19, 20] of endogenous
glucose production rate, EGP , as a function of normalized insulin concentration xEGPN
this phenomenon, tissue glucose uptake will decrease [168]. The correlation between glucose
uptake rate, RdG, and plasma FFA was captured by utilizing data from [8, 21], where
experiments were performed on healthy subjects by employing euglycemic-hyperinsulinemic
clamps. The overall glucose uptake rate was measured at various plasma FFA levels (Figure
4.13). In Figure 4.13, the y-axis represents glucose uptake rate normalized with respect to
its basal level (fFG). The x-axis represents normalized plasma FFA concentration (FN). The
gain parameter, kFG, from equation (4.22) was directly obtained from the data [8, 21]. Only
the saturation constant, sFGN , was estimated to fit the data. Once again, due to the nature
of the dynamics of fFG with respect to the normalized FFA concentration, a 3
rd-order Hill
function was selected, as shown in equation (4.22). All the parameter values are given in
Table 4.1.
98
0 0.5 1 1.5 2 2.5 3
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
FN
f F
G
 
 
Figure 4.13: Model fit (solid line) versus published data (µ ± σ) (circle) [8, 21] of normalized
glucose uptake rate, fFG, as a function of normalized FFA concentration FN
At basal steady state conditions (i.e., F (t) = FB), the value of fFG becomes equal to 1.
Hence, equations (4.20) and (4.21) reduce to:
pG1 =
EGPB
GB
− xGB (4.27)
xGB =
pG2
pG3
IB (4.28)
Here, EGPB, GB, and IB are the endogenous glucose production rate, plasma glucose
concentration, and plasma insulin concentration at the basal level, respectively.
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Parameters pG2 and pG3 from equation (4.21), representing the insulin action on tissue
glucose uptake, and parameter pG4 from equation (4.25), capturing the dynamical effect
of insulin mediated-suppression on hepatic glucose production, were estimated by using
data from Regittnig et al. [22]. In this study, a labeled-IVGTT was performed in T1DM
patients. At time t=0 min, a bolus of glucose labeled with a stable isotope tracer, D-
[6,62H2]glucose, (hot glucose) was administered intravenously. A bolus of insulin was also
injected at t=0 min, followed by a continuous insulin infusion at constant rate to maintain
the basal level (Figure 4.14). Blood samples were gathered at regular intervals to measure
the concentrations of plasma insulin, tracer glucose, and total glucose (endogenous glucose
plus the labeled exogenous glucose), as shown in Figure 4.14 and 4.15. Parameters estimated
from the labeled-IVGTT data provide a significant advantage over the unlabeled-IVGTT [5].
Due to the presence of tracer, it is possible to monitor the dynamics of glucose disappearance
only. Hence, labeled IVGTT data can separate the individual contributions of insulin on
glucose production and utilization, which is impossible to achieve from unlabeled-IVGTT
data. This technique was first introduced by Cobelli et al. [5] to minimize model errors and
ambiguities that may arise when estimating parameters of the classical minimal model [1]
from the unlabeled data only.
To estimate the parameters (pG2, pG3, and pG4) from the labeled-IVGTT data [22], two
glucose models were used simultaneously. The total glucose concentration was captured by
using equations (4.20), (4.21), (4.24), (4.25), and (4.22); this forms the cold glucose model.
On the other hand, the tracer glucose concentration was captured by a new ODE as shown
below:
dGh(t)
dt
= (−pG1Gh(t)− xG(t)Gh(t)) fFG (4.29)
Here, Gh(t) (
mg
dl
) represents concentration of the tracer glucose. Equation (4.29) along with
equations (4.21) and (4.22) forms the hot glucose model. Simultaneous fitting of the total
and tracer glucose data (as shown in Figure 4.15) by using the cold and hot glucose models,
respectively, should provide better informed parameter estimates.
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Figure 4.14: Model prediction (solid line) versus published data (µ± σ) (circle) [22] of plasma
insulin concentration in response to a labeled-IVGTT (top); normalized insulin action with
respect to their basal values on glucose uptake (solid line) and endogenous glucose production
(dashed line) due to administration of insulin bolus at t=0 min (bottom).
Exercise induces an elevation in glucose uptake rate, RdG (
mg
dl·min), by the working muscles.
To maintain glucose homeostasis in the systemic level, glucose production rate (RaG,
mg
dl·min)
is also elevated during exercise due to the accelerated rate of glycogenolysis. As mentioned
earlier, an increased FFA oxidation results in downregulation of pyruvate dehydrogenase
(PDH) [168]; this is an important enzyme for glucose oxidation. This regulatory mechanism,
which is true at rest, is overridden by other factors during exercise [168]. Hence, studies have
revealed no effect of elevated FFA on glucose uptake during exercise [168, 169]. In order to
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Figure 4.15: Model prediction (solid line) versus published data (µ ± σ) (circle) [22] of total
glucose concentration (endogenous and exogenous labeled-glucose) in response to a labeled-
IVGTT (top); model prediction (solid line) versus published data (µ ± σ) (circle) [22] of
tracer glucose concentration in response to a labeled-IVGTT (bottom)
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incorporate all these important physiological effects of mild-to-moderate short-term exercise
on glucose dynamics, equations (4.20) and (4.23) were modified as follows:
dG(t)
dt
= (−pG1G(t)− xG(t)G(t)) fFG(t)− W
VG
yGU(t) + EGP (t) +
W
VG
yGP (t)
+
uG(t)
VG
(4.30)
FN(t) =
1
FB
((1− b)F (t) + bF0) (4.31)
The dynamics of the new terms yGU(t), yGP (t), and b, can be written as:
yGU(t)
dt
= mGU1PV O
max
2 (t)−mGU2yGU(t) (4.32)
yGP (t)
dt
= mGP1PV O
max
2 (t)−mGP2yGP (t) (4.33)
b =
PV Omax2 (t)
PV Omax2 (t) + sPV
(4.34)
Here, the variables yGU(t) and yGP (t) (
mg
kg·min) represent the exercise-induced glucose uptake
and production rates. F0 represents the FFA concentration at initial (or basal) conditions
(F0 = F (0)). At rest, b becomes equal to zero, as PV O
max
2 = 0. Hence, equation (4.31)
reduces to equation (4.23). However, during exercise (PV Omax2  1) b approaches 1, as sPV
is assigned a value of 1. Therefore, equation (4.31) becomes FN(t) = F0/FB at PV O
max
2 (t)
 1. As the normalized FFA concentration is fixed at its initial condition during physical
activity, fFG remains unperturbed at its initial condition. As a result of this, the increasing
concentration of plasma FFA during exercise has no effect on glucose uptake rate. The
motivation behind selecting sPV = 1 is that at PV O
max
2 = 40% almost 97% of FN(t) is
contributed by the second part of the RHS of equation 4.31 (i.e, F0
FB
), which concur with the
experiment performed by Odland et al. [168] where elevated FFA had no significant effect
on glucose uptake rate at the same level of exercise.
In order to capture the exercise-induced changes in glucose kinetics, data was procured
from Wolfe et al. [12], where healthy subjects performed exercise at PV Omax2 = 40% for 60
min. Blood samples were obtained at regular intervals to measure glucose uptake rate and
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hepatic glucose production rate during and after exercise, as shown in Figure 4.16. From
equation (4.30), plasma glucose uptake (RdG) and production (RaG) rate can be written as:
RdG = −
[
(−pG1G(t)− xG(t)G(t)) fFG(t)− W
VG
yGU(t)
]
(4.35)
RaG = EGP (t) +
W
VG
yGP (t) (4.36)
In order to obtain the model prediction of glucose uptake rate during exercise, parameters
mGU1 and mGU2 were estimated, as shown in Figure 4.16 (top). To capture the glucose
production rate during exercise, parameters mGP1 and mGP2 were adjusted, as shown in
Figure 4.16 (middle). With the onset of exercise, both RdG and RaG were elevated. As
the production matched utilization, the overall plasma glucose homeostasis was maintained
(Figure 4.16: bottom).
During prolonged exercise, the rate of hepatic glycogenolysis diminishes due to the limited
supply of liver glycogen stores [15]. As a result of this, the net endogenous glucose production
rate also decreases. As glucose production can no longer match the uptake rate, plasma
glucose concentration declines and reaches hypoglycemic levels during prolonged exercise
[13, 15]. In order to capture the glucose dynamics during prolonged exercise, equation (4.30)
can be re-written as follows:
dG(t)
dt
= (−pG1G(t)− xG(t)G(t)) fFG(t)− W
VG
yGU(t) + EGP (t)
+
W
VG
(yGP (t)− yGly(t)) + uG(t)
VG
(4.37)
The new variable yGly(t) (
mg
kg·min) represents the dynamics associated with the rate of glycogenol-
ysis due to depletion of the available hepatic glycogen stores. It captures the same physio-
logical effects of prolonged exercise on plasma glucose level as the variable Ggly(t) (equation
3.10) used in the exercise minimal model in Section 3.2.
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Figure 4.16: Model prediction (solid line) versus published data (µ ± σ) (circle) [12] in
response to mild exercise performed at PV Omax2 = 40% intensity lasting from tEx = 0
to 60 min. Top: glucose uptake rate (in deviation form) during exercise (RdG); Middle:
glucose production rate (in deviation form) during exercise (RaG); Bottom: plasma glucose
concentration during short-term exercise (G(t)).
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Hence, the dynamics of glycogenolysis during prolonged exercise can be mathematically
expressed as follows, adapted from equation (3.10):
dyGly(t)
dt
=

0 A(t) < ATH
k A(t) ≥ ATH
−yGly(t)
T1
uEx(t) = 0
(4.38)
Here, A(t) is the integrated exercise intensity (uEx(t)) having the same mathematical ex-
pression as equation (3.11) in Section 3.2. ATH is the critical threshold value of energy
expenditure which is a function of exercise intensity and duration, same as equation (3.9)
(Section 3.2). After the commencement of exercise, as long as A is less than ATH , the rate
of glycogenolysis (yGly) remains unaffected due to the presence of sufficient hepatic glycogen
stores. However, yGly starts to decline at a rate k, once A exceeds the threshold value (ATH).
At the end of exercise, i.e., the recovery period, liver glycogen stores are replenished back
to its basal level. The time required for yGly to return back to its basal level after exercise
is represented by the pseudo-time constants T1 and T2 (equation (3.11) from Section 3.2).
In order to estimate the parameter values of k and T1, data was obtained from an
experiment performed by Ahlborg et al. [15], where healthy subjects performed moderate
level exercise (PV Omax2 = 60%) lasting for 210 min. Blood samples were taken at regular
intervals during and immediately after exercise to measure blood glucose concentration, as
shown in Figure 4.17 (bottom). With the onset of exercise, both RdG and RaG are elevated
above their basal levels, as shown in Figure 4.17 (top) and (middle) panels, respectively. As
the duration of exercise exceeded a certain threshold, the rate of glycogenolysis started to
decrease from its original value. As a result of this, RaG started to decline until the end of
exercise, causing plasma glucose to reach hypoglycemic levels (Figure 4.17: bottom).
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Figure 4.17: Model prediction (solid line) versus published data [15] (µ ± σ) (circle) in
response to moderate exercise performed at PV Omax2 = 60% intensity lasting from tEx = 0
to 210 min. Top: glucose uptake rate in deviation variables during exercise (RdG); Middle:
glucose production rate in deviation variables during exercise (RaG); Bottom: plasma glucose
concentration during prolonged exercise (G).
4.3 PARAMETRIC SENSITIVITY ANALYSIS BY FINITE DIFFERENCE
METHOD
The composite model can be expressed as a set of Nx differential equations with Nx states
(x) and M parameters (θ). The Nx by M parameter sensitivity matrix can be calculated by
using the finite difference approximation method, in which the sensitivity coefficients (si,j)
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Table 4.1: Parameter values of the composite model.
Nos. Parameters Values Source Nos. Parameters Values Source
1 kEFP 0.92889 [16] 20 pG3
(
1
min
)
0.35 –
2 sEFPN 1.169 [16] 21 pG4
(
1
min
)
0.073535 –
3 EFP0
(
µmol
L·min
)
209.09 [16] 22 mIU1
(
1
min2
)
0.0028176 –
4 kEGP 0.9909 [20, 19] 23 mIU2
(
1
min
)
1.7354 –
5 sEGPN 0.84115 [20, 19] 24 mFU1
(
mumol
kg·min2
)
0.013736 –
6 EGP0
( mg
dL·min
)
2.618 [20, 19] 25 mFU2
(
1
min
)
0.032272 –
7 sFG 1.0472 [8, 21] 26 mFU3
(
1
min
)
0.0023229 –
8 fFG0 1.202 [21] 27 mFP1
(
mumol
kg·min2
)
0.016831 –
9 kFG 0.38075 [8, 21] 28 mFP2
(
1
min
)
0.018241 –
10 n
(
1
min
)
0.38075 [1] 29 mFP3
(
1
min
)
0.024841 –
11 VI (mL) 10.133 [1] 30 mGU1
(
mg
kg·min2
)
0.0021874 –
12 pF1
(
1
min
)
0.18727 – 31 mGU2
(
1
min
)
0.058974 –
13 W (kg) 70.0 [18] 32 mGP1
(
mg
kg·min2
)
0.0009152 –
14 VF (L) 3.0 [18] 33 mGP2
(
1
min
)
1.3073 –
15 VG (dL) 117.0 [1] 34 T1 (min) 1 –
16 pF2
(
1
min
)
0.036513 – 35 k
(
1
min
)
0.0038 –
17 pF3
(
1
min
)
0.03909 – 36 sPV 1 –
18 pG1
(
1
min
)
0.0076 – 37 T2 (min) 10 –
19 pG2
(
mL
µU ·min2
)
0.00010259 – 38 mPV
(
1
min
)
0.8 [63]
are calculated from the difference of nominal and perturbed solutions [170, 171].
si,j(t) =
∂xi(t)
∂θj
=
xi(θj +∆θj, t)− xi(θj, t)
∆θj
(4.39)
Here, i ∈ [1, Nx] and j ∈ [1, M ]. To facilitate direct comparison of responses across different
parameters, a normalized sensitivity coefficient (s¯i,j) is calculated [170]:
s¯i,j(t) =
∂xi(t)
∂θj
· θj
xi
(4.40)
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For the evaluation of dynamic sensitivity, a L2-norm operation is performed to calculate the
relative sensitivity (RS) along the time axis. RS can be mathematically expressed as:
RSi,j =
1
NP
√√√√ NP∑
k=1
|s¯i,j(k)|2 (4.41)
Here, k is the point in time when a sample is collected and NP is the total number of sample
points observed.
By using this method, a parametric relative sensitivity matrix (RSi,j) of the composite
model was generated. The matrix was comprised of 16 rows (i ∈ [1 to 16]), representing
the states, and 38 columns (j ∈ [1 to 38]), representing all the parameters of the model. A
graphical representation of the RSi,j values is provided in Figure 4.18. The y-axis lists the
parameters by number; this mapping is provided in Table 4.1. The x-axis lists the states
of the model as per Table 4.2, and the z-axis represents the parametric relative sensitivity
values corresponding to each state. A higher RSi,j value indicates the state is more sensitive
to the specified parameter.
By closely observing the insulin state (I(t)), RS1,1:38, reveals that the plasma insulin is
highly sensitive to its own parameters, n and VI , which is expected (Figure 4.19: top). The
FFA state (F (t)), RS2,1:38, indicates that plasma FFA is most sensitive to parameter pF1
followed by parameter EFP0 (Figure 4.19: middle). Plasma FFA also exhibits significant
sensitivity towards the parameters associated with I(t). The parameters associated with
FFA production during exercise (mFP1, mFP2, and mFP3) are relatively more sensitive than
the parameters associated with FFA uptake during exercise (mFU1, mFU2, and mFU3). For
the glucose state (G(t)), RS3,1:38, the most sensitive parameters are the ones associated
with I(t), as shown in Figure 4.19 (bottom). Parameters associated with the endogenous
glucose production rate (kEGP , sEGP , and EGP0) are more sensitive than the parameter
pG1, which captures the effect of glucose on its own uptake rate. Parameters representing
insulin action on glucose uptake by the tissues (pG2 and pG3) are more sensitive than the
parameter representing the insulin action on suppression of endogenous glucose production
rate (pG4). Also, the parameters representing glucose uptake during exercise (mGU1 and
109
2 4
6 8
1012
1416
0
10
20
30
40
0
50
100
150
200
250
States
Parameters
R
el
. S
en
sit
ivi
ty
Figure 4.18: Parametric relative sensitivity analysis of the composite model for all the sixteen
states.
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Table 4.2: List of states of the composite model used in the parametric sensitivity analysis
Nos. Equations Nos. Equations
1 (4.1) 9 (4.3)
2 (4.13) 10 (4.16)
3 (4.37) 11 (4.17)
4 (4.2) 12 (4.18)
5 (4.6) 13 (4.19)
6 (4.11) 14 (4.32)
7 (4.21) 15 (4.33)
8 (4.25) 16 (4.38)
mGU2) are significantly more sensitive than the parameters representing glucose production
during exercise (mGP1 and mGP2).
Lots of important informations can be extracted from the parametric sensitivity analysis.
For example, endogenous glucose production plays a major role in maintaining glucose
homeostasis. Hence, more experiments are required to accurately define the correlation
between EGP (t) and I(t). Moreover, the RSi,j matrix indicates that the suppression of
insulin plays a bigger role in elevating endogenous glucose production rate during physical
activity than the exercise-mediated glucose production. However in case of FFA, the exercise-
mediated fat production was more prominent than the elevated lipolysis due to insulin
suppression during exercise. Experimental studies could be performed to verify the extent
of hypoglycemia that might be reached during short-term exercise by clamping the plasma
insulin at basal level.
4.4 VALIDATION OF THE LOWER-ORDER COMPOSITE MODEL
Once the model was formulated and the parameters were estimated from the literature data,
simulation studies were performed to validate the various components of the model. Model
predictions were compared with new data sets (i.e., data different from the ones used for
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Figure 4.19: Parametric relative sensitivity analysis of the composite model for the plasma
insulin, I(t) (top), FFA, F (t) (middle), and glucose, G(t) (bottom) states.
parameter estimation), without manipulating the estimated parameter values. As described
in Section 2.3, R2 was used to quantitate the goodness of fit.
4.4.1 Effect of Exercise on Plasma Insulin Concentration
For validation of the insulin model, a simulation test was performed at a mild level of
exercise, PV Omax2 = 30%, lasting for 120 min. With the onset of exercise, plasma insulin
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level declined due to the accelerated insulin clearance rate. During the recovery period,
plasma insulin concentration climbed back to its basal level. Model validation along with
experimental data of healthy individuals subjected to same exercise protocol [13] is shown
in Figure 4.20. The model prediction emulates the data well. Although, at the 40 min mark
the model slightly underpredicts the data.
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Figure 4.20: Plasma insulin concentration in response to mild exercise (PV Omax2 = 30)
lasting from tex = 0 to 120 min. Model simulation validation (solid line) and published data
[13] (circles) (µ ± σ) of plasma insulin [R2 = 0.936].
4.4.2 Effect of Insulin on Plasma FFA Dynamics
In order to validate the insulin effects on FFA dynamics, a MI-FSIGT simulation test was
performed, where boluses of insulin were infused at time t = 0 and 20min at a rate similar to
the experiment performed by Brehm et al. [23] (Figure 4.21: top). Due to the anti-lipolytic
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action of insulin, plasma FFA declined well below its basal level (Figure 4.21: bottom). The
model predictions, as shown in Figure 4.21, are within one standard deviation of the data.
After the two hour mark, however, the model seems to slightly underpredict the plasma FFA
data.
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Figure 4.21: Plasma FFA concentration in response to MI-FSIGT test where boluses of
insulin were administered at time t = 0 and 20 min. Model simulation validation (solid line)
and published data [23] (circles) (µ ± σ) of plasma insulin concentration [R2 = 0.999] (top);
model predictions of remote insulin xEFP1 (solid line) and xEFP2 (dashed line) concentrations
(middle); model simulation validation (solid line) and published data [23] (circles) (µ ± σ)
of plasma FFA concentration [R2 = 0.998] (bottom).
4.4.3 Effect of Exercise on Plasma FFA Dynamics
For validation of the exercise effects on plasma FFA, a simulation study of a mild level of
exercise, PV Omax2 = 30%, was performed for 2 hours. With the onset of exercise, plasma
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FFA utilization (RdF ) and production (RaF ) rate continuously increased until the end of
physical activity. As the lipolytic rate was more than the uptake rate, FFA concentration
increased steadily until the end of exercise. During the recovery period, FFA level remained
elevated for about 20-30 min before it started to gradually decline toward its basal level.
A comparison of the model prediction and experimental data from subjects undergoing the
same exercise protocol [13] is provided in Figure 4.22. The model performed well during the
exercise period, however, the model predictions during the recovery period were slower than
the data.
0 50 100 150
0
100
200
300
R
d F
(µm
o
l/L
/m
in
)
0 50 100 150
100
200
300
R
a F
(µm
o
l/L
/m
in
)
0 50 100 150
1000
1500
2000
FF
A
(µm
o
l/L
)
Time (min)
Figure 4.22: Plasma FFA concentration in response to mild exercise (PV Omax2 = 30) lasting
from tex = 0 to 120 min. Model prediction of plasma FFA uptake rate, RdF (top); model
prediction (solid line) of plasma FFA production rate, RaF (middle); model simulation
validation and published data [13] (circles) (µ ± σ) of plasma FFA concentration [R2 =
0.989] (bottom).
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4.4.4 Effect of Insulin on Plasma Glucose Dynamics
For the glucose model validation, a labeled MI-FSIGT simulation test was performed, where
boluses of insulin were administered at time t = 0 and 20 min (Figure 4.23) and a bolus of
labeled glucose was infused at t = 0 min, at a rate similar to the experiment performed by
Nagasaka et al. [24]. Model predictions of the total glucose concentration (i.e., endogenous
glucose plus the labeled exogenous glucose) and tracer glucose concentrations obtained from
the cold (equation (4.20)) and hot glucose model (equation (4.29)), respectively, along with
the data [24] are provided in Figure 4.24. The model predicted glucose kinetics after the first
insulin bolus seems to be marginally slower than the data. However, the model performed
quite well in emulating the data after the second insulin bolus.
4.4.5 Effect of Exercise on Glucose Dynamics
In order to validate the short-term exercise effects on glucose kinetics, a simulation test was
performed at moderate level exercise, PV Omax2 = 50%, for 45min. With the onset of exercise,
both RdG and RaG were elevated. As production matched uptake, the overall plasma
glucose concentration remained within the normoglycemic range. The model predictions
alongside experimental data of T1DM patients [14] are plotted in Figure (4.25). The model
predicted glucose kinetics are well within one standard deviation of the data. Validation of
the composite model using T1DM patient data increased the confidence in the model.
To validate the glucose model during prolonged exercise, a separate simulation study of
mild exercise was performed at PV Omax2 = 30% which lasted for 120 min. As the integrated
exercise intensity exceeded the threshold value, hepatic glycogen stores started to deplete;
this caused a net reduction in glucose production. Due to this imbalance between production
and utilization, plasma glucose concentration started to decline at the later stages of exercise.
A comparison between the model predictions and data obtained from a study performed by
Ahlborg et al. on healthy subjects using the same exercise protocol are provided in Figure
4.26. Once again, the model predictions are well within one standard deviation of the data.
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Figure 4.23: Plasma insulin concentration in response to labeled-MI-FSIGT test where
insulin boluses were administered at times t = 0 and 20 min. Model simulation validation
(solid line) and published data [24] (circles) (µ ± σ) of plasma insulin concentration [R2
= 0.997] (top); model predictions of normalized insulin action, xNG , (solid line) and x
N
EGP
(dashed line) with respect to their basal values (bottom).
4.4.6 Effect of FFA on Glucose Uptake Rate at Rest
At rest, an increasing FFA concentration suppresses plasma glucose uptake rate. This
inhibitory effect of FFA on RdG is captured by the dimensionless multiplicative function,
fFG (equation (4.22)). In order to validate this physiological interaction between FFA and
glucose, a simulation study was performed where euglycemic-hyperinsulinemic clamps were
employed. Insulin was elevated up to 62 µU
ml
to match the data obtained from an experimental
study performed by Thiebaud et al. [8]. Intralipids were infused at either: )i) a low rate
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Figure 4.24: Plasma glucose concentration in response to labeled-MI-FSIGT test where a
labeled-glucose bolus was infused at time t = 0 min. Model simulation validation (solid line)
and published data [24] (circles) (µ ± σ) of plasma total glucose concentration [R2 = 0.999]
(top); model simulation validation (solid line) and published data [24] (circles) (µ ± σ) of
labeled-glucose concentration [R2 = 0.99] (bottom).
to maintain basal levels of 340 µmol
l
FFA, or (ii) a high rate elevating FFA levels to 650
µmol
l
. These FFA model predictions are shown by the dashed and dotted lines in Figure
4.27 (top). In absence of intralipid infusion (control study), FFA declined freely without
any restrictions, as shown by the solid line in Figure 4.27 (top). Due to the elevated plasma
FFA levels, glucose uptake rate was suppressed as shown by the dashed and dotted lines in
Figure 4.27 (bottom). The model predictions are well within one standard deviation of the
experimental data [8], thus indicating the capability of the model to accurately predict the
glucose-FFA cycle.
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Figure 4.25: Model simulation validation (solid line) versus published data [15] (µ ± σ)
(circles) in response to moderate exercise performed at PV Omax2 = 50% intensity lasting
from tEx = 0 to 45 min. Glucose uptake rate (in deviation form) during exercise (RdG)
[R2 = 0.935] (top); glucose production rate (in deviation form) during exercise (RaG) [R
2 =
0.955] (middle); plasma glucose concentration during short-term exercise (G(t)) [R2 = 0.82]
(bottom).
4.5 SUMMARY
In this chapter, a 16-state metabolic model of insulin, glucose, and FFA was developed. The
primary goal was to characterize the dynamics of the major energy-providing substrates and
insulin at rest, as well as during exercise. The model successfully captured the physiological
effects of FFA and mild-to-moderate exercise on plasma glucose concentration. This novel
approach of incorporating both FFA and exercise effects in the glucose-insulin metabolic
119
0 50 100 150
0
0.2
0.4
R
d G
(m
g/d
L/m
in)
0 50 100 150
0
0.2
0.4
R
a G
(m
g/d
L/m
in)
0 50 100 150
65
70
75
G
lu
co
se
(m
g/d
L)
Time (min)
Figure 4.26: Model simulation validation (solid line) versus published data [13] (µ ± σ)
(circle) in response to mild arm exercise performed at PV Omax2 = 30% intensity lasting
from tEx = 0 to 120 min. Glucose uptake rate in deviation variables during exercise (RdG)
(top); glucose production rate in deviation variables during exercise (RaG) (middle); plasma
glucose concentration during prolonged exercise (G) [R2 = 0.861] (bottom).
model provides the diabetes research community with an excellent tool to investigate the
fluctuations in glucose dynamics after consumption of mixed meal or performing exercise.
The model consisted of four parts capturing the insulin, glucose, FFA, and exercise
dynamics. The plasma insulin action on FFA and glucose was divided into three sections.
The dynamical effect of insulin on lipolysis was captured by the two first-order filters (xEFP1
and xEFP2) in series. The model successfully emulated the plasma FFA dynamics during a
MI-FSIGT test and during hyperinsulinemic clamp studies. The insulin effects on glucose
were divided into two parts. The first part captured the gluco-regulatory action of insulin
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Figure 4.27: Plasma FFA concentration due to infusion of intralipids at high rate (dotted
line), low rate (dashed line), and saline (no intralipid infusion) (solid line) (top); published
data [8, 21] (µ ± σ) (circle) versus model simulation validations of plasma glucose uptake
rate at high (dotted line) [R2 = 0.923] and low (dashed line) [R2 = 0.901] intralipid infusion
rates, as well as no intralipid infusion (solid line) [R2 = 0.944] (bottom).
in promoting glucose uptake into the tissues via the filter xG. The second part captured the
insulin-mediated suppression of endogenous glucose production by considering the saturating
function EGP (t), along with the filter xEGP . Parameters of the filter equations were
estimated by using a labeled-IVGTT. This technique of using hot and cold IVGTT data
facilitates separation of the insulin action on glucose utilization and production [75, 5], thus
providing more confidence in the estimated parameters.
The exercise effects on insulin, glucose, and FFA were divided into five sections. The
exercise-induced clearance of insulin was captured by the first-order filter, yIU . For the
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glucose dynamics, the elevated rates of glucose production and utilization during exercise
were captured by yGP and yGU , respectively. During short-term mild-to-moderate exercise,
plasma glucose typically remains within the normoglycemic range as glucose production
matches the utilization rate. However, as the integrated exercise intensity exceeded a certain
threshold, the rate of glycogenolysis is expected to decline due to the depletion of available
hepatic glycogen stores. As a result of this, the net glucose production rate will also decrease.
This phenomenon was captured by incorporating the yGly variable. In order to capture the
exercise effects on FFA kinetics, four compartments were used as shown in Figure 4.10. A
set of two compartments represented the exercise-induced FFA uptake rate (y1FU and y2FU),
and the remaining two compartments captured the elevated rate of FFA production during
exercise (y1FP and y2FP ).
The model also successfully captured the inhibitory effects of FFA on glucose uptake rate
at rest. This phenomenon is also known as the glucose-FFA cycle, which was first introduced
by Randle et al. [58, 59] in the early 1960’s.
This more complete metabolic model has the potential to provide an excellent plat-
form for the control community in development of model-based closed-loop insulin delivery
systems for T1DM patients. The primary advantage of utilizing the composite model in
the development of an artificial pancreas instead of other metabolic models present in the
literature, is because of its unique ability to predict plasma glucose concentration in response
to disturbances from mixed meals (CHO and fat) consumption and from exercise. The model
can also accurately predict the interactions taking place between the major energy-providing
metabolites and hormones during rest and exercise.
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5.0 A PHYSIOLOGICALLY-BASED FFA, GLUCOSE, AND INSULIN
MODEL
In the earlier chapters, semi-empirical metabolic models were developed to capture the effects
of FFA and exercise on glucose-insulin dynamics. In Chapter 2, the extended minimal
model was synthesized by modifying the classical minimal model [1] to incorporate plasma
FFA dynamics and the interactions of FFA with glucose and insulin. The model consisted
of lumped compartments and parameters capturing the systemic physiological interactions
between FFA, glucose, and insulin. Only the necessary metabolic processes of FFA were
considered in order to maintain the simplifying approach of the minimal model. Due to the
minimum number of equations, a lesser number of parameters needed to be estimated, which
generally makes simplified models easily identifiable, as well as less time intensive to build.
However, these models do not differentiate the distribution of metabolic substrates at the
various organ/tissue levels. Typically, in such models the entire body is treated as a single
well-mixed space. Hence, the semi-empirical model fails to provide a detailed explanation of
the biology that is actually taking place in the body, particularly at the organ/tissue scale.
In contrast, physiologically-based models are much more complex in terms of number
of equations and parameters. These models provide a great deal of insight into the system
as they are derived from known physiology. Typically in such models, the body is divided
into compartments representing the major organs and tissues. Biologically relevant organ-
specific metabolism can be captured, thereby making the model more structurally accurate.
Physiologically-based models can also provide motivation to perform new experiments in
order to validate certain model components, thereby incorporating biological understanding
of tissue metabolic processes. However, such detailed models come at a price. Usually,
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these models are very time intensive to develop, and often a large number of parameters are
required to be estimated from limited available data sets.
Tiran et al. were the first to attempt to develop a physiologically-based glucose-insulin
model in the mid 1970s [76, 106]. Compartments representing the major glucose utilizing or-
gans/tissues were used. Glucose and insulin were distributed into each of these compartments
via the circulatory system. Constant glucose uptake or production rates were incorporated in
each of the physiological compartments. Later, a pharmacokinetic-pharmacodynamic model
of metabolism was developed by Sorensen [2] in the mid 1980s, which was based on an
earlier model by Guyton et al. [107]. The model was comprised of two sub-units capturing
the glucose and insulin concentrations just like the Guyton model; in addition it also included
the glucagon dynamics and its interactions with the glucose-insulin system. In the glucose
and insulin sub-units, distribution of the energy-providing substrate and the gluco-regulatory
hormone were modeled at the organ/tissue levels, respectively. The glucagon sub-unit
consisted of a single well-mixed compartment representing the glucagon concentration at
the systemic level. Metabolic rates causing addition or removal of glucose were assigned to
each of the compartments. Hyperbolic tangent functions were used to represent the sigmoidal
nonlinearities observed in the experimental data between the metabolic sinks/sources and
the regulatory hormones.
Later in the 1990s, Cobelli et al. [78] developed another semi-physiological glucose-
insulin model. The model consisted of several components representing physiologically-
based glucose and insulin interactions; however, glucose distribution at the organ level was
not considered. Most of the detailed metabolic models present in the literature do not
consider FFA dynamics. As mentioned earlier, FFA plays a vital role in providing energy
to the tissues. Also fluctuations in FFA dynamics alter glucose dynamics to a significant
level. Hence, in this chapter a physiologically-based FFA model was developed and was
coupled with the existing glucose-insulin model developed by Sorensen [2], which has a
similar structure. The objective is to predict FFA distribution at the organ/tissue levels and
to capture the interactions between glucose, insulin, and FFA through out the body.
In Section 5.1, the glucose-insulin model developed by Sorensen [2] is presented in detail.
The physiologically-based FFA model is presented in Section 5.2. The original Sorensen
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model was modified in order to integrate the FFA model, as indicated in Section 5.3.
Metabolic sinks and sources of the FFA model are presented in Section 5.4. In Section
5.5, the interconnection points between the FFA and the glucose model are discussed in
details. Finally, the simulation results of the physiologically-based model are presented in
Section 5.6.
5.1 GLUCOSE-INSULIN PHYSIOLOGICAL MODEL OF SORENSEN
The model is comprised of three sub-systems: glucose, insulin, and glucagon. Eleven
ODEs are used to define the glucose sub-system, seven define the insulin sub-system, and
one models the glucagon dynamics. The glucose model consisted of several compartments
representing the vital glucose-utilizing organs/tissues: brain, heart/lungs, kidney, liver, gut,
and periphery, as shown in Figure 5.1. The peripheral compartment represents skeletal
muscle, as well as adipose tissue (AT). The heart/lungs, kidney, liver, and gut compartments
consist of a single well-mixed space where the substrate concentrations are assumed to be
homogeneous, as shown in Figure 5.2. Each compartment is fed by the arterial blood
influx and drained by the venous blood eﬄux. In some organs and tissues (mainly the
brain and periphery) the capillary wall permeability is sufficiently low, thereby causing a
slow equilibration of substrates between the capillary and the interstitial spaces. Hence,
compartments representing such organs/tissues included two well-mixed spaces (capillary
and interstitial space) where the substrate concentrations are assumed to be homogeneous
(see Figure 5.3). Once again, substrates enter the capillary space via the arterial route and
is drained by the venous route. The substrates diffuse through the capillary wall into the
interstitial space from where they are ultimately consumed by the cells. Metabolic sinks,
representing the rate of glucose consumption due to oxidation or storage, were added to each
of these compartments. In the liver glucose flux is bi-directional, as it consumes glucose
mostly for storage purposes in the form of glycogen, as well as releases the stored glucose in
the circulatory system whenever the body requires energy. Hence, both metabolic sink and
source were incorporated in the liver compartment. The insulin model had a similar structure
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like the glucose model. Only difference is that, the brain had a single compartment unlike
the glucose model, as studies have shown that the capillary wall of the brain is impermeable
to insulin passage to the interstitial fluid space [172]. Metabolic sinks representing insulin
clearance were added to the liver, kidney, and periphery compartments. Glucagon was
modeled using a single ODE capturing the systemic glucagon concentration.
Mass balances were performed across each physiologic compartment to capture the solute
distribution. Typically, where the capillary wall resistance is negligible thus allowing a rapid
equilibration of the solute (X) between the capillary and the interstitial fluid spaces, only
one mass balance equation is sufficient to capture the dynamics, as given below:
V XJ
dCJ(t)
dt
= QXJ (CJi(t)− CJ(t))−RJU (5.1)
As indicated in the left hand side (LHS) of the above equation (5.1), the rate of mass
accumulation in the homogeneously mixed single compartment is equal to the product of
organ/tissue volume, V XJ (l
3), and the rate of change of solute concentration. CJi(t) (mass/l
3)
is the arterial blood solute concentration and CJ(t) (mass/l
3) is the solute concentration in
the organ/tissue and the outlet port, i.e., the vein. Finally, RJU (mass/time) is the rate
of solute uptake by the cells (metabolic sink). Subscript J represents the compartment.
The first term in the right hand side (RHS) of equation (5.1) represents convection and the
second term represents metabolic sink/source.
In some cases where the capillary wall resistance is significantly high (Figure 5.3), two
mass balance equations can be written to capture the solute concentrations in the capillary
and interstitial space as shown below:
V XJV
dCPV (t)
dt
= QXJ (CJi(t)− CJV (t))−
V XPI
TXJ
(CJV (t)− CJI(t)) (5.2)
V XJI
dCPI(t)
dt
=
V XPI
TXJ
(CJV (t)− CJI(t))−RJU (5.3)
Here, V XJV (l
3) is the capillary blood volume and V XJI (l
3) is the interstitial fluid volume.
The volumetric blood flow rate is given by QXJ (l
3/time). CJV (t) (mass/l
3) is the venous
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Figure 5.1: Physiologically-based metabolic model for glucose, adapted from [2]
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Figure 5.2: Schematic representation of a physiologic compartment with no capillary wall
resistance
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Figure 5.3: Schematic representation of a typical physiologic compartment with capillary
and interstitial space
solute concentration, assumed in equilibrium with the capillary space solute concentration.
The interstitial fluid solute concentration is given by CJI(t) (mass/l
3). TXJ (time) is the
transcapillary diffusion time constant.
The rate of mass accumulation in the capillary space is equal to the product of the
capillary blood volume and the rate of change of solute concentration in the capillary
(equation 5.2). This rate of mass accumulation is the net additive result of contributions by
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convection (first term on the RHS of equation (5.2)) and diffusion (second term on the RHS
of equation (5.2)). A similar mass balance equation is written for the interstitial fluid space,
as indicated by equation (5.3). In this case, the rate of mass accumulation is the result of
contribution by diffusion (first term on the RHS of equation (5.3)) and any metabolic sink
or source (second term on the RHS of equation (5.3)). Convection does not influence the
interstitial fluid space.
By applying the above mathematical analysis, mass balance equations were generated
for the glucose and insulin models at each physiologic compartments. Following are the
physiologically-based model equations along with the nomenclature (Table 5.2) and parame-
ter values (Table 5.1) adapted from [2]:
Glucose model
Brain:
dGBV (t)
dt
=
QGB
V GBV
(GH(t)−GBV (t))− VBI
V GBV T
G
B
(GBV (t)−GBI(t)) (5.4)
dGBI(t)
dt
=
1
TGB
(GBV (t) −GBI(t))− RBGU
VBI
(5.5)
Heart and Lungs:
dGH(t)
dt
=
1
V GH
(QGBGBV (t) +Q
G
LGL(t) +Q
G
KGK(t) +Q
G
PGPV (t)−QGHGH(t)) (5.6)
−RRBCU
V GH
(5.7)
Gut:
dGG(t)
dt
=
QGG
V GG
(GH(t)−GG(t))− RGGU
V GG
(5.8)
Liver:
dGL(t)
dt
=
1
V GL
(QGYGH(t) +Q
G
GGG(t)−QGLGL(t) +RHGP )−
RHGU
V GL
(5.9)
129
Kidney:
dGK(t)
dt
=
QGK
V GK
(GH(t)−GK(t))− RKGE
V GK
(5.10)
(5.11)
Periphery:
dGPV (t)
dt
=
QGP
V GPV
(GH(t)−GPV (t))− V
G
PI
V GPV T
G
P
(GPV (t)−GPI(t)) (5.12)
dGPI(t)
dt
=
1
TGP
(GPV (t)−GPI(t))− RPGU
V GPI
(5.13)
Metabolic sources and sinks:
RPGU = M
I
PGU ×MGPGU × 35 (5.14)
M IPGU = 7.03 + 6.52× tanh[0.338(INPI(t)− 5.82)] (5.15)
MGPGU = G
N
PI(t) (5.16)
RHGP = M
I
HGP ×MXHGP ×MGHGP × 155 (5.17)
dM IHGP
dt
=
1
τI
(M I∞HGP −M IHGP ) (5.18)
M I∞HGP = 1.2793− 1.0647× tanh[1.733(INL (t)− 0.849)] (5.19)
MXHGP = M
X0
HGP − f2 (5.20)
MX0HGP = 2.7× tanh[0.39XN(t)] (5.21)
df2
dt
=
1
τX
[
MX0HGP − 1
2
− f2
]
(5.22)
MGHGP = 1.42− 1.41× tanh[0.62(GNL (t)− 0.497)] (5.23)
RHGU = M
I
HGU ×MGHGU × 20 (5.24)
dM IHGU
dt
=
1
τI
(M I∞HGU −M IHGU) (5.25)
M I∞HGU = 2.0× tanh[0.55INL (t)] (5.26)
MGHGU = 5.66 + 5.66× tanh[2.44(GNL (t)− 1.48)] (5.27)
RKGE = 71 + 71× tanh[0.11(GK(t)− 460)] 0 < GK(t) < 460 mg/dL (5.28)
RKGE = −330 + 0.872G(t)K GK(t) ≥ 460 mg/dL (5.29)
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Insulin model
Brain:
dIB(t)
dt
=
QIB
V IB
(IH(t)− IB(t)) (5.30)
Heart and Lungs:
dI(t)H
dt
=
1
V IH
(QIBIB(t) +Q
I
LIL(t) +Q
I
KIK(t) +Q
I
P IP (t)−QIHIH(t)) (5.31)
Gut:
dIG(t)
dt
=
QIG
V IG
(IH(t)− IG(t)) (5.32)
Liver:
dIL(t)
dt
=
1
V IL
(QIY IH(t) +Q
I
GIG(t)−QILIL(t))−
RLIC
V IL
(5.33)
Kidney:
dIK(t)
dt
=
QIK
V IK
(IH(t)− IK(t))− RKIC
V IK
(5.34)
Muscle:
dIPV (t)
dt
=
QIP
V IPV
(IH(t)− IPV (t))− V
I
PI
V IPV T
I
P
(IPV (t)− IPI(t)) (5.35)
dIPI(t)
dt
=
1
T IP
(IPV (t)− IPI(t))− RPIC
V IPI
(5.36)
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Metabolic sources and sinks:
RLIC = fLIC(Q
I
Y IH(t) +Q
I
GIG(t)) (5.37)
RKIC = fKIC(Q
I
KIK(t)) (5.38)
RPIC =
IPI(t)(
1−fPIC
fPIC
)(
1
QIP
)
− T IP
VPI
(5.39)
Glucagon model
dXN(t)
dt
=
1
V X
(RMXCR
N
PXR
−RPXC(t)) (5.40)
Metabolic sources and sinks:
RPXC(t) = RMXCX
N(t) (5.41)
RNPXR = M
I
PXR
MGPXR (5.42)
MGPXR = 2.93− 2.10× tanh[4.18(GNH(t)− 0.61)] (5.43)
M IPXR = 1.31− 0.61× tanh[1.06(INH (t)− 0.47)] (5.44)
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Table 5.1: Parameter values of the Sorensen model, adapted from [2]
Parameters Values Parameters Values
RBGU (mg/min) 70 TGP (min) 5.0
RRBCU (mg/min) 10 fLIC 0.4
RGGU (mg/min) 20 fKIC 0.3
τI (min) 25 fPIC 0.15
τX (min) 65 V IB (L) 0.26
V GBV (dL) 3.5 V
I
H (L) 0.99
V GBI (dL) 4.5 V
I
G (L) 0.94
V GH (dL) 13.8 V
I
L (L) 1.14
V GL (dL) 25.1 V
I
K (L) 0.51
V GG (dL) 11.2 V
I
PV (L) 0.74
V GK (dL) 6.6 V
I
PI (L) 6.74
V GPV (dL) 10.4 Q
I
B (L/min) 0.45
V GPI (dL) 63.0 Q
I
H (L/min) 3.35
QGB (dL/min) 5.9 Q
I
Y (L/min) 0.18
QGH (dL/min) 43.7 Q
I
K (L/min) 0.72
QGY (dL/min) 2.5 Q
I
P (L/min) 1.28
QGL (dL/min) 12.6 Q
I
G (L/min) 0.72
QGG (dL/min) 10.1 Q
I
L (L/min) 0.9
QGK (dL/min) 10.1 T
I
P (min) 20.0
QGP (dL/min) 15.1 RMXC (L/min) 0.91
TGB (min) 2.1 V
X (L) 9.94
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Table 5.2: Nomenclature of the Sorensen model [2]
Variables Description
G Glucose concentration (mgdL )
Q Vascular blood flow ( dLmin)
R Metabolic source or sink ( mgmin)
M Multiplier function
T Transcapillary diffusion time (min)
V Volume (L)
τ time constant
t Time (min)
I insulin concentration ( µUmL)
f fractional clearance
X glucagon concentration ( pgmL)
First Subscript: Description
Physiologic Compartment
B Brain
H Heart and Lungs
G Gut
L Liver
K Kidney
P Periphery
Y Hepatic Artery tissue
Second Subscript Description
Physiologic Subcompartment
I Interstitial fluid space
V Vascular blood space
Metabolic Rate Subscript Description
BGU Brain glucose uptake
GGU Gut glucose uptake
HGU Hepatic glucose uptake
HGP Hepatic glucose production
KGE Kidney glucose excretion
PGU Periphery glucose uptake
RBCU Red blood cell glucose uptake
KIC Kidney insulin clearance
LIC Liver insulin clearance
PIC Periphery insulin clearance
PXC Plasma glucagon clearance
MXC Metabolic glucagon clearance
PXR Pancreatic glucagon release
Superscript Description
G glucose
I insulin
X glucagon
B basal value
N normalized value (divided by basal value)
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5.2 PHYSIOLOGICAL FFA MODEL STRUCTURE
A physiologically-based FFA model similar in structure to the existing glucose-insulin model
of Sorensen [2] was developed to capture FFA distribution in various tissues and its interac-
tions with other metabolic substrates and hormones. The model consists of compartments
representing the major FFA utilizing tissues and organs, as shown in Figure 5.4. In this
case, unlike the original glucose-insulin Sorensen model, the periphery compartment was
divided into AT and muscle compartments, as these have different roles in FFA dynamics.
For example, FFA movement across AT is bi-directional, unlike muscle tissues [54]. During
fasting, FFA is predominantly generated within the AT by breaking down stored triglycerides
(TG), and there is a net outflow of FFA from AT into the systemic circulation. However in
the fed state, FFA released from circulating TG is taken up by the AT for esterification and
storage as TG [173]. As shown in Figure 5.4, only the muscle and AT compartments were
divided into two sub-compartments representing the capillary and interstitial fluid spaces.
Blood pumped from the heart entered into the compartments via the arterial route and
is drained out through the venous route. The rate of consumption of FFA at the various
compartments is represented by the vertically-downward pointing arrows, as shown in Figure
5.4 (metabolic sinks). The only vertically-upward pointing arrow at the AT compartment
captured the rate of lipolysis, or, the rate of production of FFA (metabolic source). The
brain is the only organ which neither consumes nor produces FFA [174]. The mass balance
equations across each of the physiologic compartments are formulated as follows:
Brain:
dFB(t)
dt
=
QFB
V FB
(FH(t)− FB(t)) (5.45)
Heart and lungs:
dFH(t)
dt
=
1
V FH
(QFBFB(t) +Q
F
LFL(t) +Q
F
KFK(t) +Q
F
MFMV (t) +Q
F
AFAV (t)−QFHFH(t))
−RHFU
V FH
(5.46)
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Gut:
dFG(t)
dt
=
QFG
V FG
(FH(t)− FG(t))− RGFU
V FG
(5.47)
Liver:
dFL(t)
dt
=
1
V FL
(QFY FH(t) +Q
F
GFG(t)−QFLFL(t))−
RLFU
V FL
(5.48)
Kidney:
dFK(t)
dt
=
QFK
V FK
(FH(t)− FK(t))− RKFE
V FK
(5.49)
Muscle:
dFMV
dt
=
QFM
V FMV
(FH − FMV )− VMI
V FMV T
F
M
(FMV − FMI) (5.50)
dFMI
dt
=
1
T FM
(FMV − FMI)− RMFU
VMI
(5.51)
AT:
dFAV (t)
dt
=
QFA
V FAV
(FH(t)− FAV (t))− VAI
V FAV T
F
A
(FAV (t)− FAI(t)) (5.52)
dFAI(t)
dt
=
1
T FA
(FAV (t)− FAI(t))− RAFU
VAI
+
RAFP
VAI
(5.53)
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Table 5.3: Nomenclature of the physiologically-based FFA model
Variables Description
F FFA concentration (µmolL )
Q Vascular blood flow ( Lmin)
R Metabolic source or sink (µmolmin )
T Transcapillary diffusion time (min)
V Volume (L)
t Time (min)
First Subscript: Description
Physiologic Compartment
B Brain
H Heart and Lungs
G Gut
L Liver
K Kidney
M Muscle
A Adipose tissue
Y Hepatic Artery tissue
Second Subscript Description
Physiologic Subcompartment
I Interstitial fluid space
V Vascular blood space
Metabolic Rate Subscript Description
BFU Brain FFA uptake
HFU heart/lungs FFA uptake
GFU Gut FFA uptake
LFU Liver FFA uptake
KFE Kidney FFA uptake
MFU Muscle FFA uptake
AFU AT FFA uptake
AFP AT FFA production
Superscript Description
F FFA model
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MEAL
V FB FB
H
M
V FH
V FL
V FG
V FK
V FMI
V FAV
V FAI
L
G
K
V FMV
AT
FH
FG
FL
FK
FMI
FAV
FAI
FMV
RHFU
RLFU
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RGFU
QFB
QFK
QFG
QFM
QFA
QFL
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QFH
B
QFA
RAFU RAFP
RKFU
QFG
Figure 5.4: Physiologically-based FFA model block diagram. B: Brain; H: Heart and lungs;
G: Gut; L: Liver; K: Kidney; M: Muscle; AT: Adipose tissue.
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Table 5.4: Parameter values of the physiologically-based FFA model
Parameters Values Source Parameters Values Source
QFB (L/min) 0.4 [175] V
F
H (L) 0.84 [175]
QFK (L/min) 0.7 [175] V
F
G (L) 0.94 [175]
QFM (L/min) 0.42 [175] V
F
L (L) 1.02 [175]
QFA (L/min) 0.15 [175] V
F
MV (L) 0.51 [176]
QFY (L/min) 0.2 [175] V
F
MI (L) 2.4 [176]
QFG (L/min) 0.62 [175] V
F
AV (L) 0.057 [176]
QFL (L/min) 0.82 [175] V
F
AI (L) 0.77 [176]
QFH (L/min) 2.49 [175] T
F
M (min) 2.95 –
V FB (L) 0.82 [175] T
F
A (min) 15.45 –
V FK (L) 0.16 [175] TAFP (min) 0.11 –
The FFA model with 7 physiologic compartments consist of 9 ODEs (including the
sub-compartments of muscle and AT). The nomenclature of the FFA model is provided in
Table 5.3 and corresponds with the symbols used in the schematic diagram (Figure 5.4). In
general the first subscript represents the various organs/tissues, and if required, the second
subscript represents the fluid spaces within the physiologic compartments. The superscript
‘F’ indicates the FFA model in order to distinguish similar parameter nomenclature used in
different models (glucose, insulin, glucagon, and FFA) having different numeric values. All
the physiologic parameters (flow rates, QFi , and volumes, V
F
i ) were directly obtained from
the published literature [175, 176], as shown in Table 5.4. The metabolic rate at which FFA
is consumed from, or released back into, the circulatory system is predominantly a function
of its own concentration [54] and the concentration of insulin [54, 173]. This phenomenon
was captured in the model by using the metabolic sink and source functions. In general,
the rates for consumption or release of FFA have the following mathematical formulation
(adapted from Sorensen [2]):
Rj = M
G
j ×M Ij ×MFj ×RBj (5.54)
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Here, Rj (mass/time) is the metabolic rate of mass addition/removal via process j. M
G
j ,M
I
j ,
and MFj (dimensionless) are the multiplicative effects of glucose, insulin, and FFA, respec-
tively on process Rj. Finally, R
B
j (mass/time) is the metabolic rate of mass addition/removal
in the basal state. Since hyperbolic tangent functions have been found to be readily suitable
for representing the sigmoidal nonlinearities commonly observed in biological systems, the
rate multiplier functions will have the following mathematical form (adapted from [2]):
M qj = A+B × tanh[C(q(t)−D)] (5.55)
Here, q(t) is insulin, glucose, or FFA concentration, and A, B, C, and D are the parameters.
Wherever sufficient data was available to support the relationship between metabolic
rates and glucose/insulin/FFA concentration, the multiplier functions were fitted using the
nonlinear least square technique (see Section 2.3) by adjusting the four parameters. Data
were obtained primarily from published literature where regional FFA uptake rates were
calculated by measuring the arterial-venous FFA concentration difference coupled with blood
flow rate across a particular organ or tissue [25, 26, 28].
5.3 MODIFIED VERSION OF THE SORENSEN GLUCOSE-INSULIN
MODEL
Some modifications were made to the original glucose-insulin model of Sorensen [2] in order
to facilitate the incorporation of the FFA model. Mainly, the periphery compartment in the
glucose and insulin models (which consists of 0.75 weight fraction of muscle tissue and the
remaining is adipocytes [2, 177]) was partitioned into two compartments: muscle and AT.
This facilitated the separate capture of the glucose and insulin distributions and dynamics in
the muscle and adipose tissues, respectively. Just like the periphery compartment, both the
muscle and AT compartments were further divided into two subcompartments representing
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the capillary and interstitial fluid spaces, in order to incorporate the effect of capillary wall
resistance.
In the glucose model (Section 5.1), equations (5.12) and (5.13) representing the glucose
dynamics in the periphery compartment were replaced by new equations capturing the
glucose dynamics in the muscle and AT compartments. Hence, the mass balance equations
for the muscle compartment can be written as follows:
dGMV (t)
dt
=
QGM
V GMV
(GH(t)−GMV (t))− V
G
MI
V GMV T
G
M
(GMV (t)−GMI(t)) (5.56)
dGMI(t)
dt
=
1
TGM
(GMV (t)−GMI(t))− RMGU
V GMI
(5.57)
Here, the first subscriptM for the physiologic parameters represents the muscle compartment
and the subscriptMGU in the metabolic sink term (RMGU) represents muscle glucose uptake.
Peripheral glucose uptake rate (equation (5.14)) in Section 5.1 is replaced by the rate of
muscle glucose uptake which can be written as follows:
RMGU = M
I
MGU ×MGMGU × 35× fM (5.58)
M IMGU = 7.03 + 6.52× tanh[0.338(INMI(t)− 5.82)] (5.59)
MGMGU = G
N
MI(t) (5.60)
The term fM represents the mass fraction of muscle in the periphery compartment, which
is considered to be 0.75 [2, 177]. The multiplier functions M IMGU and M
G
MGU capture the
muscle glucose uptake rate as a function of insulin and glucose concentrations, respectively.
Similarly, the mass balance equation for the AT compartment can be written as shown
below:
dGAV (t)
dt
=
QGA
V GAV
(GH(t)−GAV (t))− VAI
V GAV T
G
A
(GAV (t)−GAI(t)) (5.61)
dGAI(t)
dt
=
1
TGA
(GAV (t)−GAI(t))− RAGU
VAI
(5.62)
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In this case, the first subscript A for the physiologic parameters represents the AT compart-
ment. Subscript AGU in the metabolic sink term (RAGU) represents AT glucose uptake.
The AT glucose uptake rate can be written as follows:
RAGU = M
I
AGU ×MGAGU × 35× fA (5.63)
M IAGU = 7.03 + 6.52× tanh[0.338(INAI(t)− 5.82)] (5.64)
MGAGU = G
N
AI(t) (5.65)
Mass fraction of AT in the periphery compartment is given by fA = 0.25 [2, 177]. The AT
glucose uptake rate as a function of insulin concentration is captured by M IAGU , whereas
MGAGU represents the effect of glucose concentration on AT glucose uptake rate. All the
physiologic parameters of the muscle and AT compartments belonging to the glucose model
are provided in Table 5.5. The flow rate and volumes of the muscle compartment were
obtained by multiplying fM with the equivalent parameters of the periphery compartment,
while the physiologic parameters of the AT compartment were calculated by multiplying fA
with the equivalent parameters of the periphery compartment in the glucose model.
Table 5.5: Parameter values of the modified glucose model
Parameters Values Parameters Values
QGM (dL/min) 11.33 Q
G
A (dL/min) 3.77
V GMV (dL) 7.8 V
G
AV (dL) 2.6
V GMI (dL) 47.25 V
G
AI (dL) 15.75
TGM (min) 5.0 T
G
A (min) 5.0
Similarly, in the insulin model (Section 5.1), equations (5.35) and (5.36) representing the
insulin dynamics in the periphery compartment were replaced by new equations capturing the
insulin dynamics in the muscle and AT compartments. Hence, the mass balance equations
for the muscle compartment can be written as follows:
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dIMV (t)
dt
=
QIM
V IMV
(IH(t)− IMV (t))− V
I
MI
V IMV T
I
M
(IMV (t)− IMI(t)) (5.66)
dIMI(t)
dt
=
1
T IM
(IMV (t)− IMI(t))− RMIC
V IMI
(5.67)
Once again, the first subscript M in the physiologic parameters represent the muscle com-
partment and the subscriptMIC in the metabolic sink term (RMIC) indicates muscle insulin
clearance. Hence, the peripheral insulin clearance rate (equation (5.39)) is replaced by muscle
insulin clearance rate, as shown below:
RMIC =
IMI(t)(
1−fMIC
fMIC
)(
1
QIM
)
− T IM
VMI
(5.68)
Similarly, the mass balance equation for the AT compartment can be written as:
dIAV (t)
dt
=
QIA
V IAV
(IH(t)− IAV (t))− V
I
AI
V IAV T
I
A
(IAV (t)− IAI(t)) (5.69)
dIAI(t)
dt
=
1
T IA
(IAV (t)− IAI(t))− RAIC
V IAI
(5.70)
Again, the first subscript A for the physiologic parameters represents the AT compartment.
Subscript AIC in the metabolic sink term (RAIC) represents AT insulin clearance. The AT
insulin clearance rate can be written as follows:
RAIC =
IAI(t)(
1−fAIC
fAIC
)(
1
QIA
)
− T IA
VAI
(5.71)
The fractional insulin clearance by the muscle tissues and the AT are represented by fMIC
(equation (5.68)) and fAIC (equation (5.71)), respectively. All the parameter values of
the insulin model are given in Table 5.6. Once again, the flow rates and volumes of the
muscle compartment were obtained by multiplying fM with the equivalent parameters of
the periphery compartment, while the physiologic parameters of the AT compartment were
calculated by multiplying fA with the equivalent parameters of the periphery compartment
in the insulin model (Table 5.6).
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Table 5.6: Parameter values of the modified insulin model
Parameters Values Parameters Values
QIM (L/min) 1.01 Q
I
A (L/min) 0.27
V IMV (L) 0.55 V
I
AV (L) 0.19
V IMI (dL) 5.05 V
I
AI (dL) 1.68
T IM (min) 20.0 T
I
A (min) 20.0
fMIC 0.15 fAIC 0.15
5.4 METABOLIC SINKS AND SOURCES OF THE FFA MODEL
5.4.1 Heart and Lungs FFA Uptake Rate (RHFU)
FFA is a major energy source for myocardial oxidative metabolism in the resting, postabsorp-
tive state [27]. Uptake of FFA across the heart was calculated by measuring the myocardial
blood flow together with venous and arterial FFA concentration difference [25, 26, 27]. Basal
heart and lungs uptake rate of FFA (RBHFU) was estimated from published literature and
was fixed at 18 µmol
min
[25, 26]. The rate of FFA uptake by the heart and lungs is mediated
by changes in FFA concentration at the heart/lungs compartment [178], and it is largely
unaffected by fluctuations in glucose or insulin concentrations [54]. It can be mathematically
expressed as:
RHFU = M
F
HFU ×RBHFU (5.72)
The FFA multiplicative function, MFHFU , can be written as:
MFHFU = 0.8894 + 1.0674× tanh(1.2617(FNH (t)− 0.9497)) (5.73)
Here FNH is the normalized FFA concentration at heart and lungs with respect to its basal
value (FNH = FH/F
B
H , where F
B
H is the basal FFA concentration at heart/lungs). The
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parameters of equation (5.73) were estimated from published data [25, 26, 27] as shown
in Figure 5.5. The figure indicates the effect of FFA concentration on FFA uptake rate in
the heart/lungs compartment.
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Figure 5.5: Model fit (line) versus published data (µ ± σ) (circle) [25, 26, 27] of FFA uptake
rate multiplier function in the heart/lungs compartment, MFHFU , as a function of normalized
heart/lungs FFA concentration, FNH
5.4.2 Gut FFA Uptake Rate (RGFU)
The gut, mainly comprised of the gastrointestinal tract, pancreas, and spleen, metabolizes
FFA at a rate of 27 µmol
min
[179]. FFA utilization by gut tissue appears to be relatively
insensitive to FFA, glucose, or insulin concentration. Hence, the value of RGFU was fixed at
27 µmol
min
.
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5.4.3 Liver FFA Uptake Rate (RLFU)
Liver is an important site for removal of FFA from plasma [29]. Other than β-oxidation, a
substantial amount of the consumed FFA in the liver is converted to glucose by a process
known as gluconeogenesis [180]. Liver FFA uptake rate is calculated by measuring the
arterial-venous difference of FFA concentration along with hepatic blood flow rate [28]. Once
again, the liver FFA uptake rate is predominantly a function of the liver FFA concentration.
The mathematical expression for RLFU can be written as:
RLFU = M
F
LFU ×RBLFU (5.74)
MFLFU = 0.6007 + 0.6931× tanh(1.4279(FNL (t)− 0.91324)) (5.75)
The basal rate of liver FFA uptake rate, RBLFU , was fixed at 232
µmol
min
[28]. In equation (5.75),
FNL represents the normalized liver FFA concentration. Parameters in equation (5.75) were
estimated from published literature [29, 28], as shown in Figure 5.6.
5.4.4 Kidney FFA Uptake Rate (RKFU)
Studies have revealed that the kidney is an important organ for FFA disposal [181]. Arterial-
venous differences of plasma FFA concentration across the kidney have indicated a significant
drop in venous FFA concentration. Data obtained from both animal and human studies
have not indicated any significant change in FFA uptake rate with varying arterial FFA
concentration [181]. Hence, the rate of kidney FFA uptake, RKFU , was fixed at 20
µmol
min
[181].
5.4.5 Muscle FFA Uptake Rate (RMFU)
FFA is the major source of skeletal muscle energy at rest [30]. Almost 75-80% of the resting
muscle energy is provided by FFA oxidation [178]. The importance of FFA as an energy
source is best highlighted by their rapid plasma turnover that allows for the transfer of
high energy carbons from the AT stores to the muscle cells. Once FFA diffuses into the
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Figure 5.6: Model fit (line) versus published data (µ ± σ) (circle) [28, 29] of FFA uptake
rate multiplier function in the liver compartment, MFLFU , as a function of normalized liver
FFA concentration, FNL
muscle cells, FFA is oxidized to acetyl CoA, which then enters the Krebs cycle and results
in production of ATP [178]. Arterial-venous FFA concentration measurement along with
blood flow rate across the muscle tissue was used to estimate muscle FFA uptake rates
[30, 31]. Muscular FFA uptake is primarily a function of the muscle FFA concentration.
Mathematically, RMFU can be expressed as:
RMFU = M
F
MFU ×RBMFU (5.76)
MFMFU = 0.78016 + 0.88336× tanh(1.4145(FNMI(t)− 0.98)) (5.77)
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Here, MFMFU is the multiplier function capturing the effect of muscle interstitial space FFA
concentration on the rate of muscle FFA uptake. FNMI is the normalized FFA concentration
at the interstitial space of muscle tissue. The parameters of equation (5.77) were estimated
from published data [30, 31], as shown in Figure 5.7. Basal rate of FFA uptake, RBMFU , was
fixed at 130 µmol
min
[31].
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Figure 5.7: Model fit (line) versus published data (µ ± σ) (circle) [30, 31] of FFA uptake rate
multiplier function in the muscle compartment, MFMFU , as a function of normalized muscle
interstitial space FFA concentration, FNMI
5.4.6 AT FFA Production Rate (RAFP )
The main function of AT is to store and release energy in the form of fatty acids [182]. During
the pre-prandial period, FFA are predominantly generated in the adipocyte by the action of
hormone sensitive lipase (HSL), which hydrolyzes stored TG into FFA and glycerol. Once
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hydrolyzed, FFA enters into the common intracellular pool from where it might be released
into the circulatory system. This process is known as lipolysis. Insulin is reported to have
a profound inhibiting effect on lipolysis [173, 182]. Insulin reduces the intracellular levels
of cAMP, thus reducing the activation of HSL [182]. This suppression of lipolysis under
the influence of insulin lowers the rate of FFA production from AT, thereby reducing the
circulating levels of FFA. For modeling purposes, RAFP could be written as:
RAFP = M
I
AFP ×RBAFP (5.78)
dM IAFP
dt
=
1
TAFP
(M I∞AFP −M IAFP ) (5.79)
M I∞AFP =
[
6.2937× I
N
AI(t)
INAI(t) + 12.297
+ 0.57879
]−1
(5.80)
The inhibitory effect of insulin on lipolysis is captured by the multiplier functionM I∞AFP . The
superscript ‘∞’ indicates that this is the steady state effect of insulin on lipolysis. Parameters
in equation (5.80) were estimated from data obtained from Campbell et al. [16], where the
lipolytic rate of healthy humans was measured at various hyperinsulinemic levels, as shown
in Figure 5.8. INAI represents the normalized interstitial space AT insulin concentration. The
basal rate of FFA production, RBAFP , was fixed at 575.35
µmol
min
[16]. Due to the nature of the
dynamics as observed in the data, an inverse Michaelis-Menten expression (equation (5.80))
was used instead of a hyperbolic tangent function to capture the correlation between AT
FFA production and insulin. A hyperbolic tangent function was inadequate to capture the
slow decrease in M I∞AFP after the IAI concentration exceeded 15-fold of its basal value.
In order to capture the time course of insulin inhibition on lipolysis, a first-order filter,
equation (5.79) was introduced. The time constant, TAFP , was estimated from a study
performed by Howard et al. [4], where euglycemic-hyperinsulinemic clamps were employed.
Plasma insulin concentration was elevated to 20, 30, and 100 µU
ml
(10 µU
ml
being the basal
level), as shown in the top, middle, and bottom plots in Figure 5.9. Due to the elevation of
plasma insulin concentration, FFA concentration was suppressed in all the three cases.
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Figure 5.8: Model fit (line) versus published data (µ ± σ) (circle) [16] of normalized FFA
production rate in the AT compartment,M I∞AFP , as a function of normalized adipocyte insulin
concentration INAI . The inset includes magnified coordinates, x-axis ∈ [0 to 45] and y-axis ∈
[0 to 2]
5.4.7 AT FFA Uptake Rate (RAFU)
.
As discussed earlier, FFA is mainly taken up by the AT for storage purpose in the
form of TG [54, 182]. This phenomenon is known as lipogenesis. Lipoprotein lipase (LPL)
enzyme present in the adipocyte capillary hydrolyzes circulating chylomicrons, low-density
lipoproteins (LDL) and very low-density lipoproteins (VLDL) into FFA and glycerol. The
released FFA then enters into the AT where it is esterified into TG. Fatty acids influx
into the adipocytes depends mainly upon the existence of an FFA concentration gradient
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Figure 5.9: Model predicted (line) and published (µ ± σ) (circle) [4] plasma FFA
concentration in response to euglycemic hyperinsulinemic clamps. Plasma insulin
concentration was maintained at 20 µU
ml
(top), 30 µU
ml
(middle), 100 µU
ml
(bottom)
[54]. Researchers have estimated the rate of lipogenesis by measuring the arterial-venous
differences in vivo [173, 183]. Data obtained from such studies are quite scattered and
hence portray less confidence. In the model, AT FFA uptake rate was used to close the
FFA mass balance. Studies performed by Howard et al. [4] was used to calculate the
correlation between RAFU and FFA concentration, where plasma fatty acid concentrations
were measured at various hyperinsulinemic levels. From the steady state FFA values at given
hyperinsulinemic levels, the total FFA uptake rates, RTot (where, RTot = RHFU + RLFU +
RKFU + RGFU + RMFU), and the AT FFA production rate, RAFP , were estimated by using
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the above FFA metabolic sink/source rate equations. AT FFA uptake rates (RAFU) were
calculated by taking the difference between RTot and RAFP values, as shown in Table 5.7.
Mathematically RAFU can be written as:
RAFU = M
F
AFU ×RBAFU (5.81)
MFAFU = 0.63198 + 2.3088× tanh(0.4434(FNAI(t)− 0.6339)) (5.82)
Here, FNAI is the normalized AT interstitial space FFA concentration. The basal rate of AT
FFA uptake, RBAFU , was fixed at 218.62
µmol
min
[4]. The uptake of FFA in the AT is unaffected
by fluctuations in insulin or glucose concentrations [54].
Table 5.7: Closing the FFA mass balance at RAFU . Symbol † indicates mean data obtained
from [4]
Basal Steady State Total Uptake Rate (RTot) RAFP RAFU
FFA† Insulin† FFA† Insulin† = RHFU + RLFU + RKFU = RAFP − RTot
(µmolL ) (
µU
mL) (
µmol
L ) (
µU
mL) + RGFU + RMFU (
µmol
min ) (
µmol
min ) (
µmol
min )
377 10 377 10 328.22 546.85 218.62
377 10 285 20 227.1 394.28 164.12
419 10 230 30 156.68 317.33 118.28
352 10 110 100 98.27 169.14 66.16
5.5 INTER-CONNECTING POINTS BETWEEN THE FFA AND
GLUCOSE MODEL
Randle and colleagues [184] were the first to postulate a glucose-fatty acid cycle in which
FFA competes with glucose as an energy providing metabolic substrate. Over the years
research has demonstrated that FFA reduces skeletal muscle and hepatic glucose uptake
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rate [185, 186], thereby leading to glucose intolerance [8]. Studies performed by Boden et
al. [21] have revealed that an increase in FFA oxidation in the muscle inhibits pyruvate
dehydrogenase, which is a key enzyme for controlling glucose oxidation. The authors also
reported that high FFA concentration is associated with an increase in tissue glucose-6-
phosphate levels, which decreases glucose transport into cells.
To capture this inhibitory effect of FFA on muscular and hepatic glucose uptake rate,
multiplier functions representing FFA effects were added to the equations (5.58) and (5.24),
respectively. Therefore, the updated version of equation (5.58) is given by:
RMGU = M
G
MGU ×M IMGU ×MFMGU × 35× fM (5.83)
The only new term, MFMGU , captures the correlation between the muscular glucose uptake
rate and FFA concentration, and can be mathematically written as:
MFMGU = 1.4228 + 0.52007× tanh(−1.86(FNMI(t)− 0.42743)) (5.84)
Here, FNMI is the normalized FFA concentration at the interstitial space of the muscle.
Parameters in equation (5.84) were estimated using data from [8, 21], where euglycemic-
hyperinsulinemic clamps were employed to healthy subjects and then peripheral and hepatic
glucose uptake rates were measured at various plasma FFA levels. Figure 5.10 clearly
indicates the inhibitory effects of FFA on muscle glucose uptake rate. Similarly, the hepatic
glucose uptake rate (equation 5.24), was updated by adding MFHGU , which captured the
inhibitory effects of FFA on RHGU . This can be mathematically written as:
RHGU = M
G
HGU ×M IHGU ×MFHGU × 20 (5.85)
MFHGU = 1.0557 + 0.3308× tanh(−1.6429(FNL (t)− 0.91148)) (5.86)
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Here, FNL is the normalized liver FFA concentration. Parameters in equation (5.86) were
estimated using data from [8, 21], as shown in Figure 5.11. Once again, it could be observed
from the figure that increasing FFA downregulates RHGU .
Historically, it is believed that insulin is the primary direct regulator of hepatic glucose
production (HGP) [32]. However, recent studies have revealed that some of insulin’s HGP
regulatory effect is indirect and may be mediated by plasma FFA concentration [32, 187].
Experiments performed by Boden et al. [21] have revealed that elevated plasma FFA concen-
tration inhibited insulin-induced suppression of hepatic glucose production by attenuating
the insulin suppression of glycogenolysis. In another euglycemic-hyperinsulinemic study
performed by Rebrin et al. [35], FFA was either allowed to fall or was prevented from falling
with liposyn plus heparin infusion. It was observed that preventing the fall in FFA at higher
insulin level significantly prevented the fall in HGP rate. The effect of FFA concentration
on hepatic glucose production can be captured by the following multiplier function:
MF∞HGP = 0.96123 + 0.34199× tanh(1.8663(FNL (t)− 0.85815)) (5.87)
Parameters in equation (5.87) were estimated using data obtained from [32, 33], where
hepatic glucose production rate was estimated at various FFA concentrations and constant
basal insulin level, as shown in Figure 5.12.
In the original Sorensen model [2], the rate of hepatic glucose production is math-
ematically expressed as shown in equation (5.17). Multiplier functions M IHGP , M
X
HGP ,
and MGHGP capture the effects of insulin, glucagon, and glucose concentration on hepatic
glucose production, as represented by equations (5.18), (5.20), and (5.23), respectively. The
function M I∞HGP (equation (5.19)) captures the effect of steady state insulin on RHGP . In
order to estimate the parameters of M I∞HGP , data were obtained from [19, 20] where FFA
concentration was allowed to fluctuate freely along with changing levels of insulin without
any restriction. Hence, M I∞HGP basically represented the combined effect of insulin and FFA
on RHGP . Therefore, in order to separate the effects of insulin and FFA on the rate of hepatic
glucose production, equation (5.19) was modified as follows:
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M I∞HGP = M
IF∞
HGP (5.88)
M IF∞HGP = M
Io∞
HGP ×MF∞HGP (5.89)
M Io∞HGP = 1.019 + 0.3512× tanh(2.095(INL (t)− 0.97867)) (5.90)
Here, the multiplier function M IF∞HGP , represents the combined steady state effect of FFA and
insulin concentrations on hepatic glucose production rate. INL is the normalized liver insulin
concentration. The multiplier function,M Io∞HGP , captures the steady state effect of only insulin
concentration on hepatic glucose production rate. The steady state FFA effect on hepatic
glucose production represented by the multiplier function MF∞HGP is given in equation (5.87).
Parameters of equation (5.90) were estimated to emulate the dynamics of M I∞HGP obtained
from the Sorensen model [2]. The three dimensional surface plot in Figure 5.13 captures
the combined steady state effect of insulin and FFA concentrations on RHGP . The data
obtained from several studies, including the one used to estimate the parameters in equation
(5.19), [19, 21, 32, 34, 35, 36] coincided with the surface within one standard deviation
(Figure 5.13). It is clear from the surface plot that an increasing liver insulin concentration
suppresses hepatic glucose production rate. On the other hand, an increasing liver FFA
concentration promotes hepatic glucose production rate.
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Figure 5.10: Model fit (line) versus published data (µ ± σ) (circle) of glucose uptake rate
multiplier function in the muscle compartment, MFMGU , as a function of normalized muscle
interstitial space FFA concentration, FNMI , data obtained from [8, 21]
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Figure 5.11: Model fit (line) versus published data (µ ± σ) (circle) of glucose uptake rate
multiplier function in the liver compartment, MFHGU , as a function of normalized liver FFA
concentration, FNL , data obtained from [8, 21]
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Figure 5.12: Model fit (line) versus published data (µ ± σ) (circle) of glucose production
rate multiplier function in the liver compartment, MFHGP , as a function of normalized liver
FFA concentration, FNL , data obtained from [32, 33]
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Figure 5.13: Surface plot of the multiplier function, M IF∞HGP , as a function of normalized liver
insulin, INL , and FFA concentration, F
N
L , versus published data (cross) (µ ± σ) of normalized
hepatic glucose production rate with respect to its basal value [19, 21, 32, 34, 35, 36]
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5.6 THE PHYSIOLOGICALLY-BASED FFA, GLUCOSE, AND INSULIN
MODEL
5.6.1 Modified-Insulin Frequently Sampled Intravenous Glucose Tolerance Test
(MI-FSIGT)
For the MI-FSIGT simulation study, a bolus of glucose was infused at t = 0 min and boluses
of insulin were infused at t = 0 and t = 20 min, in order to emulate the data obtained from
Sumner et al. [17]. Due to the second insulin peak, glucose concentration was suppressed
below its original basal level between 50 and 100 min. The insulin boluses caused the FFA
level to decline and achieve a nadir at around 70 min. After the 80 min mark, FFA level
rose gradually and returned to its original basal state. The model predictions captured the
data well, except the last 70 min of the FFA dynamics where the fatty acid level of the data
reached a pseudo-basal level which is higher than the original basal condition. The authors
have suggested that this phenomenon is due to the diurnal variation of the FFA level and has
nothing to do with insulin or glucose kinetics [17]. The muscle (T FM) and AT (T
F
A ) diffusion
time constants were estimated to fit the data [17], as shown in Figure 5.14. The parameter
values are given in Table 5.4.
5.6.2 Validation of the Physiologically-Based Model
5.6.2.1 MI-FSIGT: For validation purpose all the model parameters were fixed and
then a MI-FSIGT simulation study was performed, where a bolus of glucose was infused
at t = 0 and boluses of insulin were infused at t = 0 and t = 20 min at a rate similar to
the experiment performed by Brehm et al. [37]. Due to the insulin boluses, FFA level was
suppressed much below its original basal level. After the 60 min mark, FFA level increased
gradually in order to return to its basal state. The comparison between model predictions
and experimental data are provided in Figure 5.15. The model predictions are within one
standard deviation of the experimental data.
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Figure 5.14: Model fit (line) and experimental data (µ±σ) (circle) [17] of a MI-FSIGT test.
Glucose bolus was infused at time (t) = 0 min and insulin boluses were infused at t = 0 min
and t = 20 min to obtain predictions of insulin (top); glucose (middle); and FFA (bottom)
concentrations
5.6.2.2 Effect of plasma FFA on plasma glucose levels: In order to validate the
inhibitory effect of insulin on glucose uptake and insulin-mediated HGP suppression, a
simulation study was performed where plasma FFA concentration was elevated at a rate
similar to Staehr et al. [33]. Plasma insulin concentration was maintained at the basal
level. Due to the elevation of plasma FFA level, plasma glucose concentration reached
hyperglycemic levels, as shown in Figure 5.16.
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Figure 5.15: Model validation (line) versus experimental data (µ ± σ) (circle) [37] of a MI-
FSIGT test. Glucose bolus was infused at time (t) = 0 min and insulin boluses were infused
at t = 0 min and t = 20 min to obtain predictions of insulin (top), glucose (middle), and
FFA (bottom) concentrations.
5.7 SUMMARY
In this chapter, a physiological FFA model was developed and incorporated with the existing
glucose-insulin model of Sorensen [2]. The FFA model has the same structural formulation as
the Sorensen model. Here, the human body was divided into seven physiologic compartments
representing the major FFA utilizing organs/tissues. Mass balances were performed across
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Figure 5.16: Model validation (line) versus experimental data (µ ± σ) (circle) [33] of the
effects of high FFA levels on plasma glucose concentration. Plasma glucose concentration
reached hyperglycemic levels (top) due to elevation of FFA concentration by lipid infusion
(bottom)
each compartment to obtain the FFA distribution at various organ/tissue levels. Metabolic
sinks and sources, representing the rate of FFA consumption and addition, respectively,
were added to the compartments. The insulin model [2] was linked with the FFA model at
the AT compartment to capture the anti-lipolytic effect of insulin. In order to capture the
effects of fatty acids on glucose, the FFA model was linked with the glucose model [2] at
the muscle and liver compartments. The physiologically-based model successfully emulated
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insulin, glucose, and FFA concentrations after a MI-FSIGT test. The model is also capable
of predicting the physiological effects of FFA on glucose at the organ/tissue level.
Such a detailed physiological model enables the diabetes research community to visualize
the profiles of the major energy-providing substrates at the organ/tissue levels, particularly at
the postprandial period. It also helps researchers to better understand the various physiologic
interactions taking place between glucose, FFA, and insulin at the various body parts. But,
such a level of detailed knowledge comes at the cost of model complexity. The physiologically-
based model as proposed, consists of 34 ODEs. Even though the complexity of the model in
terms of dynamic order and total number of parameters is high, majority of the physiologic
parameters (i.e., volumes and flow rates) can be directly obtained from the literature. The
only estimated parameters were the trans-capillary time constants and those belonging to
the metabolic sink/source equations.
The model is capable of generating ‘what-if’ scenarios to investigate the effect of fluc-
tuating FFA levels on plasma glucose concentration. With the long-term goal of synthe-
sizing an automatic closed-loop model-based insulin delivery system, this more complete
physiologically-based model of the major energy-providing metabolic substrates gives the
control community a more detailed model for use in control design. This detailed model
could contribute substantially in developing a realistic (true-to-life) artificial pancreas, which
would be capable of maintaining normoglycemia by rejecting disturbances such as mixed meal
consumption.
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6.0 MODEL PREDICTIVE CONTROL OF BLOOD GLUCOSE FOR T1DM
PATIENTS1
As mentioned in Chapter 1, the long-term goal is to develop a closed-loop artificial pancreas
system to control blood glucose levels for T1DM patients. The three major components of an
artificial pancreas are a continuous insulin pump, a continuous glucose sensor, and a control
algorithm to regulate the insulin pump in order to maintain normoglycemia [48, 47, 65]. In
a model-based control approach, a diabetic patient model is integrated in the controller, as
shown in Figure 6.1. Based on the model output and the current measurement obtained from
the sensor, the controller calculates the next manipulated input value. Theoretically, such a
device can produce tight glucose control during pre- and post-prandial conditions [48]. Hence,
fully automatic glucose control by an artificial pancreatic system can efficiently prevent or
delay the chronic complications of hyperglycemia and lower the risk of hypoglycemia.
Various types of control algorithms for blood glucose control have been reported in the
literature. Some of these algorithms include: Biostator and related nonlinear PD control [110,
112], PID control [117, 120, 188], optimal control [121, 122], MPC [65, 124, 126], control based
on neural networks incorporating MPC [81, 189], advanced model-based control technique
using parametric programming algorithms [190], etc. Some of these control algorithms were
tested on T1DM patients [120, 126], whereas, others were mainly simulation studies. The
main purpose of all of the published closed-loop algorithms is to maintain the blood glucose
level near its basal value.
The control algorithm used in the first commercially available closed-loop insulin delivery
system, Biostator, was adapted from the nonlinear control algorithm synthesized by Albisser
et al. [110]. Mathematically, the Albisser algorithm can be expressed as follows:
1Portions of this chapter have been published in [130]
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Diabetic Patient
y(t)u(t)
y˜(t)
Figure 6.1: A schematic diagram of the closed-loop model-based insulin delivery system.
Here, r(t) is the desired glucose setpoint, u(t) is the manipulated variable (exogenous insulin),
y(t) is the measured variable, and y˜(t) is the model predicted output
ui(t) =
1
2
Mi [1 + tanh(Si(Gp(t)−Bi))] (6.1)
ud(t) =
1
2
Md [1 + tanh(Sd(Gp(t)−Bd))] (6.2)
Here, subscripts i and d represent insulin and glucose (dextrose) infusions, respectively. The
insulin infusion was based on projected blood glucose, Gp(t), which included a difference
factor, DF(t):
Gp(t) = G(t) +DF (t) (6.3)
DF (t) = K1
[
exp
(
dG(t)/dt
K2
)
− 1
]
(6.4)
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The rate of change of glucose (dG(t)/dt) was averaged over the previous 4min. For adjusting
insulin infusion rate, five tuning parameters were available (Mi, Si, Bi, K1, and K2). Later,
Clemens et al. [112] modified the Albisser algorithm by including a quadratic function of
the derivative of glucose with time in order to expedite the insulin infusion dynamics during
post-prandial periods. All these Biostator-related algorithms can be classified as nonlinear
PD controllers [48].
A closely studied control approach for the automated insulin delivery system is the PID
controller [120, 117]. The PID algorithm has the following mathematical representation
[191]:
u(t) = u0 + kc
[
e(t) +
1
τI
∫
e(t) + τD
de(t)
dt
]
(6.5)
Here, e(t) (error) is the difference between the desired glucose concentration and the mea-
sured glucose signal, u(t) is the insulin infusion rate, and u0 is the basal insulin infusion rate.
The PID controller is composed of three functions: (i) a term directly proportional to the
error (tuning parameter kc); (ii) a correction proportional to the integral of the error (tuning
parameter τI); and (iii) a term proportional to the derivative of the error (tuning parameter
τD). The PID-based insulin pump currently under development by Medtronic MiniMed is
aptly named as the external Physiologic Insulin Delivery (ePID) system [120, 117, 192, 51].
Linear quadratic (LQ) optimal control of blood glucose for diabetic patient, compares
the model predicted output obtained from a linear state–space model of the glucose-insulin
system with the actual measured output, updates the model, and calculates the next ma-
nipulated input value by minimizing a quadratic cost function [121, 122]. The cost function
can be mathematically written as follows (adapted from [121]):
J(u) =
∫ ∞
0
{
[x1(t)− xd]2 + ρu2(t)
}
dt (6.6)
Here, xd denotes a predetermined glucose setpoint value. x1(t) and u(t) represent the state
and input variables obtained from the state–space model. Constant ρ (> 0) is a weighting
factor; higher values of ρ will make the control performance sluggish. The main goal here is
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to determine the positive, bounded, control u(t) in order to minimize the deviation of blood
glucose from the desired setpoint while penalizing usage of large amounts of infused insulin.
One of the most promising control approaches for diabetes is MPC [6, 65, 124, 126]. It
was primarily developed by the petrochemical industry in the 1970s to control large-scale
constrained processes with many manipulated inputs and measured outputs [193]. Compared
to a LQ controller, a model predictive controller is more robust to measurement noise and
plant-model mismatch [194], which is primarily a result of the MPC controller being a
discrete-time relaxation of the LQ controller in the linear model case. The gained robustness
is critical in the diabetes implementation given the prevalence of glucose sensor noise and
model inaccuracy (both structural and parametric). Also, nonlinear MPC formulations can
be constructed and constraints are handled in a straightforward manner in the optimization
problem. A detailed description of the model predictive controller is presented in the
following Section (6.1).
6.1 MODEL PREDICTIVE CONTROLLER
The MPC controller solves an optimization problem at each time step by calculating the
manipulated variable sequence (in this case, insulin delivery rate) that minimizes a user-
specified objective function. The optimization scheme uses the process model (in this case,
a diabetic patient model) to generate future output predictions. Based on these future
model predictions (in this case, glucose concentration), the user-defined objective function is
minimized by computing a manipulated variable sequence. Process measurements obtained
at each sampling time are used to update the optimization, thus incorporating feedback in
the control scheme. From the calculated manipulated variable sequence, only the first step
is implemented, and the algorithm is repeated for the next sampling time [195].
The control algorithm minimizes the following 2-norm squared objective function:
min
4U(k|k)
‖Γy(R(k + 1|k)− Y (k + 1|k))‖22 + ‖Γu4U(k|k)‖22 (6.7)
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Here, vectors R(k+1|k) and Y (k+1|k) of length p are the desired future glucose trajectory
and the future model prediction resulting from the open-loop optimal control sequence vector
4U(k|k) of length m (where, m ≤ p). The goal is to minimize the objective function
(equation (6.7)) by manipulating 4U(k|k). The first part of equation (6.7) represents the
error in setpoint tracking, and the second part represents the penalization factor which
restricts the controller from making drastic changes in the manipulated variable sequence.
Γy and Γu are the weighing matrices for setpoint tracking and control move penalization,
respectively. Controller tuning involves adjustments to the four parameters p, m, Γy, and
Γu.
Figure 6.2 presents the schematic diagram of implementation of the MPC algorithm.
The x-axis represents the time scale. The reference trajectory, representing the desired
blood glucose concentration, is indicated by the horizontal dashed line. At current time,
k, the diabetes model calculates blood glucose concentration for a predetermined future
horizon p, in absence of further control action. The same model is used to calculate a
sequence of control moves (u(k), . . .,u(k+m− 1)), as indicated by the solid line, in order to
minimize the objective function (equation (6.7)) subject to prespecified operating constraints
so that the desired output behavior for p time steps into the future (dash-dotted line with
circles) is obtained. To incorporate the unmodeled errors in the optimization process, glucose
measurements from the sensor (ym(k)) are obtained at every sampling time to compare with
the model prediction (y(k)), and the prediction error, (k) = ym(k) − y(k), thus obtained is
used to update future predictions.
As the optimization process of MPC relies on the forecast of process behavior obtained
from a model, therefore the process model is regarded as an essential component of the MPC
[196, 195]. Based on the type of the model used and the constraints used, model predictive
control algorithms can be classified into linear and nonlinear MPC. A linear model predictive
controller (LMPC) refers to a particular case when the process model linear. A state–space
linear model used in an LMPC has the following form (adapted from [195]):
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Figure 6.2: A schematic diagram of the MPC algorithm implementation
dx(t)
dt
= Ax(t) +Bu(t) (6.8)
y(t) = Cx(t) (6.9)
Here, vector x(t), y(t), and u(t) represent state variables, measured output variables, and
input variables. A, B, and C are constant coefficient matrices. A quadratic objective
function is commonly used for the online optimization subjected to linear input and output
constraints (if present).
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In case of a nonlinear model predictive controller (NMPC), a nonlinear process model is
used. The motivation of using a nonlinear model is the possibility to improve control action
by improving the quality of the forecasting, particularly in systems with a high degree of
nonlinearity [196, 195]. A state space form of a nonlinear model used in a MPC can be
written as follows (adapted from [196]):
dx(t)
dt
= f(x(t), u(t)) (6.10)
y(t) = g(x(t)) (6.11)
Functions f(·, ·) and g(·) are smooth nonlinear mappings for the state and output variables,
respectively. The objective function can be non-quadratic. In addition, the optimization
problem can be subjected to nonlinear input and output constraints.
The MPC has an edge over the other control algorithms for blood glucose control because
of its characteristics. For example, an unconstrained MPC can guarantee optimal insulin
dosage when Γu = 0 [127]. Also for safety reasons and mechanical limitations of the pump,
input constraints can be intrinsically formulated in the MPC algorithm [127]. Moreover, the
MPC can take control actions much before a hyper- or hypo-glycemic event has occurred un-
der certain formulations. Successful implementation of MPC for meal disturbance rejection
in simulations and to maintain glucose homeostasis during fasting state in T1DM patients
can be found in [65, 124] and [126], respectively.
Previously, closed-loop simulation studies have been performed to evaluate the perfor-
mance of MPC in the presence of a CHO-containing meal disturbance [65, 124]. Closed-loop
performance in response to mixed meal containing fat and protein along with CHO has been
ignored, mainly due to lack of lipid-based metabolic models. In this chapter, performance of
closed-loop MPC algorithms for maintenance of normoglycemia in presence of mixed meals
was evaluated. In Section 6.2.1, both NMPC and LMPC algorithms were synthesized based
on the extended minimal model from Chapter 2. In the following Section (6.2.2), a separate
closed-loop simulation study was performed where both NMPC and LMPC algorithms were
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developed by using the composite model from Chapter 4. Finally, the Chapter ends with a
brief Summary 6.3.
6.2 CLOSED-LOOP SIMULATION OF MIXED MEAL DISTURBANCE
REJECTION
6.2.1 MPC Formulation Based on the Extended Minimal Model
Both linear and nonlinear MPC algorithms were synthesized based on the extended minimal
model for disturbance rejection from mixed meal ingestion. The optimization problem was
solved by minimizing the quadratic objective function as presented in Equation (6.7). In a
diabetic system, input magnitude constraints are essential, mainly for safety reasons. This
makes the MPC an ideal candidate for the glucose-insulin feedback system, as the algorithm
can explicitly enforce constraints. It has been observed that the plasma insulin level can
reach upto 70 µU
ml
in healthy patients after consumption of 108 g of mixed meal [10]. Hence
the upper bound of insulin delivery rate was set at 100 mU
min
which corresponded to a plasma
insulin concentration of 69.5 µU
ml
. The insulin input magnitude bounds used for the simulation
study can be written as:
0 ≤ U(k|k) ≤ 100mU
min
(6.12)
In order to make sure that the maximum change in insulin delivery rate is not higher than
the mechanical characteristics of the pump, a maximum rate of change of input constraint
was employed as shown below:
|4U(k)| ≤ 50 mU
min · 4Ts (6.13)
In case of the NMPC (NMPCE−E), the controller model was represented by the extended
minimal model developed in Chapter 2. For simulation purposes, the diabetic patient
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measurements were also obtained from the extended minimal model, thus assuming a perfect
model scenario (no plant-model mismatch). For the LMPC (LMPCE−LE) case, the extended
minimal model was linearized using a first-order Taylor series expansion (see Appendix).
Plant-model mismatch was considered by incorporating the unmodeled disturbances at
every sampling time (4Ts) given by the difference between the plant (patient) measure-
ment, obtained from the original extended minimal model, and the controller model output
represented by the linearized extended minimal model. A mixed meal of 108 g (CHO = 70
g, protein = 18 g, and FFA = 20 g) was consumed by the simulated patient, at t = 20 min.
Gut absorption kinetics of the nutrients from mixed meal into the circulatory system was
captured by the meal model presented in Section 2.5.1. The controller tuning parameters
were adjusted such that the setpoint sum squared error (SSE) (i.e., the deviation of glucose
concentration from the reference trajectory) was minimized. Best controller performance was
achieved when the tuning parameters were: p = 10, m = 2, Γy = 1, and Γu = 0.002; sampling
time (4Ts) was set at 5 min. Comparison between the NMPCE−E and the LMPCE−LE are
provided in Figure 6.3. It can be observed that the performance of LMPCE−LE is closely
comparable with the performance of NMPCE−E (Table 6.1).
For comparison purposes, another set of NMPC (NMPCE−B) and LMPC (LMPCE−LB)
algorithms were synthesized. For the NMPCE−B formulation, the model was represented
by the original Bergman minimal model [1] (from Section 2.1) and the patient (plant)
measurements were obtained from the original extended minimal model. In case of the
LMPCE−LB formulation, a linearized version of the Bergman minimal model (see Appendix)
was used to represent the controller model and, once again, the patient measurements were
obtained from the original extended minimal model. A mixed meal of equal mass and
composition as above was consumed by the simulated patient. Unlike the extended minimal
model, the Bergman model and its linearized version does not consider FFA dynamics.
Tuning parameters and input constraints were the same as above. Closed-loop simulation
results of LMPCE−LE, NMPCE−B, and LMPCE−LB are shown in Figure 6.4. Based on the
simulated performance of the three controllers (see Table 6.1), it can be concluded that
LMPCE−LE provides a tighter glucose control than the NMPCE−B or LMPCE−LB. The
oscillation in the closed-loop performances of NMPCE−B and LMPCE−LB is due to the
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Figure 6.3: Comparison between mixed meal disturbance rejection by LMPCE−LE (solid
line) and NMPCE−E (dashed line) with input constraint. Setpoint (dotted line) is set at 81
mg
dl
plant-model mismatch between the extended minimal model (plant) and the original/linear
Bergman minimal model (controller model). Presence of FFA dynamics in the extended
minimal model caused the plasma glucose to subside slower than the Bergman minimal
model (original/linear) after consumption of a mixed meal.
6.2.2 MPC Formulation Based on the Composite Model
In order to evaluate the closed-loop performance of the composite model developed in
Chapter 4, both LMPC and NMPC algorithms were developed based on the composite model.
Once again, the objective of the closed-loop simulation was to maintain normoglycemia by
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Figure 6.4: Comparison between mixed meal disturbance rejection by LMPCE−LE (solid
line), NMPCE−B (dashed line), and LMPCE−LB (dotted line) with input constraint. Setpoint
(dotted line) is set at 81 mg
dl
Table 6.1: Performance of NMPCE−E, LMPCE−LE, NMPCE−B, and LMPCE−LB
NMPCE−E LMPCE−LE NMPCE−B LMPCE−LB
Maximum glucose (mg/dL) 184.2 184.2 186.2 199
Minimum glucose (mg/dL) 74.61 72.48 66.87 66.74
99% Settling time (min) 355 355 545 435
Setpoint SSE 1.007e5 1.007e5 1.066e5 1.026e6
Infused insulin
above basal (mU) 14620 14633 15845 19621
rejecting disturbances from mixed meal ingestion. The insulin infusion magnitude constraint
and the maximum rate of change of insulin infusion were same as equations (6.12) and (6.13),
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respectively. The quadratic objective function, as presented in equation (6.7), was minimized
to achieve the desired control action.
For the NMPC (NMPCPB−C) case, the in-built controller model was represented by
the composite model. To simulate the diabetic patient (plant), a physiologically-based
metabolic model from Chapter 5 was used. This strategy of using a higher-order model
for the plant and a lower-order model for the controller model introduced a plant-model
mismatch in the closed-loop system; a phenomenon which is expected if implemented in a
clinical setup due to inter- and intra-patient variability. In case of the LMPC (LMPCPB−LC),
the composite model was linearized using a first-order Taylor-series expansion, just like the
previous section (see Appendix). The linearized composite model represented the controller
model and patient data was obtained from the physiologically-based metabolic model for
feedback to the controller in order to incorporate the unmodeled errors. A mixed meal
of same size and composition as the previous section (108 g of 65% CHO, 17% protein,
and 18% fat) was ingested by the simulated patient at t = 20 min. The controller tuning
parameters were adjusted such that sum-squared deviation of glucose concentration from
reference trajectory (81 mg
dl
) was minimized. Best closed-loop performance was achieved at
p = 18, m = 2, and Γy = 2 and Γu = 0.02. Once again, measurements were obtained
at every 5 min intervals. Comparison between the closed-loop simulations of NMPCPB−C
and LMPCPB−LC are provided in Figure 6.5. It is clearly noticable that NMPCPB−C (solid
lines in Figure 6.5 (top)) produced tighter glucose control. In case of the LMPCPB−LC ,
hypoglycemia was reached after 170 min of meal consumption and blood glucose remained
suppressed below the normal level for more than 200 min. The mismatch between the plant
data obtained from the physiologically-based model and the model prediction procured from
the linearized composite model was significantly high when the insulin infusion rate deviated
more than 4-fold of its basal value, thereby causing hypoglycemia.
For comparison purposes, LMPC and NMPC algorithms were developed using the Bergman
minimal model [1] (Section 2.1). In case of the NMPC (NMPCPB−B), the controller model
was represented by the original Bergman minimal model, whereas the diabetic patient was
simulated by the physiologically-based metabolic model. Input constraints and controller
tuning parameters were used as above. As pointed out by Quon et al. [87] and Cobelli et al.
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Figure 6.5: Comparison between mixed meal disturbance rejection by NMPCPB−C (solid
line) and LMPCPB−LC (dashed line) with input constraints. Setpoint (dotted line) is set at
81 mg
dl
[5], the parameters of the minimal model estimated from unlabeled (cold) IVGTT data [1], as
presented in Table 2.1, resulted in underestimation of insulin sensitivity and overestimation
of glucose effectiveness. The disparity in insulin sensitivity between the plant and model
resulted in a sustained oscillation of the blood glucose during a closed-loop simulation of
mixed-meal disturbance rejection, as shown in Figure 6.6.
To overcome this limitation, parameter values of p1, p2, and p3 of the minimal model
(equations (2.3) and (2.2) in Chapter 2) were obtained from Cobelli et al. [5], where parame-
ter estimation was performed by fitting cold and hot (labeled) IVGTT data, simultaneously.
Glucose effectiveness and insulin sensitivity values obtained from the revised (hot and cold)
minimal model were almost identical to the measured values procured by the hepatic arterial-
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Figure 6.6: Mixed meal disturbance rejection by NMPCPB−B with input constraints.
Setpoint (dotted line) is set at 81 mg
dl
. Controller model parameters were obtained from
Bergman et al. [1].
venous difference technique [5], thereby validating the model estimates. The new parameter
values of the minimal model are provided in Table 6.2. A more stable closed-loop performance
of the NMPCPB−B was obtained by using the minimal model with the new parameter values,
as shown by the solid lines in Figure 6.7 (top).
The LMPC (LMPCPB−LB) algorithm was developed based on a linearized version of the
Bergman minimal model. Once again, patient data was obtained from the physiologically-
based model. Closed-loop performance of the LMPCPB−LB algorithm is presented in Figure
6.7 (dashed-lines). Due to plant-model mismatch, both the NMPCPB−B and LMPCPB−LB
algorithms produced hypoglycemic events; especially, in the case of LMPCPB−LB the mini-
mum glucose concentration was dangerously low. The performances of all the four control
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Figure 6.7: Comparison between mixed meal disturbance rejection by NMPCPB−B (solid
line) and LMPCPB−LB (dashed line) with input constraints. Setpoint (dotted line) is set at
81 mg
dl
. The Bergman minimal model parameters were obtained from Table 6.2.
Table 6.2: New Parameters of the Bergman minimal model, from [5]
Parameter Value Unit
p1 0.0092 1min
p2 0.116 1min
p3 0.00068 1min
algorithms are highlighted in Table 6.3. It is quite evident that NMPCPB−C produced the
tightest glucose control. Both the LMPC algorithms caused blood glucose concentration to
reach below 60 mg
dl
, which could be a source of major concern as hypoglycemia may lead to
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unconsciousness or even death. Once again, the closed-loop simulation results revealed that
incorporation of FFA dynamics significantly improved the controller performance.
Table 6.3: Performance of NMPCPB−C , LMPCPB−LC , NMPCPB−B and LMPCPB−LB
NMPCPB−C LMPCPB−LC NMPCPB−B LMPCPB−LB
Maximum glucose (mg/dL) 186 189.2 199.2 204
Minimum glucose (mg/dL) 74.65 55.47 66.77 47.59
99% Settling time (min) 415 650 345 820
Setpoint SSE 9.228e4 1.119e6 1.538e5 1.119e6
Infused insulin
above basal (mU) 10495 10404 10541 10150
For comparison purposes, a closed-loop NMPC formulation (NMPCPB−PB) was designed
with no plant-model mismatch. In other words, the model was assumed to be perfect. Hence,
both the plant (patient) and the controller model were represented by the physiologically-
based model (from Chapter 5). In such an ideal case, best possible glucose control is expected
due to the absence of unmodelled errors. A mixed meal of the same size and composition as
the above cases was ingested at t = 20min. No alterations were made to the controller tuning
parameters. The simulation results as shown in Figure 6.8 (and Table 6.4) revealed a much
superior control performance than any other previously studied closed-loop formulations in
terms of the minimum glucose level, and 99% settling time.
6.3 SUMMARY
For a tighter blood glucose control of T1DM patients, the current focus is on developing
automated closed-loop insulin delivery systems. One of the most optimistic approaches for
controlling an insulin pump is the MPC algorithm. In this chapter, both nonlinear and linear
MPC algorithms were developed to evaluate the effects of FFA on closed-loop glucose control.
The simulated controller performances were evaluated by perturbing the system with mixed
meal ingestion. MPC algorithms based on the extended minimal model (Chapter 2) and
the composite model (Chapter 4) provided a tighter glucose control as compared to MPC
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Figure 6.8: Mixed meal disturbance rejection by NMPCPB−PB with input constraints.
Setpoint (dotted line) is set at 81 mg
dl
Table 6.4: Performance of NMPCPB−PB
NMPCPB−PB
Maximum glucose (mg/dL) 185.8
Minimum glucose (mg/dL) 76.25
99% Settling time (min) 165
Setpoint SSE 9.163e4
Infused insulin
above basal (mU) 10250
algorithms based on the Bergman minimal model [1]. Hence, the simulated results indicated
that inclusion of FFA absorption from mixed meal and its interactions with glucose improved
the quality of the controller performance.
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In case of plant-model mismatch simulations, where the plant was represented by the
higher-order physiologically-based model (Chapter 5), the NMPC performances were far su-
perior than the LMPC formulations. Prolonged hypoglycemia was observed for LMPCPB−LC
and LMPCPB−LB. The deviation in glucose prediction between the linearized models and
their original nonlinear forms was significantly high when the insulin infusion rate exceeded
4-fold of its basal value. This is mainly due to the presence of the saturation terms in the
physiologically-based model describing the effects of insulin on glucose uptake and hepatic
glucose production rates. During higher insulin infusion rates (4-fold above basal), the effects
of insulin on tissue glucose uptake and hepatic glucose production rates reach a saturation
point for the physiologically-based model. Such a biologically-relevant characteristic is absent
in the linearized composite or the Bergman minimal model (both linear and nonlinear forms).
The LMPC formulations, especially LMPCPB−LC , performed far better when the mixed meal
load was reduced to 67 g with the same composition (which is equivalent to approximately
50 g of glucose).
The simulated results demonstrated the capability of the closed-loop algorithms to pro-
duce tight blood glucose control by rejecting disturbances from meals containing all the
major nutrients. The inclusion of gut absorption of FFA and protein, along with glucose
in the closed-loop simulation might prove to be beneficial for the control community in
development of robust automated artificial pancreas equipped to handle disturbances which
are confronted in real life. In order to minimize hypoglycemic events after meal consumption
without sacrificing controller aggressiveness, the MPC framework can be tailored by altering
the objective function [6, 128]. More details of such advanced control strategies are provided
in Chapter 7.
Efforts have been made to develop automated insulin delivery systems since the 1960s
[109]. Commercial pumps to deliver insulin subcutaneously have been available since the
1980s [197], continuous glucose monitoring sensors have been available since the late 1990s
[198], and controller algorithms for delivery of insulin have been in development since the
early 1960s [69]. Still, there are many reasons that not a single closed-loop automated
insulin delivery pump is available commercially [188]. Starting with the continuous glucose
sensors, the accuracy of such a device is in the 15 - 20% error range [199]. Also the
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reliability of continuous monitoring systems is questionable mainly because of the time
lag due to glucose equilibration between blood and subcutaneous interstitial fluid [200].
Insulin delivery is likely to be either intravenous using an external insulin pump (as shown
in Figure 6.1), or intraperitoneal using an implantable pump [188]. Both delivery sites
introduce additional dynamics in the insulin kinetics [201]. Closed-loop algorithms have
not adequately demonstrated ability to efficiently handle these delays especially during meal
intake and exercise [188]. Also, closed-loop controller performance is significantly affected by
the intra-patient variability of insulin sensitivity throughout the day [188, 201]. Extensive
research and validation is still required before a fully automated insulin delivery system could
be used by a T1DM patient at home.
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7.0 SUMMARY AND FUTURE RECOMMENDATIONS
The work presented in this dissertation focused on incorporation of the physiological effects of
FFA and exercise into existing glucose-insulin metabolic models [1, 2]. Both low-order semi-
empirical model structures and higher-order physiologically-based model structures were
investigated. A mixed meal model was also developed to emulate the absorption kinetics of
major nutrients (CHO, protein, and fat) present in a mixed meal into the circulatory system.
The meal model outputs served as disturbance inputs for the metabolic models. One of the
major goal of developing metabolic models accounting for all the major energy-providing
metabolites was to evaluate the closed-loop performance of a model-based controller in
maintaining normoglycemia during the post-prandial period, particularly after ingestion of
a mixed meal. Hence, MPC algorithms were synthesized based on the newly developed
metabolic models for maintenance of glucose homeostasis. The contribution of each of the
investigations have been presented in the summary section of each chapter. The following
section once again summarizes the major findings of this dissertation.
7.1 SUMMARY
7.1.1 Semi-Empirical Metabolic Models
The glucose-insulin metabolic model developed by Bergman et al. [1] was extended to include
FFA dynamics and its interactions with glucose and insulin. Three additional ODEs were
added to the original model to capture the dynamics of plasma FFA, the anti-lipolytic action
of insulin on FFA, and the inhibitory effect of FFA on glucose uptake rate. Due to inclusion
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of FFA dynamics, the extended minimal model in its present form is capable of predicting
FFA fluctuations and its effects on plasma glucose dynamics. Also, the extended minimal
model coupled with a mixed meal model can be utilized to determine the dynamics of plasma
glucose and FFA after mixed meal ingestion of varying sizes and compositions. This more
complete minimal model of the major energy-providing metabolic substrates may provide
the control community a better tool for the design of model-based controllers.
In a separate study, a semi-empirical model of exercise effects on the glucose-insulin
system was developed. Once again, the Bergman minimal model [1] was extended to
incorporate mild-to-moderate exercise effects on plasma glucose and insulin. Linear ODEs
were added in the model to capture the exercise-induced accelerated clearance rate of plasma
insulin, elevated glucose consumption rate, and increased hepatic glucose production rate.
During prolonged exercise, the model successfully captured the decline in hepatic glucose
production due to depletion of the rate of glycogenolysis leading towards hypoglycemia.
With the ultimate goal of developing a closed-loop model-based insulin delivery system, it
is essential to synthesize control-relevant metabolic models that are capable of predicting
fluctuations in glucose dynamics during exercise. Hence, the exercise minimal model can
provide the control community an alternative tool for use in controller design for maintenance
of glucose homeostasis especially during exercise. Open-loop simulations from such models
can also give prior intimation to T1DM patients regarding the time-span during which
exercise could be performed at a given intensity without reaching hypoglycemia.
Although, the extended minimal model developed in Chapter 2 successfully captured
FFA, glucose, and insulin dynamics, the effects of exercise on these metabolites and hormones
were neglected. Similarly, the exercise minimal model developed in Chapter 3 success-
fully captured the effects of exercise on plasma glucose and insulin levels; however, the
model overlooked the contributions (interactions) of FFA. Hence, in order to obtain a single
metabolic model capturing the effects of FFA and exercise, a composite model was developed
by integrating the extended minimal model with the exercise minimal model. To make
the composite model more biologically relevant, necessary modifications were made to the
original model structures. The model consisted of four parts capturing the insulin, glucose,
FFA, and exercise dynamics. The dynamical effects of insulin on glucose and FFA were
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divided into three sections: the anti-lipolytic action to suppress endogenous FFA release;
the gluco-regulatory action to promote glucose uptake in the tissues; and, the suppression of
hepatic glucose production. Parameters of the insulin action on glucose were fitted by using
labeled-IVGTT data which facilitated separation of insulin action on glucose utilization and
production. Exercise effects on insulin, glucose, and FFA were divided into five sections.
Mainly, these effects are the exercise-mediated plasma insulin clearance, elevated glucose
uptake and production rate during exercise, and elevated FFA uptake and production rate
during exercise. The model also captured the decline of plasma glucose concentration during
prolonged exercise due to the depletion of glycogen leading to a decrease in the rate of hepatic
glycogenolysis. The model can be used in development of model-based controller for blood
glucose control particularly in presence of disturbances from mixed meal ingestion, as well
as exercise.
7.1.2 Physiologically-Based Metabolic Model
A detailed physiologically-based circulation model of FFA was developed, where the body
was divided into compartments representing the major organs/tissues. FFA was distributed
to each of these physiologic compartments via the circulatory system. Mass balances were
considered at each compartment to obtain the FFA distribution at various organ/tissue
levels. Metabolic sinks and sources were added to represent the rate of FFA consumption
and addition at various organs and tissues, respectively. The FFA model was integrated with
the existing glucose-insulin model developed by Sorensen [2], which has a similar structure.
The model successfully captured the glucose, FFA, and insulin dynamics after a modified
insulin-frequently sampled intravenous glucose tolerance test. It also captured the effects of
FFA on tissue glucose uptake rate and hepatic glucose production rate.
Such a detailed model can prove to be a valuable tool for the diabetes research community
for better understanding of the various physiologic interactions taking place between glucose,
FFA, and insulin at the organ/tissue levels. The integrated physiologically-based model
accounting for all the major energy-providing substrates has a better chance of accurately
predicting glucose concentration at the major organs/tissues after consumption of a mixed
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meal. The model can also provide more insight regarding the combined effects of insulin and
FFA on hepatic glucose production rate. However, such in-depth knowledge comes at the
cost of model complexity in terms of number of states and parameters.
7.1.3 Model-Based Control of Blood Glucose for T1DM
Both linear and nonlinear MPC were developed to evaluate the effects of mixed meal ingestion
on closed-loop performance of blood glucose control. The MPC algorithms were tested after
perturbing the system with mixed meal ingestion. The control algorithms based on the
extended minimal model (Chapter 2) and the composite model (Chapter 4) provided superior
blood glucose control when compared to controller based on the Bergman minimal model [1].
Hence, the closed-loop results indicated that inclusion of FFA dynamics and its interactions
with glucose improved the quality of the controller performance in rejecting disturbances
from mixed meal ingestion. In case of the plant-model mismatch, the patient data (plant)
was obtained either from the extended minimal model or the physiologically-based model
(Chapter 5), and the controller model was represented either by the composite model or
the Bergman minimal model. The nonlinear MPC formulations provided a tighter glucose
control in terms of maximum glucose level, minimum glucose level, and 99% settling time,
than the linear MPC formulations.
7.2 FUTURE RECOMMENDATIONS
7.2.1 Incorporating Exercise Effects in the Physiologically-Based Model
The physiologically-based model developed in Chapter 5 did not include the exercise effects
on FFA, glucose, and insulin. As discussed earlier, exercise plays a significant role in
altering the dynamics of the major energy-providing metabolites. With the long-term goal of
developing model-based controllers for the maintenance of glucose homeostasis by rejecting
disturbances from mixed meal ingestion and exercise, it is essential to develop accurate
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metabolic models capturing all the major energy-providing metabolites (glucose and FFA)
at rest and during exercise.
Lenart and Parker [202] modified the physiologically-based glucose-insulin model devel-
oped by Sorensen [2] to incorporate the effects of short-term mild-to-moderate exercise. The
model captured the changes in blood flow dynamics associated with exercise. An increase in
glucose uptake by the active muscles during exercise was also captured successfully for t <
90 min. However, the model as proposed considered liver to be an infinite source of glucose
in the form of glycogen, which is not physiologically accurate.
A similar strategy can be implemented to incorporate exercise effects in the physiologically-
based FFA model developed in Chapter 5. To capture the increased muscle FFA uptake
(RMFU) during exercise, multiplier functions representing the exercise effects on RMFU
(MEMFU) can be incorporated in equation (5.76) (Chapter 5). Hence, the modified form
of equation (5.76) can be written as follows:
RMFU = M
F
MFU ×MEMFU ×RBMFU (7.1)
The correlation between the exercise intensity and muscle FFA uptake (MEMFU) can
be obtained from published literature [162, 203], where stable isotope tracer and indirect
calorimetry techniques were used to evaluate regulation of FFA metabolism at various levels
and duration of exercise. Data from these studies revealed that the contribution of plasma
FFA as a source of muscle fuel declines as the exercise intensity increases from 25% to 65%
PV Omax2 .
Similarly, exercise effects on the rate of FFA release from the AT into the circulatory
system (lipolysis) can be captured by incorporating a multiplier function,MEAFP , in equation
(5.78) (Chapter 5), as shown below:
RAFP = M
I
AFP ×MEAFP ×RBAFP (7.2)
Once again, the correlation between the exercise intensity and the lipolytic rate (MEAFP ) can
be procured from the same studies as above [162, 203]. The experimental results showed
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that, unlike the endogenous glucose production rate, the lipolytic rate was maximum at mild
intensity exercise (PV Omax2 = 25%), and decreased with increasing exercise intensity.
The hepatic glucose production rate due to exercise can be represented by two separate
multiplying functions capturing the gluconeogenesis and glycogenolysis process, as the rel-
ative contributions of these processes in total glucose production change according to the
exercise duration and intensity [204]. This will enable the model to capture the depletion of
glycogenolysis due to exhaustion of hepatic glycogen reservoir during prolonged exercise.
7.2.2 A Priori Structural Identifiability of the Metabolic Models
Dynamical models representing biological systems usually contains unknown parameters
describing unobservable states. Typically, these parameters cannot be directly measured,
and are required to be estimated from data collected experimentally by measuring the
observable model variables (inputs and outputs). An important criterion for the parameter
estimation to be well posed is global identifiability of the parametric model [205, 206, 207].
In other words, under ideal conditions of noise free measurements and error free model
structure, the unknown parameters of the proposed model can be uniquely recovered from
the specially designed input-output experimental data [205]. If the proposed model is not
a priori identifiable, then the estimates of the unknown parameters could be unreliable and
erroneous [205, 208].
Identifiability also impacts on the design of the experimental study by providing guide-
lines on the selection of input and output sites to allow unique identifiability [209]. It has
been shown that a priori identifiability results can be used to formulate a minimal (necessary
and sufficient) input-output configuration for experimental data.
For a priori global identifiability of linear and nonlinear models, various approaches have
been proposed: power series [210], differential algebra [207], and similarity transformation
methods [206]. Audoli et al. developed an algorithm to test a priori global identifiability of
a class of nonlinear models [208]. The algorithm automatically tests a priori identifiability
of nonlinear models of state space structure with a general input/output experimental
configuration, as shown below:
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dx(t)
dt
= f(x(t), p) +
m∑
i=1
gi(x(t), p)ui(t) (7.3)
y(t) = h(u(t), x(t), p) (7.4)
Here, x(t) is the n-dimensional state variable, u(t) is the m-dimensional input vector, and
y(t) is the r-dimensional output vector. The υ-dimensional vector of unknown parameters
is represented by p ∈ P . The entries f , G = [g1, ..., gm] and h are assumed to be polynomial
functions of their arguments with no fraction or negative order expressions.
The algorithm resorts to tools from differential algebra; in particular, it is based on
the characteristic set of a differential ideal generated by the polynomial defining the model
[208]. A characteristic set is a special (“minimal”) set of differential polynomials which
consists only the input-output relation of the dynamic system. It generates r polynomial
differential equations involving only variables u(t) and y(t) [211]. Studies have shown that
the characteristic set of a dynamic system in state space form has a special structure which
easily allows parameter identifiability testing [205, 208, 209]. The algorithm computes the
characteristic set via Ritt’s pseudo-division algorithm [211].
An analysis of a priori parameter identifiability of the extended minimal model and
the exercise minimal model developed in Chapter 2 and 3, respectively, can be performed
by employing the software developed by Audoli et al. [208]. A priori global identifiability
will guarantee uniqueness of the solution for the unknown model parameters from measured
input-output data. It can also be helpful to provide guidelines to deal with non-identifiability,
either by providing information on how to simplify the model structure or indicating when
more information (in terms of measured data) is needed for the specific experiment.
7.2.3 Advanced MPC for Blood Glucose Control of T1DM
Advanced control strategies using the MPC framework can be developed to deliver exoge-
nous insulin to T1DM patients in order to improve the closed-loop control performance by
minimizing hypoglycemic events in the post-prandial condition without sacrificing controller
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aggressiveness during hyperglycemia [6, 212]. Two types of controller formulations can be
studied: (i) asymmetric objective function MPC, and (ii) prioritized objective MPC.
7.2.3.1 Asymmetric objective function: For diabetic patients, the performance re-
quirement of a controller is asymmetric in nature, as hypoglycemic events are much less
tolerable than hyperglycemia. To capture this asymmetric performance requirement, an
alternative formulation of equation (6.7) (Chapter 6) is required. One way is to use different
weights for positive and negative deviation of glucose from the reference trajectory [6].
The objective function equation, (6.7), can be re-written as:
min
4U(k|k)
[
eT (k + 1|k)ΓTy Γye(k + 1|k) +4UT (k|k)ΓTuΓu4U(k|k)
]
(7.5)
subject to:
R(k + 1|k)− Y (k + 1|k) ≤ e(k + 1|k) (7.6)
−R(k + 1|k) + Y (k + 1|k) ≤ e(k + 1|k) (7.7)
Here, e(k + 1|k) is the reference error across the prediction horizon which is given by:
e(k + 1|k) = |R(k + 1|k)− Y (k + 1|k)| (7.8)
Equation (7.6) is an active constraint when the error term is positive (glucose concentration is
below the desired level) and equation (7.7) becomes active when the error is negative (glucose
concentration is above the desired level). For asymmetric objective function weighting, the
above two equations (7.6), (7.7) can be written as:
R(k + 1|k)− Y (k + 1|k) ≤ Γ−e(k + 1|k) (7.9)
−R(k + 1|k) + Y (k + 1|k) ≤ Γ+e(k + 1|k) (7.10)
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Here, two different weights, Γ− and Γ+, are used such that positive and negative deviations
of glucose have different contributions to the objective function value. The optimization
may be performed by using the fmincon function from the MATLAB Optimization Toolbox
( c©2008 The Mathworks Inc., Natick, MA).
7.2.3.2 Prioritized objective function: Another way of formulating MPC to ensure
desired objectives are met is by designing a prioritized objective function (PO). Just like the
asymmetric objective formulation, PO is a technique to implement soft output constraints
[213], avoiding possible numerical infeasibilities associated with hard output constraints in
MPC [214, 215]. One major advantage of such a formulation is that control objectives
are explicitly stated and prioritized, making it easy to follow for people from non-technical
backgrounds. In PO MPC, the objective function equation (6.7) is modified to describe
whether the objectives were met in a pre-specified ranking of priority or not. Large objective
function penalties are assigned if a specified objective is not met, and even larger penalties
are implemented on not meeting in order of their priority. PO MPC incorporates both binary
(0 or 1) and continuous variables making it a standard mixed-integer optimization problem
(MIP).
In a PO formulation, the following objective function is minimized at each sampling time
(adapted from [212]):
min
4U(k|k),P,O
[−ΓpP − ΓoO + ‖Γy(R(k + 1|k)− Y (k + 1|k))‖22 + ‖Γu4U(k|k)‖22] (7.11)
Here, P and O are the vectors of priority and objective variables which can be mathematically
written as (adapted from [212]):
P = [p1, p2, .....pN ] (7.12)
O = [o1, o2, .....oN ] (7.13)
pj, oj ∈ {0, 1} ∀j = 1, 2, ...N (7.14)
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The binary variables, pj and oj, represent the status of objectives met in order of priority
and the satisfied objective for the control problem, respectively. Objectives are implemented
by defining ranges (±Bj) in the output (and/or input) variables as shown below (adapted
from [6]):
|R(k + i)− Y (k + i)| < Bj(k + i)
∀, i = 1.....p; ∀, j = 1.....N (7.15)
The objective constraints can be written as (adapted from [6]):
R(k + i)− Y (k + i)−Bj(k + i) ≤ Ow(1− oj) (7.16)
−R(k + i) + Y (k + i)−Bj(k + i) ≤ Ow(1− oj) (7.17)
where, Ow is a large number. When the objective constraint, Eq. (7.15), is satisfied, the
left hand side of Eq. (7.16) and (7.17) will always be negative; hence, the value of oj can
be 1. These constraints can be relaxed by setting Bj(k + i) = ∞, ∀ i = 0.....φ, where φ
is the number of steps over which objective constraint is relaxed. The binary values of pj
can be used to weight heavily for objectives to be met according to their level of priority. If
objective j cannot be met, then the variable for the corresponding priority must be 0. This
can be expressed mathematically as:
p1 ≤ o1
...
pN ≤ oN
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The constraints are imposed such that the priorities are met according to their level of
importance (priority). If priority j is not met, then the values of lower priorities, j + 1 to
j +N , are forced to be 0. This can be mathematically expressed as:
p2 ≤ p1
...
pN ≤ pN−1
Table 7.1, adapted from [6], represents the discretized objectives that could be used in
PO MPC. The optimization problem may be formulated in MATLAB. However, as it is
an MIP optimization, the fmincon.m function might not be able to efficiently handle the
problem. In such a case, other optimization tools, like CPLEX, might be considered for
solving the problem. By using such tailored objective functions for a MPC-based insulin
delivery system, hypoglycemic events could be minimized thereby preventing insulin shock
leading towards unconsciousness or even death for T1DM patients, thus enforcing safety
without compromising controller performance.
Table 7.1: Discretized objectives that could be used in PO MPC, numbered in order of
priority. The glucose measurement is represented as G(k + φ) mg
dl
, where φ is the number of
steps over which the objective is not enforced (adapted from [6]).
No. Objectives No. Objectives
1. G > 70, φ = 2 6. G > 75, φ = 0
2. G > 70, φ = 1 7. G < 110, φ = 2
3. G > 70, φ = 0 8. G < 110, φ = 1
4. G > 75, φ = 2 9. G < 110, φ = 0
5. G > 75, φ = 1
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APPENDIX
LINEARIZATION USING TAYLOR SERIES EXPANSION
A general nonlinear model can be written as follows (adapted from [191]):
dx
dt
= f(x, u) (.1)
y = h(x) (.2)
Here, f(·, ·) is a generalized nonlinear function of process state variables (x) and process
input (u). The process output is indicated by y, and the relationship between y and x is
captured by another nonlinear function h(·).
The linearization of the nonlinear model can be obtained by employing Taylor series
expansion around the point (xs,us), as follows (adapted from [191]):
dx(t)
dt
= f(xs, us) +
(
∂f
∂x
)
(xs,us)
(x− xs) + . . .+
(
∂nf
∂xn
)
(xs,us)
(x− xs)n
n!
+ . . .
+
(
∂f
∂u
)
(xs,us)
(u− us) + . . .+
(
∂nf
∂un
)
(xs,us)
(u− us)n
n!
(.3)
y(t) = h(xs) +
(
∂h
∂x
)
(xs)
(x− xs) + . . .+
(
∂nh
∂xn
)
(xs)
(x− xs)n
n!
(.4)
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Ignoring the higher order terms, the linear approximation can be written as:
dx
dt
= f(xs, us) + a(xs, us)(x− xs) + b(xs, us)(u− us) (.5)
y = h(xs) + c(xs)(x− xs) (.6)
where,
a(·, ·) =
(
∂f
∂x
)
(xs,us)
(.7)
b(·, ·) =
(
∂f
∂u
)
(xs,us)
(.8)
c(·, ·) =
(
∂h
∂x
)
(xs)
(.9)
Usually, equations (.5) and (.6) are written in deviation variables:
x˜ = x− xs (.10)
u˜ = u− us (.11)
y˜ = y − ys (.12)
In addition to this, linearization point (xs, us) is chosen to be a steady state operating
condition. Hence, equations (.5) and (.6) can be written as:
dx˜
dt
= ax˜+ bu˜ (.13)
y˜ = cx˜ (.14)
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